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behorende bij het proefschrift “Structure a n d fu n c tio n s  o f  heparan sulfate  
pro teog lycans in  the hum an glom erular basem ent m em brane”
1. H et “core eiw it” van perlecan speelt w aarschijnlijk  een rol in de b inding van 
lipoproteïnen aan de extracellulaire matrix.
2. De hoge concentratie agrine in de g lom erulaire basaalm em braan suggereert een 
belangrijke functie in het bepalen van de selectieve doorlaatbaarheid van deze structuur.
3. De affiniteit van agrine voor enerzijds de m atrixcom ponent lam inine en anderzijds de 
celoppervlakte-eiw itten a -dystrog lycan  en integrine w ijst op een m ogelijke functie in 
signaaltransductie.
4. A angezien het tripeptide SGD in perlecan en betaglycan als aanhechtingsplaats voor 
heparansulfaat kan fungeren, dient het heden gebruikte patroon SG x G  (w aarin  voor x  
elk am inozuur kan w orden ingevuld) in de PR O SITE  database te w orden genuanceerd.
López-Casillas et al. (1994), J. Cell Biol. 124:557-568 
Costell et al. (1997), Eur. J. Biochem. 243:115-121
5. M oleculaire defecten in de structuur van de glom erulaire filtratieporiën als oorzaak van 
proteinurie verdienen m eer aandacht.
Kestila et al. (1998), Mol. Cell 1:575-82
Matsui et al. (1999), Nephrol. Dial. Transplant. 14:9-11
6. D e beschikbaarheid van conditioneel geïm m ortaliseerde podocyten is van zeer grote 
w aarde voor het onderzoek naar de invloed van m oleculaire processen op hun cellulaire 
differentiatie.
Mundel et al. (1997), Exp. Cell Res. 236:248-58
7. In de biom edische w etenschappen is vaardigheid in het gebruik van het Internet 
onontbeerlijk.
8. H et geslacht van een alligator w ordt niet door genetica bepaald, m aar door de 
om gevingstem peratuur van het ei.
Ferguson en Joanen (1982), Nature 296:850-853
9. D e m ens veronderstelt vaak ten onrechte het ultiem e doel van de evolutie te zijn 
geweest.
Richard Dawkins (1986), The Blind Watchmaker
10. Chaperons zijn niet alleen belangrijk  in het sociale leven.
Kuznetsov en Nigam (1998), N. Engl. J. Med. 339:1688-1695
11. A sielzoekers m ogen blij zijn dat ze niet in een asociale buurt in V ught terechtkom en.
12. M et de ontdekking van telom erase is het einde nog niet in zicht.
Sander Groffen 
Nijmegen, 9 februari 1999
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chapter one A s th e  first b a rrie r  to  b e  c ro s s e d  on  th e  w a y  to  u rinary  s p a c e ,  th e  
g lo m eru la r b a s e m e n t  m e m b ra n e  (GBM ) p lay s  a  key  ro le in rena l 
function . B e s id e s  provid ing  m e c h a n ic a l s u p p o rt to  th e  g lo m e ru la r  
cap illary  wall, th e  GBM re g u la te s  th e  a c c e s s  of p la s m a  m o le c u le s  
to  th e  tu b u la r  sy s te m  of th e  n e p h ro n . T h e  pe rm eab ility  for a  g iven  
m o lecu le  is highly d e p e n d e n t  on  its s ize , s h a p e  a n d  c h a rg e . A s 
ea rly  a s  in 1 9 8 0  th e  c h a rg e -se le c tiv e  p e rm eab ility  w a s  d e m o n ­
s tra te d  to  re la te  to  th e  e le c tro s ta t ic  p ro p e r tie s  of co v a len tly  b o u n d  
h e p a ra n  su lfa te s  w ithin th e  GBM  [1,2]. S in c e  th en , th e  invo lvem en t 
of h e p a ra n  su lfa te  p ro te o g ly c a n s  in c h a rg e -se le c tiv e  ultrafiltration 
h a s  r e a c h e d  a  g e n e ra l c o n s e n s u s .  In th is  se c tio n , c u rre n t in sigh ts  
in th e  s tru c tu re  of th e  GBM a n d  e sp e c ia lly  th e  ro le of h e p a ra n  su l­
fa te  p ro te o g ly c a n s  a re  d is c u s s e d  in re la tion  to  ren a l function  a n d  
pa tho logy . T h e  aim  of th e  s tu d y  is d e sc r ib e d .T o Index
T h e  g l o m e r u l u s
The role of the glomerulus in renal function
The kidney is m ade up o f a large num ber 
o f  functional units, called the nephrons. 
Each nephron is com posed o f  a glom eru­
lus, proxim al tubule, loop o f  H enle and 
distal tubule (see Figure 1). A  single neph­
ron traverses all parts o f  the kidney 
including the cortex, outer and inner m e­
dulla, and connects to  the collecting ducts, 
pelvis and ureter. Each section o f  the 
nephron contributes to  the specificity o f 
renal clearance. The first step in urinary 
excretion called ultrafiltration takes place 
in the glom erulus, and is driven by the 
high blood pressure w ithin the glom erular 
capillaries. The specificity o f  excretion 
depends upon the selective perm eability o f 
the glom erular basem ent m em brane 
(G BM ) that surrounds the capillary wall. 
P lasm a com ponents that traverse the GBM  
are collected in the prim ary urine, con­
tained w ithin B ow m an's capsule. 
Subsequently resorption and secretion pro­
cesses determ ine the ultim ate urine 
com position. The w ork described in this 
thesis focuses on the contribution o f  the 
glom erulus to renal function. In this chap­
ter, the up-to-date know ledge o f  the 
structural and functional properties o f  the 
GBM  will be introduced. To illustrate the
Figure 1: Structure of the nephron. AA: afferent arte­
riole, BC: Bowman s capsule, CD: collecting duct, 
DCT: distal convoluted tubule, EA: efferent arteriole, G: 
glomerulus (dotted circle), GC: glomerular capillaries; 
LH: loop of Henle; PCT: proximal convoluted tubule.
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clinical relevance o f  these data, various g lom erular nephropathies will be described briefly.
Figure 2. A typical glomerular 
capillary loop with capillary lu­
men (Cap), endothelial wall (En),
GBM, podocyte (P), urinary 
space (US), mesangial cell (Mes) 
and mesangial matrix (MM).
Electron microscopic view repro­
duced from [186] with permission 
by Prof. W. Kriz.
Figure 3. Structure of the filtering 
membrane. The fenestrae of the 
capillary endothelium (fe), and the 
interdigitating foot processes with slit 
diaphragms (fp, sd) are indicated. 
Reproduced from [186] with kind 
permission by Prof. W. Kriz.
Anatomy of the glomerulus
The glom erulus (also designated the M alphigian body) is encapsulated by a layer o f  pa­
rietal epithelial cells, called B ow m an's capsule. It contains a large num ber o f  blood 
capillaries that appear in a looped conform ation, supported by m esangial cells adhering to 
the term ini o f  each loop (Figure 2). The wall o f  the glom erular capillary consists o f  a single 
layer o f  fenestrated endothelial cells. This thin structure is surrounded com pletely by the 
GBM , a dense netw ork o f  extracellular m atrix m olecules. In various electron m icroscopic 
studies, the G BM  has been subdivided into three layers o f  alternating density, the central 
layer being the m ost dense. A lthough the term s "lam ina rara interna", "lam ina densa", and 
"lam ina rara externa" are still used at present, this subdivision m ay be based on artifacts 
introduced during dehydration o f  tissue sections. The GBM  presum ably form s a single 
layer o f  hom ogenous density [3]. The outer surface o f  the GBM , w here not associated w ith 
the m esangium , is covered w ith visceral epithelial cells (Figure 3). W ith reference to  their 
strongly branched appearance, these cells are also called podocytes. Their term inal ex­
trem ities (called the foot processes) are intervened by slit diaphragm s and covered by a
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glycocalyx (a layer rich in sialoglycoproteins such as podocalyxin). The association o f the 
foot processes w ith the glycocalyx m ay stabilize their shape and m aintain the aperture o f 
the slit diaphragm s [4].
T h e  s e l e c t iv e  p e r m e a b il it y  o f  t h e  g l o m e r u l a r  b a s e m e n t  m e m b r a n e
The G B M  is a m olecular scaffold that provides the structural support that the capillary wall 
needs to endure the high local blood pressure. It also acts as a filter-like m em brane that 
regulates the access o f plasm a com ponents to the urinary space. A ugm ented G B M  perm e­
ability m anifests clinically as a nephrotic syndrom e, characterized by album inuria, 
hypoproteinem ia, and edema.
The perm eability o f the G B M  for a given m olecule depends strongly on its size, shape and 
charge. The size- and shape-dependent perm eability is ascribed to  the strongly cross-linked 
nature o f the BM , giving rise to a dense netw ork w ith relatively small m eshes. The charge- 
selectivity is associated w ith the presence o f polyanionic charges in the GBM , disabling 
acidic m acrom olecules to penetrate by m eans o f  electrostatic repulsion. The distribution o f 
anionic sites has been studied by staining the G B M  w ith various cationic probes, including 
cationized colloidal gold, polyethyleneim ine, cuprolinic blue, lysozym e, colloidal iron, 
m odified ferritin, poly-L-lysine, protam ine sulfate, hexam ethrine, ruthenium  red, A lcian 
blue, safranine O and others [5]. Figure 4 shows an exam ple o f  cationic staining using 
m odified ferritin [6]. H eparan sulfate proteoglycans (H SPG s) are thought to  play the lead­
ing part in G BM  charge-selectivity based on a long history o f  research. Their significance 
in renal ultrafiltration becam e evident w hen heparan sulfate (HS) w as rem oved from  the rat 
GBM  by perfusion w ith heparitinase, w hich resulted in an increased perm eability for ani­
onic ferritin [1]. Similarly, perfusion w ith anti-HS antibodies led to  selective album inuria 
[7]. D espite the crucial role o f  H SPG s, additional factors m ay be relevant for charge- 
selective u ltrafiltration [8]. The glycocalyx that decorates the epithelial border also adds 
polyanionic charge to  the GBM . W hen this structure becom es detached from  the GBM , 
anionic m acrom olecules w ere observed to  cross the G BM  [9]. Finally hyaluronic acid, 
chondroitin sulfates and carboxyl groups o f  glutam ic and aspartic acid m ay convey addi­
tional anionic charge to the G BM  [4].
Figure 4: Perfusion of kidney with cationized ferritin shows the regular appearance of HS-associated 
anionic sites in the GBM. US: urinary space, Cap: capillary lumen, En: endothelium, fp: foot processes, LRI: 
lamina rara interna, LRE: lamina rara externa, LD: lamina densa. Reproduced from [23] with permission by 
Prof. Y. Kanwar.
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M o l e c u l a r  s t r u c t u r e  o f  t h e  g l o m e r u l a r  b a s e m e n t  m e m b r a n e
A  m ajor step forw ard in the investigation o f the m olecular organization o f  B M s w as the 
characterization o f  the Engelbreth-H olm -Sw arm  (EHS) m ouse tum or, that produces high 
am ounts o f  extracellular m atrix [10]. The m ain m olecular com ponents w ere identified as 
type IV  collagens, lam inins, nidogen and proteoglycans [11]. As H SPG s are the m ain sub­
jec t o f  the present study, their characteristics are discussed in a separate section.
Type IV collagen
A  basic scaffold o f  the G BM  is form ed by collagen type IV, a fibrillar protein that aggre­
gates into a polym eric m eshwork. As depicted in Figure 5, each collagen type IV  m onom er 
consists o f  three polypeptide chains folded into a triple-stranded helix [12-14]. The N - 
term inal dom ain, nam ed 7S, is com posed o f  the three small globules. The central and larg­
est part o f  the m onom er is form ed by the triple-helical, or collagenous domain. The C- 
term inal globules o f  the individual chains assem ble into the NC1 (non-collagenous) do ­
main. C ollagen type IV  m onom ers then aggregate into a large polym er network. This
Single chain
N-terminus
Monomer
C-terminus
I
7S | 
domain
Collagenous domain NC1
domain
I
Polymerized network
Dimerization at C-terminus ^
V  *
Tetramerization at N-terminus
v ^
%
\ I
k
Side-by-side interaction
Figure 5: Assembly of a collagen type IV monomer from three polypeptide chains and formation of a 
polymeric network. Thick arrows indicate three distinct types of interaction that stabilize the network. Draw­
ing based on [12, 14].
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structure is stabilized by three types o f  hom otypic interaction (Figure 5): the covalent asso­
ciation o f  NC1 dom ains into dimers, the covalent association o f  7S dom ains into tetram ers, 
and the lateral interaction betw een adjacent collagenous segm ents [14].
Six genes encoding type IV  collagen polypeptide chains have been identified, nam ed a1  
through a 6 . N ot all com binations assem ble into a functional polym er netw ork. Only two 
stable collagen IV  netw orks have been characterized; the first com posed o f  only the a 1  and 
a 2  chains, and the second containing a 3 , a 4  and a 5  [15-17]. The a 3 - a 4 - a 5  netw ork is 
stronger, presum ably because these collagenous triple helices have an increased cross­
linking potential [18]. This is illustrated by the progressively disrupted structure o f  the 
GBM  in A lport syndrom e, w here the deficiency o f  a 3 - a 4 - a 5  netw ork assem bly is associ­
ated w ith a sustained expression o f  the a 1  and a 2  chains [13,19,20]. W hereas the a 1  and 
a 2  chains predom inate in m ost BM s, the m ature GBM  predom inantly contains the collagen 
type IV  chains a 3 ,  a 4  and a 5  [21,22].
Laminins
Lam inins are assem bled by three polypeptide 
chains designated the lam inin a ,  b and g chain 
[24]. Lam inins typically resem ble a Latin 
cross, its four arm s flexible and w ith globular 
dom ains (Figure 6). Lam inin can self-assem ble 
in vitro  into a large polymer, w hich may be the 
m ain netw ork o f  collagen-free extracellular 
m atrices know n to exist e.g. in em bryogenesis 
[14]. The polym erization o f  lam inin takes 
place via interaction o f the term inal globules o f 
its arms, and is calcium -dependent [26].
F or each individual lam inin chain, different 
isoform s w ere identified designated a 1 - a 5 ,  
P 1 -P 4  and g1-g3. W hile m ost variants are en­
coded by a different gene, truncated chains 
m ay also be produced by alternative splicing 
(e.g. a 3 )  [27] or proteolytic processing (e.g. 
a 2 , b3 and g2) [28]. M any com binations o f  a ,  
b and g chains can form  a stable complex, 
y ielding a large variety o f  lam inins (Table 1). 
The functions o f the lam inins vary from  oli­
gom erization to cell adhesion, m igration and 
differentiation. The lam inins that occur in the 
adult GBM  are predom inantly com posed o f  the 
chains a 5 , b2 and g1 (lam inin-11) [27,29-32]. 
This lam inin isoform  also occurs in the B M  of 
the neurom uscular junction  [33]. The lam inin 
b2 chain seem s to  have an im portant function 
in the GBM , since m utant m ice that lack this 
chain display (besides abnorm alities in the neu­
rom uscular junction) a nephrotic syndrom e in 
the second w eek after birth. Interestingly, their 
m assive proteinuria is associated w ith fusion o f 
the foot processes, resem bling the phenotype o f
Figure 6. The typical structure of a laminin, 
shown by rotary shadowing electron micros­
copy. Reproduced from [25] with permission by 
Prof. R. Timpl.
Table 1: Laminins and their composition [24, 
« ] .
Name Composition Trivial name
Laminin-1 a1p1g1 EHS laminin
Laminin-2 a2p1g1 merosin
Laminin-3 a1p2g1 s-laminin
Laminin-4 a2p2g1 s-merosin
Laminin-5 a3p3g1 kalinin
Laminin-6 a3p1g1 k-laminin
Laminin-7 a3p2g1 ks-laminin
Laminin-8 a4p1g1 -
Laminin-9 a4p2g1 -
Laminin-10 a5p1g1 -
Laminin-11 a5p2g1 -
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m inim al change nephrosis [29,34]. The short arm  originating from  the g1 chain has a nido- 
gen-binding activity [35], and the long arm o f  the a 1  chain w as shown to bind the H SPG  
agrin [36]. In addition, the long arm w as shown to m ediate cell attachm ent [26].
Nidogen
N idogen, also called entactin, is a 158 kD a large single-chain glycoprotein first purified 
from  the extracellular m atrix produced by the EHS tumor. It is com posed o f  three globular 
dom ains (G1, G2 and G3) separated by rod-like segm ents [37]. The carboxy-term inal g lob ­
ule (G3) binds non-covalently and in equim olar am ounts to  dom ain III o f  the lam inin g1 
chain [35,38]. D om ain G2 associates w ith collagen IV, thus linking the collagen m atrix to 
the lam inin network. This dom ain has also a perlecan-binding function [39,40]. G iven 
these cross-linking properties, nidogen is an im portant com ponent in the assem bly o f  BM s 
[11,14,26,41].
Other basem ent m em brane com ponents
BM -40, also called SPARC or osteonectin, is a 33-kD a extracellular glycoprotein w ith anti­
adhesive properties. It is activated by partial proteolysis and binds calcium  and collagen 
type IV  [42-44]. Fibronectin  is a large dim eric m olecule that adheres to m any extracellular 
m atrix com ponents including collagens, heparan sulfate and fibrin. In association w ith 
certain cell types fibronectin is assem bled into a fibrillar netw ork. Fibronectin  also binds to 
the cell surface v ia integrin, an interaction that is conferred by the A rg-G ly-A sp tripeptide 
sequence. By these m echanism s, fibronectin has adhesive properties for m any cell types 
and in some cases it induces cell m igration. In the glom erulus, fibronectin is m ainly found 
in the m esangial m atrix [4]. A nother basem ent m em brane m olecule is tenascin-C . The in­
corporation o f  this m olecule w as dem onstrated to  depend on the presence o f  H SPG s in the 
extracellular m atrix, and tenascin-C  colocalized w ith perlecan and fibronectin [45]. A  
function for tenascin-C  in cell m igration on fibronectin-containing m atrices w as suggested 
[46]. A nd finally, fibulins are m icrofibrillar com ponents o f  extracellular m atrices that con­
sist o f  three dom ains, the second containing calcium -binding EG F-like repeats. Two 
isoform s encoded by different genes w ere characterized. B oth fibulin-1 and -2 w ere dem­
onstrated to bind lam inin, nidogen, fibronectin [47,48] and to  form  hom odim ers [47,49]. 
Fibulin-2 b inding to  perlecan w as also reported [50].
H e p a ra n  s u l f a t e  p r o t e o g ly c a n s  
Structural characteristics of proteoglycans
Proteoglycans are defined as proteins that carry glycosam inoglycan chains. The polypep­
tide part is called the core protein. Each glycosam inoglycan chain is a polysaccharide 
com posed o f  repeating disaccharide units. D ifferent types o f glycosam inoglycans exist: 
hyaluronate, keratan sulfate, derm atan sulfate (DS), chondroitin sulfate (CS), heparin and 
HS. The structure o f  the disaccharide repeats differs betw een the types (Figure 7A). M ost 
glycosam inoglycans are covalently linked to  a serine acceptor residue on the core protein 
o f  a proteoglycan. In these cases the chain is linked to  a serine acceptor residue via a trisac­
charide com posed o f one xylose and tw o galactose residues (Figure 7C). In exception, 
hyaluronic acid and heparin are norm ally present in free form. H eparin is synthesized on a 
small core protein called serglycin and subsequently split o ff  at secretion. A  variety o f  core 
proteins exists for HSPGs.
Although the largest proportion o f  proteoglycans in the B M  is form ed by HSPG s, other 
proteoglycan types are certainly present. Chondroitin sulfate proteoglycans (CSPG s) form
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Figure 7. A) The repeating disaccharide units in various types of glycosaminoglycans, B) possible 
modifications that occur in heparan sulfate and heparin, and C) the attachment of heparan sulfate to a 
serine residue of the core protein of a proteoglycan. Abbreviated names are shown in italics (Gal: galac­
tose, GalNAc: N-acetylgalactosamine, GlcA: glucuronic acid; GlcNAc: N-acetylglucosamine, GlcNSO3, N- 
sulfated glucosamine, IduA: iduronic acid, Xyl: xylose).
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the second largest group in m ost BM s. A  C SPG  that occurs in the EHS m atrix w as recently 
cloned and nam ed bam acan [51,52].
The heterogeneous structure of heparan sulfates
The nascent HS and heparin chains consist o f  alternating glucuronic acid and N -acetyl- 
glucosam ine residues (Figure 7C). A fter extension, the G A G  chain m ay be subjected to 
various types o f  m odification (Figure 7B) [53]. The first m odification is the subsequent de- 
acetylation and sulfation o f  the am ino group o f glucuronic acid, catalyzed by the b ifunc­
tional enzym e N -deacetylase/N -sulfotransferase [54]. Second, epim erization o f these 
glucuronic acid residues to  iduronic acid m ay take place and finally, the 2-O, 3-O and/or 6-
O atom s m ay be sulfated. Together, the various types o f  m odification enable the disaccha­
rides to  assum e m any different structures. The fine structure o f  HS chains is highly variable 
and depends strongly on the type o f  core protein and the cellular environm ent. A lso w ithin 
a single chain, sulfate-rich regions alternate w ith poorly sulfated dom ains. In heparin m ore 
sulfate- and iduronic acid-rich dom ains are present than in heparan sulfate.
Factors that influence heparan sulfate attachm ent
The synthesis o f  glycosam inoglycans attached to  a core protein is a post-translational proc­
ess. The elem ents required for HS attachm ent are only partly understood. A  first 
requirem ent is the presence o f  a Ser-Gly dipeptide, providing the acceptor site for O -linked 
glycosylation (Figure 7C). This dipeptide m ay be part o f  a tetrapeptide motif, m atching the 
consensus Ser-G ly-X-Gly (where X  represents any am ino acid) [55,56]. It m ay also occur 
in the tripeptide sequence Ser-G ly-Asp [56,62]. A  second elem ent that influences glyco­
sylation is the consensus in w hich the attachm ent site is located. Clusters o f  acidic am ino 
acids neighboring the G A G  attachm ent site w ere shown to prom ote HS attachm ent [57]. In 
addition, the proxim al occurrence o f  m ultiple Ser-Gly repeats favours glycosylation w ith 
HS [58]. Besides these elem ents o f  prim ary structure, a m o tif o f  secondary structure has 
been associated w ith O -linked glycosylation. This m otif w as called the SEA m odule w ith 
reference to the m olecules in w hich it w as first found: sperm  protein, enterokinase, and ag- 
rin [59]. The m echanism  by w hich this m odule prom otes G A G  attachm ent is unclear, and 
experim ental evidence for its involvem ent has not yet been obtained. In each case, the sites 
o f  glycosylation w ere found adjacent to  the SEA domain. In addition to the above elem ents 
that are included in the core protein structure, the cell type in w hich proteoglycans are pro­
duced also influences the glycosylation process. This is dem onstrated by the different types 
o f  glycosylation o f  recom binant perlecan fragm ents synthesized in different cellular envi­
ronm ents [51,60-65].
Heparan sulfate protein interactions
The heterogeneous fine structure o f  HS leads to  a broad variety o f  functional properties 
[66-68]. M any proteins w ith affinity for heparin or HS w ere described including basic f i­
broblast grow th factor, antithrom bin III, lipoprotein lipase, apolipoprotein B-100, 
apolipoprotein E, hepatic triglyceride lipase, throm bin, b-throm boglobulin , throm- 
bospondin, vitronectin, fibronectin, platelet factor 4, heparin-binding epiderm al grow th 
factor, agrin, perlecan, and others [50,69-71]. A  consensus m otif in the protein ligand was 
identified as the structure XBBX BX , X B BB X X B X , w here B represents a basic am ino acid 
(arginine, lysine, histidine) and X  a nonbasic am ino acid. A lternatively, a consensus se­
quence TX X BX X TB X X X TB B w as proposed w here T represents a turn  in the peptide 
chain [70,72]. The structure w ithin HS that contributes to  the binding o f proteins is know n 
only in a few  cases: basic fibroblast grow th factor [73], antithrom bin III [74] and lipopro­
tein lipase [75]. The m inim al length o f  HS fragm ents required for binding is typically five
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to  seven disaccharides. The structural analysis o f  glycosam inoglycan chains is ham pered 
by technical lim itations, and the developm ent o f  system atic techniques fo r this purpose is 
o f  great interest.
P e r l e c a n : a  h s p g  p r e s e n t  in  v ir t u a l l y  a l l  b a s e m e n t  m e m b r a n e s
M any different H SPG s have been identified thus far, m ost o f w hich are associated w ith the 
cell surface. The first m olecule identified as a H SPG  o f  basem ent m em branes w as perlecan. 
Later, also the extracellular m atrix com ponent agrin w as recognized as a HSPG. Here, the 
structure and functions o f perlecan are described. The properties o f  agrin are introduced in 
a separate section.
Structure of perlecan
Perlecan, a w idely expressed H S PG  o f  BM s, was 
first isolated from  the EH S tum or in 1980 [2]. The 
nam e refers to  the beads-on-a-string-like appear­
ance observed in rotary shadow ing electron 
m icroscopy (Figure 8) [76]. Perlecan consists o f  a 
large (467 kD a) core protein, carrying three HS 
chains attached to  its N -term inal dom ain [62,77].
D om ain V  m ay also be substituted w ith glycosam i- 
noglycans [50]. The HS residues contribute to 
approxim ately 50% o f  the total m olecular m ass o f 
the proteoglycan. It is im portant to  note that the 
perlecan core protein can alternatively be substi­
tuted w ith CS and/or DS, and in some cases HS is 
totally absent from  the proteoglycan [51,63-65].
O ther types o f  post-translational m odifications in­
clude palm itoylation, m yristoylation and N - 
g lycosylation [78].
The hum an gene encoding perlecan (nam ed 
H SPG 2) is located on the short arm  o f  chrom osom e 1 (1p35-p36.1), com prises over 120 kb 
and contains 94 exons [79-81]. The cD N A  sequence o f hum an perlecan (14 kb in length) 
shows a five-dom ain organization (Figure 9, rom an num bers) [77,82,83]. The N -term inal 
dom ain has a prim ary structure unique for perlecan. B ased on secondary structure predic­
tion, this dom ain w as identified as a SEA m odule [59]. It contains three functional 
attachm ent sites fo r HS [76]. D om ain II is com posed o f  four low -density-lipoprotein re­
ceptor class A  (LA) m odules. The sim ilarity w ith the low -density-lipoprotein receptor 
includes the ligand-binding dom ain o f  the receptor. Im m ediately dow nstream  lies a single 
IgG  repeat that resem bles the 21 m ore repeats found in the N -C A M -like dom ain (see be­
low). D om ain III shares sim ilarity w ith the short arm s o f  lam inin chains. This dom ain 
contains four cysteine-rich L E  m odules sim ilar to  dom ain III o f the lam inin short arms, a l­
ternated by three cysteine-free (Lam B) m odules resem bling dom ain IV  o f the lam inin short 
arms. D om ain IV, encoded by 2010 nucleotides, is the largest dom ain o f  perlecan. The 21 
Ig-like repeats found in this dom ain are sim ilar to  neural cell adhesion m olecules (N- 
CAM ), and presum ably fold into a g lobular structure typical for the im m unoglobulin super­
family. D om ain V, finally, displays sim ilarity to  the large globular G  dom ain located on the 
long arm o f  the lam inin a 1  chain. D om ain V  also contains several SG X G  sequences, but 
these m ay not be functional in HS attachment. To fold into the final m olecular structure o f
Figure 8. The appearance of perlecan in 
rotary shadowing electron microscopy.
Reproduced from [76] with permission by 
Prof. M. Paulsson.
1 8  CHAPTER ONE
I  ; I I
L L L L
A
A A A
II
LamB
f$
^ H K ‘am^ K K I
Figure 9. The five-domain organization of human perlecan. SS: signal peptide; SEA: module first found in 
sperm protein, enterokinase and agrin; LA: LDL-receptor class A module; Ig: Ig-like repeat similar to those of 
neural cell adhesion molecule; LE: laminin-III-like EGF repeat; LamB: laminin-IV-like domain; EG: EGF-like 
repeat; lamG: laminin-G-like domain [59, 77, 82, 83]. Arrows indicate glycosaminoglycan attachment sites.
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perlecan (Figure 8), dom ains I and II likely constitute the first globule. D om ain III provides 
the second, third and fourth globule, dom ain IV  the fifth and dom ain V  represents the car- 
boxy-term inal globule [76,77,82-85].
Functions of perlecan
Perlecan is expressed in the B M s o f  all hum an tissues analyzed in a thorough study, in­
cluding skin, lung, colon, liver, heart, connective tissue, thym us, prostate, spleen, pituitary 
gland, kidney, placenta, skeletal m uscle and blood vessels [86]. M any functions are postu­
lated for perlecan. V arious interactions superim pose strength on the polym eric BM  
structure, including self-assem bly o f  the perlecan core protein, nidogen-m ediated associa­
tion w ith lam inins, and binding o f  collagen IV  and fibronectin [87-90]. B y virtue o f  its 
heavily glycosylated nature, perlecan m ay confer hydrophilic properties to  the m atrix, thus 
increasing its accessibility for plasm a and solutes [4]. Perlecan also m ediates cell attach­
m ent as shown for endothelial cells and fibroblasts, and acts as a repulsive com ponent for 
other cell types [91-93]. R ecom binant dom ain V  w as dem onstrated to  be responsible for 
integrin p1-m ediated cell attachm ent [50]. This region also binds nidogen, heparin and 
fibulin-2.
Furtherm ore, the HS residues o f  perlecan w ere shown to participate in m itogenesis and an- 
giogenesis. This activity is m ediated by basic fibroblast-grow th factor (bFGF). A fter HS 
binding, bFG F becom es activated and subsequently presented to its functional receptor lo­
cated on the cell surface [94,95]. The oligosaccharide structure involved in bFG F binding 
appears to occur preferentially on perlecan, since the cell surface H SPG s syndecan, fibro- 
glycan and glypican showed no bFG F binding capacity [73,96,97]. The bFG F-m ediated 
m itogenic activity o f  perlecan explains the strongly m itogenic and angiogenic behavior o f 
perlecan-expressing tum ors [98]. Consistently, antisense perlecan cD N A  transcription re­
duces the m etastatic potential o f  hum an m elanom a cells [99-101]. Besides bFG F, also 
other grow th factors w ere shown to b ind to  HS. These include heparin-binding epidermal 
grow th factor, acidic FGF, platelet-derived grow th factor, granulocyte-m acrophage colony 
stim ulating factor, hepatocyte growth factor/scatter factor, interferon-g and several in ter­
leukins [102-104].
In addition perlecan m ay be involved in lipoporotein m etabolism  [84]. L ipoprotein lipase 
w as shown to interact w ith HS [105]. The core protein m ay contain a binding site for lipo­
proteins, since the prim ary structure o f  dom ain II is very sim ilar to  the ligand-binding
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Figure 10. The domain organization of human agrin. SS: signal peptide; NtA: N-terminal Agrin (laminin- 
binding domain); FS: follistatin-like; LE: laminin-III-like EGF repeat; S/T: serine/threonine-rich; SEA: module 
first found in sperm protein, enterokinase and agrin; EG: EGF-like repeat; lamG: laminin-G-like domain [119 
121]. The arrows indicate glycosaminoglycan attachment sites.
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region o f  the low -density lipoprotein receptor. Thus, a com plex w ould be assem bled con­
taining H SPG , lipoprotein lipase and lipoprotein. This resem bles the com plexes form ed on 
the cell surface, w here the com plex is internalized prior to  m etabolic processing [75,105­
109]. H ow ever, experim ental evidence to  confirm  this hypothesis is still lacking.
In addition to  the above m entioned functions, perlecan w as initially assum ed to  play a cru­
cial role in the g lom erular perm selectivity barrier. For m ore than a decade, perlecan w as 
the only H SPG  know n to be associated w ith basem ent m em branes. The hypothesis that 
perlecan could be a crucial determ inant o f G B M -associated polyanionic sites therefore re­
ceived considerable attention. D espite this, no clear evidence w as obtained for such a 
function o f  perlecan. Recently, the generation o f  w ell-defined m onoclonal antibodies 
against perlecan [86,110] has enabled a m ore accurate analysis o f  the identity o f  the in­
volved proteoglycans. Surprisingly, ultrastructural studies dem onstrated the absence o f 
perlecan in large parts o f  the glom erular capillary loop (chapter 5) [111].
A g r in : a  h s p g  w it h  s y n a p t o g e n ic  a n d  f il t r a t io n - a s s o c ia t e d  f u n c t io n s
A t the interface betw een an outgrow ing axon and the differentiating m yotube, a series o f 
m olecular events occur that eventually result in the form ation o f  a highly differentiated 
neurom uscular synapse. Agrin, w hich proved to  be a H S PG  [112], is a key factor in this 
process [113,114]. It has therefore been the subject o f  extensive investigations in the field 
o f  neuroscience, especially in the developing chick, rat and m ouse (e.g. [115-117]). A grin 
also proved to  occur in other tissues, especially kidney and lung [118,119]. In this section 
the structure and function o f  agrin is reviewed, together w ith recent new  insights that ex­
tend the relevance o f  agrin expression to  glom erular function.
Structure of agrin
The hum an agrin gene, nam ed AGRN, w as assigned to  the locus 1p36.1-1pter [120]. This 
is relatively close to  the perlecan gene (1p35-1p36). The hum an agrin m R N A  m olecule ex­
ceeds 7 kb in length and encodes a core protein o f  212 kDa, containing three G A G  
attachm ent sites [119]. Experim ental evidence showed that the core protein is glycosylated 
w ith HS. The prim ary structure shows a m ultim odular com position containing a globular 
lam inin-binding dom ain, nine follistatin-like protease inhibitor dom ains, tw o lam inin-like 
EG F repeats, tw o serine/threonine-rich dom ains, a SEA m odule, four EG F repeats and 
three dom ains sharing hom ology w ith globules o f  lam inin a  (Figure 10) [119,121-123]. 
The four g lobular dom ains (the lam inin-binding and lam inin-like dom ains) can be distin­
guished by electron m icroscopy (Figure 11). A lso the three HS side chains are visibly 
attached to  the central region o f  the m olecule as dem onstrated for recom binant chick agrin 
[124]. The rem ainder o f  the agrin m olecule behaves as long flexible rod-like structures. 
V arious isoform s o f  agrin are expressed through tissue-dependent alternative splicing. The 
four sites at w hich splice variants w ere reported are designated c, x, y  and z  in m am m alian
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species (C, A  and B in chick). A  sum m ary o f  observed am ino acid inserts for each site is 
given in table 2. The com position o f  the y  site is regulated by an intronic enhancer, posi­
tioned im m ediately dow nstream  from  this site [125]. The differences betw een agrin splice 
variants are restricted to  short oligopeptide sequences, and therefore they cannot be distin­
guished by polyacrylam ide gel electrophoresis.
Functions of agrin
A grin plays a key role in the form ation o f  the 
neurom uscular junction  (NM J). N eurons and 
m uscle cells produce different splice variants 
o f  agrin, each w ith different functional proper­
ties. N euronal agrin triggers the clustering o f 
acetylcholine receptors (AChRs) on the m uscle 
cell m em brane [114,126,127]. This activity re­
quires the presence o f  an insert at the z  splice 
site [116,128]. The clustering process involves 
the activation o f  a m uscle-specific kinase 
(M uSK ) [129]. M uSK  becom es im m obilized in 
the synaptic region, w here it is finally included 
in a large m ultim olecular netw ork that travers­
es the cell m em brane. O ther com ponents 
included in this structure are neuregulins,
AChRs, rapsyn-associated transm em brane 
linker, rapsyn, the dystrophin-associated gly­
coprotein com plex and the cytoskeleton 
[114,130,131]. A dhesion o f  agrin to  integrin 
a v b 1  m ay also play a role in the synaptogenic 
process [132]. M uscle-specific isoform s o f  ag- 
rin do not have A C hR  clustering activity. These isoform s induce the differentiation o f the 
nerve term inal, an activity w hich m ay take place through the clustering o f  synaptotagm in in 
the developing presynaptic densities [133].
A grin cross-links the assem bling supram olecular com plex tightly into the synaptic BM  
through its interaction w ith lam inin. This represents another m ajor function o f  agrin, for 
w hich the N -term inal dom ain is responsible [36]. The binding to  agrin w as dem onstrated 
for lam inin-1, -2 and -4, and w as localized to a central segm ent o f  the lam inin long arm 
[124].
A grin expression is not restricted to  the developing NM J, but also occurs in num erous 
other em bryonal tissues [135]. The highest expression o f  agrin is seen in B M s o f  the vas­
cular system, kidney and lung [111,114,118,119,136]. N on-neuronal agrin isoform s have a 
low  A C hR -aggregating activity, suggesting distinct functional properties [118]. As far as 
known, they are devoid o f  splice inserts at the y  and z  site, bu t 9-am ino acid insertions in 
the x site w ere observed [114,115,119]. The expression pattern o f  non-neural agrin iso­
form s suggests a possible function in the selective exchange o f  m olecules betw een 
com partm ents. In the developing blood-brain barrier, the onset o f  agrin expression coin­
cides w ith the tim e at w hich the B M  o f  capillary vessels becom es im perm eable [136]. A  
possible function o f  agrin in regulating the m olecular access through BM s is especially in­
triguing w ith respect to  renal function. H SPG s are know n to  contribute im portantly to  the 
polyanionic charge o f  the GBM , as described elsew here in this introduction. Renal agrin is 
expressed prim arily along the glom erular capillary loops. In im m uno-electron m icroscopy, 
anti-agrin antisera decorate the w hole w idth and length o f  the G BM  (Figure 12). These
Figure 11. The conformation of agrin in rotary 
shadowing electron microscopy. This picture 
shows the conformation of a recombinant chick 
agrin molecule. Bar, 50 nm. Reproduced from 
[124] with permission by Prof. M.A. Ruegg.
CHAPTER ONE 2 1
Figure 12. The ultrastructural distribution of agrin in mouse glomeruli ana­
lyzed by immuno-electron microscopy. Anti-agrin antiserum strongly stained the 
GBM in a homogenous linear way. A less intense staining was observed in the 
mesangial matrix. Used antibodies and procedures are described elsewhere [111].
Bar = 1 pm.
properties suggest that agrin could play a m ajor role in determ ining glom erular perm selec- 
tivity.
The peripheral m em brane receptor a-dystrog lycan  w as identified as a high-affinity ligand 
o f  agrin. a -D ystrog lycan  also binds lam inin and is linked to the dystrophin-associated gly­
coprotein complex, and thus also to  the cytoskeleton. The interaction o f  agrin w ith a -  
dystroglycan is not related to its A C hR  clustering activity. C arboxy-term inal fragm ents o f 
agrin that are sufficient for A C hR  clustering activity do not bind a -dystrog lycan  [137,138]. 
A grin splice variants that lack the y  and z  inserts (like those that occur in kidney) are inac­
tive in A C hR  clustering but have a sim ilar capability to  bind a -dystrog lycan . This w as 
experim entally confirm ed by co-im m unoprecipitation o f  agrin from  adult kidney w ith a -  
dystroglycan [139]. a -D ystrog lycan  w as shown to be present on the m em brane o f  kidney 
epithelial cells from  the m om ent o f  m esenchym al-to-epithelial transition. It m ay play an 
im portant role in branching o f  the nephron during m orphogenesis [140-142]. a /b -  
D ystroglycan is also prom inently expressed in the adult hum an GBM  [143]. By binding 
both a -dystrog lycan  and lam inin, agrin m ay be one o f  the com ponents involved in the 
strong adhesion o f  the podocyte's foot processes to  the GBM .
Finally, another com ponent that interacts w ith agrin is heparin (a useful property for purifi­
cation procedures). N ot all agrin isoform s show this activity; the b inding requires the 
presence o f  a basic tetrapeptide cluster at the y  splice site [69]. H eparin  b inding could be a 
m echanism  to m odulate the ability o f agrin to  bind a-dystroglycan . In isoform s containing 
a four-am ino-acid insert at the y  site, a -dystrog lycan  binding is still possible but it can be 
inhibited in presence o f  heparin [69,134,144]. Consistently, the a -dystrog lycan  binding ac ­
tivity o f isoform s that lack the y  insert is not inhibited by heparin [69,134]. Additional
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functions o f  agrin m ay be related to  protease inhibition [135] or various interactions w ith 
grow th factors [145].
Table 2. Amino acid composition of agrin splice variants at four sites designated c, x, y  and z. The
y and z site are named A and B in chicken. Previously reported sequence data are listed for chick, rat,
mouse and human agrin.
Site Species Symbol Amino acid composition Reference/Accession #
c chick Co EHCVE.............. DKPNS 361
C7 EHCVEEHRKLLADKPNS U35613
mouse Co EFCVE.............. DKPGI U844o7
man Co EFCVE.............. DKPGT U844o6
x rat Xo RFLDF................... AATGT 1221
X9 RFLDFDWFPTFFTGAATGT M6478o
mouse Xo RFLDF................... AATRT 12G]
X9 RFLDFDWFPTFFTGAATRT M92657
man Xo RFMDF................... ATSGA 119]
X9 RFMDFDWFPAFITGATSGA AFoi69o3
y chick Ao MGESP----VPHAF 121]
A4 MGESPKSRKVPHAF M94271
rat Yo LGESP----VPHTM 122
Y4 LGESPKSRKVPHTM M6478o
mouse Yo LGESP----VPHTM 1 2 o]
Y4 LGESPKSRKVPHTM M92657
man Yo LGESP----VPHTV 119
z chick Bo AVIKS ............................... ......... EKALQ 121
B8 AVIKSHLSNEIPA ............ ......... EKALQ 134
B11 AVIKS.................PDALDYPAEPSEKALQ M94271
B19 AVIKSHLSNEIPAPDALDYPAEPSEKALQ
rat Zo AVIES ............................... ......... EKALQ 122
Z8 AVIESELTNEIPA ............ ......... EKALQ 1 2 o
Z11 AVIES.................PETLDSRALFSEKALQ 69|
Z19 AVIESELTNEIPAPETLDSRALFSEKALQ
mouse Zo AVTES ............................... ......... EKALQ 12o]
Z8 AVTESELTNEIPA ............ ......... EKALQ M92657
Z11 AVTES.................PETLDSRALFSEKALQ
Z19 AVTESELTNEIPAPETLDSRALFSEKALQ
man Zo NAVTS ............................... ......... EKALQ 119]
A d d it io n a l  H S P G s  in  t h e  g l o m e r u l a r  b a s e m e n t  m e m b r a n e
A lthough agrin and perlecan are the only identified H SPG s in the GBM , several lines o f 
evidence indicate the existence o f  an additional species. Fractionation o f  proteoglycans 
from  G B M  extracts yielded distinct classes that could be distinguished by density [146]. In 
addition to  the low -density H SPG s (such as perlecan and agrin), high-density H SPG s were 
described that contain four HS chains and a relatively small core protein. The im m unologi­
cal relatedness o f  different H SPG s extracted from  the GBM , w ith core proteins o f  250, 150 
and 75 kDa, suggested that they could be generated by proteolytic processing o f perlecan 
[147]. This finding how ever did not rule out the possibility that additional H S PG  species 
exist in the GBM . M ore recently, the presence o f  a “unique” high-density H S PG  w ith a 
core protein o f  22 kD a in the hum an GBM  w as convincingly dem onstrated [204,205]. 
Tryptic fragm ents from  this basem ent m em brane-associated m olecule contained am ino acid 
sequences that do not occur in hum an perlecan and hum an agrin. The identity and prim ary 
structure o f this H S PG  are yet unknown.
D e v e l o p m e n t a l  c h a n g e s  in g b m  c o m p o s it io n
K idney developm ent starts in early em bryogenesis by outgrow th o f  the ureteric bud into 
the m esenchym e (Figure 13) [21,27,148,149]. The m esenchym e condenses around the tip 
o f  the ureteric bud and induces it to  elongate and branch, giving rise to  the collecting 
ducts. This epithelial-m esench ym al interaction requires the expression o f H SPG s [150].
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Figure 13. A schematic overview of nephrogenesis. A. Branching of the ureteric bud and aggregation of 
mesenchymal cells, B. Comma-shaped body stage, C. S-shaped body stage, D. Immature glomerulus stage 
(formation of capillary loops and tubules), E. Mature glomerulus. Arrowheads indicate the location of the an­
cestral GBM.
The m esenchym al cells assum e epithelial-like characteristics, and start to form  vesicles. A t 
this tim e, collagen IV  and lam inin are expressed to form  an epithelial BM. The lam inin 
chains a 1 , a 4 , p i and g1 (lam inin-1 and -8) predom inate in this ancestral basal lam ina 
[24,27], w hereas the collagen netw ork is m ainly com posed o f  a 1  and a 2  chains [151]. 
Each epithelial vesicle subsequently develops into a com m a-shaped and S-shaped body, f i ­
nally form ing a com plete nephron including the tubular, glom erular parietal and glom erular 
visceral epithelium  [152,153]. D uring this process (w hich is com pleted postpartum ) the a 1 , 
a 4  and p i  lam inin chains o f  the ancestral G BM  are gradually substituted by a  5 and p2 
[27,154]. The collagen IV  com position alters from  a 1 - a 2  to a 3 - a 4 - a 5  [21,148]. Transient 
transcription o f  collagen type II was reported [155]. A lso the proteoglycan com position 
changes betw een fetal and adult stages, the fetal G BM  having a higher CSPG  content than 
the m ature GBM . The CSPG  bam acan is expressed transiently during the S-shaped body 
and pre-capillary stage o f  nephrogenesis, and gradually disappears in the m aturing G BM
[156]. This is rem arkable since bam acan rem ains present in all other BM s o f  the nephron
[157]. Perlecan transcription and expression w as observed from  the onset o f  nephrogenesis 
[65]. H ow ever, it is uncertain how  perlecan is glycosylated during different stages o f  de­
Table 3. Developmental changes in the composition of the GBM
Stage Collagen IV
[21,22,148]
Laminins
[27]
Proteoglycans
[65,118,139,156-158]
Vesicle a1 , a 2 a1,4 p1 g1 perlecan
Comma-shaped body a1 , a 2 a1,4 p1 g1 perlecan
S-shaped body a1 , a 2 a1,4,5 p1 g1 perlecan, bamacan
Pre-capillary stage a1 , a 2 a5,1,4 p2,1 g1 perlecan, agrin, bamacan
Immature glomerulus a1 - a 5 a5,1,4 p2,1 g1 agrin, perlecan, bamacan
Mature glomerulus a 3  - a 5 a5 p2 g1 agrin >> perlecan
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velopm ent. The tim e o f  onset o f  agrin expression is not known, but agrin m R N A  w as ob­
served from  pre-capillary stages o f  15-day old chicken em bryos on [118,139,158]. D uring 
further kidney developm ent, agrin m R N A  is im portantly upregulated [119]. A grin strongly 
accum ulates in the m ature GBM , w hereas perlecan m ainly resides in all other B M s o f  the 
nephron [111]. The m orphological and com positional changes during nephrogenesis re­
quire com plex processes o f  regulation [155,159]. A m ong the m any signaling m olecules 
involved, the transcription factors W T1 and Pax2 play im portant roles [160,161].
T h e  r o l e  o f  GBM  H S P G s  in v a r io u s  n e p h r o p a th ie s
The essential role o f  H SPG s in glom erular ultrafiltration suggested that alterations in their 
structure or quantity could be a cause o f  proteinuria under pathogenic conditions. U nder 
experim ental conditions this proved indeed possible, as a selective degradation o f  HS- 
associated polyanionic sites induced the passage o f  anionic ferritin [1]. H um an diseases 
m arked by a defective perm selectivity o f  the renal ultrafiltration barrier m ay how ever 
originate from  m ore com plex m echanism s o f  pathogenesis. N um erous investigations were 
perform ed to  investigate the quantity and structure o f GBM  H SPG  in various nephropa­
thies. This section describes both prim ary renal diseases and secondary nephropathies that 
are caused by, or lead to, alterations in the structure and com position o f  GBM  HSPGs.
Minimal change d isease
A m ongst children, m inim al change disease (M CD) accounts for 85%  o f  the cases o f  ne­
phrotic syndrome. M ost cases o f M CD  present before the age o f  6 years, typically w ith 
edem a and a heavy proteinuria o f  high selectivity. As M CD  is successfully treated by ster­
oids the prognosis is good, although m ultiple relapses o f  the nephrotic syndrom e are 
comm on. The glom eruli appear norm al by light m icroscopy but on electron m icroscopic 
level, effacem ent o f  the epithelial foot processes becom es visible [162,163]. The nephrotic 
syndrom e w as show n to be associated w ith a loss o f  GBM  polyanionic sites [164,165]. 
Im m unological studies showed a reduction o f  HS in the GBM , w hile an antibody against 
the agrin core protein produced undim inished staining [166]. This suggests that the HS 
chains m ay be altered in structure or reduced in length or num ber. The pathogenesis is still 
elusive [165,167].
Focal segm ental glom erulosclerosis
Focal segm ental glom erulosclerosis (FSGS) is a histological appearance found in patients 
w ith a persistent, steroid-resistant nephrotic syndrome. Progression to  end-stage renal fa il­
ure is com m on, necessitating kidney transplantation. Recurrence o f  the disease after renal 
transplantation can be observed. This suggests the involvem ent o f  a circulating factor 
[162,163]. M orphologic features o f  FSG S biopsies include sclerotic lesions o f  focal (i.e. 
not all glom eruli are affected) and segm ental (i.e. not the w hole glom erulus is affected) 
nature. W hen the affected segm ents are analysed by electron m icroscopy, the GBM  shows 
a thickened and lam inated m orphology. Podocytes, often adhering to the Bow m an's cap­
sule, becom e detached from  the GBM . Basic fibroblast grow th factor (bFGF) is possibly 
involved in the m echanism  o f  pathogenesis, since the prolonged exposure o f  glom eruli to 
this m olecule induced FSG S in rats [168]. Cellular signalling by bFG F requires its activa­
tion by binding to  a specific structure in HS, indicating a speculative role for H SPG s in the 
process.
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Congenital nephrotic syndrom e of the Finnish type
The congenital nephrotic syndrom e o f  the F innish type (CN S-F) is a rare disorder in m ost 
populations, w ith the highest incidence in F inland (1 per 8000 deliveries) [169]. In line 
w ith its autosom al recessive m ode o f  inheritance, the disorder is often associated w ith a 
consanguinous fam ilial background. Typicial clinical features include a prem ature delivery 
w ith enlarged placenta, proteinuria starting in fetal stages as dem onstrated by the increase 
o f a -fe top ro te in  in the am niotic fluid, and edem a observed im m ediately postpartum  or soon 
after birth  [162,163,170]. M orphological abnorm alities include enlarged glom eruli and in­
creased m esangial cells and matrix. In electron m icroscopy the GBM  shows a norm al w idth 
[171], bu t the epithelial filtration slits are reduced in num ber [172,173]. A lthough a causal 
role o f  H SPG s in the pathogenesis o f  CNS-F has been suggested [174,175], several other 
investigations have contradicted this hypothesis [176-178]. L inkage analysis in both F in ­
nish and non-Finnish pedigrees m apped the responsible gene to  the long arm o f 
chrom osom e 19 (locus 19q13.1) [179,180]. Recently, this novel gene w as characterized 
and nam ed nephrin [181]. The nephrin gene product is a cell surface protein expressed spe­
cifically in glom erular slit diaphragm s, suggesting an im portant role in renal ultrafiltration 
[181]. The possibility that nephrin is a H SPG  has not yet been excludud.
Denys Drash Syndrome
D enys-D rash Syndrom e (D D S) is a severe congenital disease characterized by renal and 
gonadal abnorm alities, including the appearance o f  W ilm s' tum ors and severe nephrotic 
syndrom e [182]. The cause o f  DD S is a m utation that affects the D N A -binding dom ains o f 
the W T-1 gene product, a transcription factor that is expressed during the m esenchym al-to- 
epithelial transition o f  developing kidney and gonads [183,184]. In the m ature nephron, the 
expression o f  W T-1 is sustained in the podocytes. To investigate the involvem ent o f H SPG  
in the developm ent o f  the nephrotic syndrom e, a patient w ith DDS w as analyzed for glyco- 
sam inoglycan content. A lthough the total glycosam inoglycan content w as norm al, the 
GBM  in DD S showed a reduced HS content, and CS levels appeared to  be elevated [185]. 
Im m unoreactivity o f  the agrin core protein w as o f  norm al level [111, 185].
Diabetic glomerulopathy
D iabetic nephropathy is perheps the m ost illustrative exam ple o f  a disease w here protein­
uria is associated w ith alterations in H S PG  com position o f  the GBM . Patients w ith diabetes 
m ellitus are at high risk o f  developing nephropathy as a secondary effect. A bout 40%  o f 
diabetic patients develop m icroalbum inuria after 10-15 years, w hich can subsequently p ro­
gress into overt proteinuria. Especially in juvenile-onset diabetes end-stage renal failure 
develops frequently. M ost cases o f  diabetic nephropathy originate from  structural altera­
tions in the glom erulus (diabetic glom erulopathy). G lom eruli typically show  a substantial 
w idening o f  the G BM  and expansion o f  the m esangial matrix. This reflects the increased 
production o f  m atrix com ponents such as collagens, lam inin and fibronectin [187-189]. 
The thickened diabetic G BM  w as also shown to contain the C SPG  bam acan, w hich is ab­
norm al for the m ature G B M  [190]. N um erous independent studies have dem onstrated a 
relative decrease o f  H SPG  in the diabetic G B M  and in the m atrix produced by cultured 
glom erular epithelial cells in m edium  containing high glucose levels [189,191-198]. Poorly 
understood is the interesting finding that heparin adm inistration has a protective effect on 
the structure and function o f  diabetic glom eruli. H eparin treatm ent prevented the thicken­
ing o f  the GBM , the decrease in anionic content and the increase in album in excretion 
[188,199-201]. Perlecan transcription is inhibited by high glucose [195], bu t a m ajor im­
pact o f  this on GBM  perm selectivity is not likely. M ore im portant, agrin m ay be down- 
regulated in diabetes as shown by a reduced staining o f  its core protein [189,191]. E lucida­
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tion o f  the m olecular m echanism s that influence agrin expression in diabetic glom erulopa­
thy will be o f  great interest to  gain insight in its m ode o f pathogenesis.
Postexercise proteinuria
The induction o f  proteinuria by m axim al exercise is com m on in healthy subjects [202]. The 
m echanism  that underlies this phenom enon is largely unknow n, but data suggest that both 
increased glom erular perm eability and reduced tubular uptake are involved [203]. The 
proteinuria is associated w ith a tem porary decrease in the electrostatic charge o f  the GBM  
[202] and urinary excretion o f  an unidentified G B M  H SPG  [204]. This H SPG  contains a 22 
kD a core protein and is unrelated to  perlecan and agrin. Standardized exercise protocols 
m ay provide a pow erful tool to  investigate i f  altered expression o f  this small H S PG  could 
be involved in various types o f  nephropathy, w ithout the need for a kidney biopsy 
[204,205].
A im  o f  t h e  s t u d y  a n d  s c o p e  o f  t h is  t h e s is
A t the start o f  this investigation, clear evidence had convincingly dem onstrated the im por­
tance o f heparan sulfate proteoglycans in the G BM  for renal ultrafiltration. Perlecan w as at 
that tim e the only H SPG  know n to occur in basem ent m em branes. Consistently w ith this, 
perlecan w as hypothesized to be the m ajor determ inant o f  the polyanionic charge o f the 
GBM . The availability o f  the com plete cD N A  structure o f  hum an perlecan facilitated sev­
eral new  approaches to study the value o f  this hypothesis. These approaches include the 
production o f  recom binant dom ains o f  hum an perlecan for functional studies, and m utation 
detection in perlecan m R N A  in patients w ith nephrotic syndrom es. B esides these directions 
o f  research , the question arose w hether additional H SPG  species could be present in the 
GBM.
The production o f  individual dom ains o f  hum an perlecan as recom binant proteins w as per­
form ed in three different in  v itro  expression systems. First, the baculovirus expression 
system  w as used for expression o f  perlecan dom ains I and II (C hapter 2). The host cell line 
Spodoptera frugiperda SF21 supports a w ide range o f  post-translational m odifications typ i­
cal for h igher eukaryotes. C onsistent w ith this, the produced recom binant m olecule 
contained glycosam inoglycan side chains, identified as chondroitin sulfate. The results 
provide experim ental evidence for a functional role o f  the perlecan SEA m odule in glyco- 
sam inoglycan attachm ent.
C hapter 3 describes the biosynthesis o f  tw o perlecan fragm ents in the P ichia pastoris 
(yeast) expression system. The recom binant proteins include dom ain II that shares sim ilar­
ity w ith the low -density-lipoprotein receptor. These proteins w ere used to investigate the 
possible role o f  perlecan in lipoprotein binding.
As described in C hapter 4, a bacterial fusion protein w as engineered containing perlecan 
dom ains I and II. The hybrid protein was purified and used for im m unization o f  mice. W e 
generated a novel m onoclonal antibody 95J10 that recognizes the perlecan core protein. 
This antibody w as used to  investigate the spatial distribution o f  perlecan in the kidney and 
various other tissues. U sing im m uno-electron m icrocopy we found that perlecan is absent 
from  m any regions o f  the GBM  (and hence it cannot be the m ajor determ inant o f its 
charge-selective perm eability). A nother m onoclonal antibody, that recognizes purified 
GBM  H SPG , produced a clearly different staining suggesting the existence o f  an unrelated 
proteoglycan. G iven its high expression in the GBM , the identity o f this m olecule w as o f 
great interest to  gain insight in the m olecular m echanism s o f  selective ultrafiltration. 
Prom pted by the detection o f  agrin-like oligopeptide structures in H SPG s from  bovine k id ­
ney and the finding that agrin is a H S PG  [112], w e investigated the possible relationship
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betw een GBM  H SPG  and agrin. V arious experim ental approaches, including im m uno- 
electron m icroscopy, w ere applied to  identify agrin as a H SPG  o f  the GBM . The relative 
concentrations o f  agrin and perlecan w ere com pared (C hapter 5).
To gain insight in the structure o f  this G B M  H SPG , w e next elucidated the com plete cD N A  
structure o f  the m ature agrin core protein (Chapter 6). The derived protein structure a l­
low ed predictions for structure-function relationships in accordance w ith the structures 
know n for rat and chick agrin. Furtherm ore w e used a cD N A  probe to  determ ine transcrip­
tion levels in m ultiple hum an tissues, and com pared these data w ith the accum ulation o f 
agrin im m unoreactivity in the B M  o f  these organs.
In a previous investigation, our laboratory generated a large panel o f  m onoclonal antibod­
ies against H SPG  isolated from  the GBM . In Chapter 7 w e investigated i f  these recognize a 
series o f  19 different recom binant fragm ents o f  hum an agrin. U sing these recom binant 
peptides, w e localized the epitopes recognised by 25 m A bs on distinct regions o f the agrin 
core protein. The fusion protein containing the N -term inal agrin dom ain (the lam inin- 
b inding dom ain) show ed affinity for im m obilised lam inin. This activity w as exploited to 
visualize lam inin-associated binding sites for agrin in the kidney cortex. Furtherm ore we 
analysed the cellular origin o f  agrin in the GBM.
One function o f  H SPG s is the binding and activation o f  basic fibroblast grow th factor 
(bFGF). In Chapter 8 w e describe a study to  assess the role o f  bFG F in the pathogenesis o f 
focal segm ental glom erulosclerosis (FSGS). Increased concentrations o f  bFG F in som e p a ­
tients w ith FSG S suggest a possible role for this grow th factor in the developm ent o f 
proteinuria. Chapter 9 concludes this thesis w ith a survey and indications for future re­
search.
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chap te r tw o S u m m a ry  W e p re s e n t  th e  in  vitro  e x p re s s io n  a n d  purification of 
N -term inal f ra g m e n ts  of h u m a n  p e r le c a n  in in se c t cells. T h re e  
"ta ilo red” f ra g m e n ts  of h u m a n  p e r le c a n  cD N A  w e re  in tro d u ced  into 
th e  po lyhedrin  lo cu s of b acu lo v iru s  e x p re s s io n  v e c to rs  (BEV s) 
e n c o d in g  am in o  a c id s  1 -1 9 6  (d o m ain  I), 1 - 4 0 4  (d o m ain  I a n d  IIa) 
a n d  1 - 5 0 6  (d o m ain  I, IIa a n d  IIb). T h e  integrity of th e  B EV s w a s  
c h e c k e d  by DNA s e q u e n c in g , p o ly m e ra s e  c h a in  reac tio n , restric tion  
e n z y m e  a n a ly s is  a n d  S o u th e rn  blotting. N orthern  hybrid ization  a n d  
m eta b o lic  labeling  w ith [35S ]m e th io n in e  s h o w e d  th a t e x p re s s io n  of 
th e  p e r le c a n - (1 -4 0 4 ) - f ra g m e n t a n d  th e  p e r le c a n - (1 -5 0 6 ) -f ra g m e n t 
w a s  su c c e s s fu l , bu t in th e  c a s e  of th e  p e r le c a n -(1 -1 9 6 )-f ra g m e n t 
no  re c o m b in a n t p ro te in  w a s  p ro d u c e d . Im m unoblo tting  s h o w e d  th a t 
bo th  th e  (1 -4 0 4 )-f ra g m e n t a n d  th e  (1 -5 0 6 )-f ra g m e n t a re  
re c o g n iz e d  by 9 5 J1 0 , a  m o n o clo n a l an tib o d y  th a t  w a s  p rev iously  
ra is e d  a g a in s t  p e r le c a n - (2 4 -4 0 4 ) - f ra g m e n t e x p re s s e d  in 
E sc h e r ic h ia  coli. G el p e rm e a tio n  a n d  an io n  e x c h a n g e  
c h ro m a to g ra p h y  w e re  a p p lie d  to  purify th e  re c o m b in a n t p ro te in s. 
G ly c o sa m in o g ly c a n s  w e re  d e m o n s tra te d  to  b e  p re se n t. 
D eg lycosy la tion  with c h o n d ro itin a se  ABC sh o w e d  th a t  th e  (1 -4 0 4 ) -  
f ra g m e n t w a s  g ly co sy la te d  w ith chond ro itin  su lfa te  re s id u e s . 
C o n s is te n t  with th e s e  re su lts , g ly c o sa m in o g ly c a n s  iso la ted  from  th e  
(1 -4 0 4 )-f ra g m e n t w e re  identified  a s  chondro itin  su lfa te  by a g a ro s e  
gel e le c tro p h o re s is . F u r th e rm o re  th e  (1 -4 0 4 )-f ra g m e n t s h o w e d  
affinity to  im m obilized  b a s ic  f ib ro b last g row th  fac to r. T h e  availability  
of b a c u lo v iru s-d e riv ed  re c o m b in a n t p e r le c a n  f ra g m e n ts  will fac ilita te  
d o m ain -sp e c if ic  in v estiga tion  of th e  s tru c tu ra l a n d  functional 
p ro p e r tie s  of p e r le c a n  in th e  fu ture.
In t r o d u c t io n
H eparan sulfate proteoglycans are essential com ponents o f  cell surface and basem ent 
m em branes serving a diversity o f  functions. Perlecan (H SPG 2) is a large proteoglycan o f 
basem ent m em branes consisting o f  a 467 kD a core protein w ith three heparan sulfate chains 
attached to its N -term inal domain. The other dom ains share hom ology w ith the LD L-receptor 
(dom ain II), lam inin a 1 , B1 and g1 short arm s (dom ain III), neural cell-adhesion m olecule 
(dom ain IV) and the globular end o f  lam inin a 1  (dom ain V) [1-3]. The perlecan gene is 
m apped to  the short arm  o f  chrom osom e 1 and com prises over 120 kb, consisting o f  94 exons 
[4, 5]. C onsistent w ith its m ultidom ain structure, the core protein o f perlecan serves m ultiple 
functions. The proteoglycan is anchored w ithin the basem ent m em brane through binding to 
lam inins (an interaction that is enhanced in presence o f  nidogen/entactin), fibronectin and 
collagen types IV  and V I(a2 ) [6-8]. These interactions m ay increase the rigidity o f  the 
basem ent m em brane and im m obilize perlecan w ithin the matrix. U p to  date, little inform ation 
is available regarding the functionality o f  the individual dom ains o f  the core protein. 
How ever, some insight into the roles o f  dom ain III and I has been gained by previous in  v itro  
expression studies. D om ain III o f  m ouse perlecan w as produced by H T1080 cells [9]. The 
recom binant protein binds to  the cell surface through interaction o f  R G D  peptide sequences 
w ith integrins [10]. A lthough this tripeptide is not conserved in hum an perlecan an alternative
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cell binding m echanism  m ay exist. In another study, dom ain III o f hum an perlecan was 
expressed successfully in E scherich ia  c o li . A  m onoclonal antibody w as raised and used to 
dem onstrate the ubiquity o f  perlecan in hum an basem ent m em branes [3]. Furtherm ore, 
expression o f  m urine dom ain I in chinese ham ster ovary cells provided evidence for the 
location o f  the glycosam inoglycan attachm ent sites near the N -term inus o f  perlecan [11].
The presence o f  the strongly anionic heparan sulfate is essential for the charge-selective 
perm eability o f  the glom erular basem ent m em brane [12]. H eparan sulfate has also been 
shown to bind a w ide range o f  grow th factors like heparin-binding epidermal grow th factor, 
interferon-g, granulocyte-m acrophage colony stim ulating factor, interleukins IL-3, IL-8 and 
bFG F [13-16]. The biological activity o f  bFG F requires the presence o f  a specific 
oligosaccharide sequence w ithin heparan sulfate or heparin [14, 17]. B inding to  this 
oligosaccharide is essential for the grow th factor to  trigger its cell surface receptor. It was 
dem onstrated that bFG F activation in vivo  is solely dependent on the heparan sulfate chains o f 
perlecan [13].
Together w ith cell surface H SPG s o f  the vascular endothelium , perlecan also plays a role in 
the regulation o f  coagulation. A ntithrom bin III binding to  heparan sulfate increases its anti­
coagulant activity [18, 19]. Finally, perlecan m ay be involved in lipoprotein m etabolism . 
H eparan sulfate chains are know n to bind lipoprotein lipase, a key enzym e in lipoprotein 
m etabolism  [20, 21]. Regarding the strong sim ilarity betw een dom ain II and the low -density 
lipoprotein receptor it can be speculated that the heparan sulfate residues, lipoprotein lipase, 
low -density lipoprotein and dom ain II m ight associate som ehow  into a large com plex [22]. 
H ow ever, no experim ental evidence w as obtained thus far to  support this hypothesis.
In the present study w e have used recom binant baculovirus expression vectors (BEV s) to 
produce truncated perlecan fragm ents that are both glycosylated and expressed at high level. 
The baculovirus expression system utilizes the extrem ely strong polyhedrin prom oter by 
substituting the polyhedrin gene for a cD N A  sequence encoding the protein o f  interest [23, 
24]. M any post-translational m odifications are w ell-described in insect cells, including O- 
glycosylation [25], N -glycosylation, palm itoylation and m yristoylation. A lthough chondroitin 
sulfate and heparan sulfate proteoglycans have been observed in the fruit fly D rosophila  
m elanogaster  [26], no evidence is available yet for the correct synthesis o f  H SPG s during late 
stages o f  baculovirus infection.
M a t e r ia l s  a n d  m e t h o d s  
Materials
Vent® polym erase, T4 polynucleotide kinase, X cm I and D raIII  endonuclease (N ew  England 
B iolabs), Bam H l, N otI, P stI  endonuclease, T4 D N A  ligase, bFG F, m ethionine-deficient 
G race’s m edium , fetal bovine serum  (Life Technologies), SrfI  endonuclease, pCR -Script 
plasm id (Stratagene Cloning System s), pVL1393 plasm id (Invitrogen), Spodoptera  
fru g ip erd a  SF21 cells, w ildtype A cN PV  strain C6, transfection reagent, BacPA K 6 linearized 
viral D N A  (Clontech Laboratories), “ SD S-6B” biotinylated m arker, Brij35, TN M -FH  insect 
culture m edium  (Sigm a Chem ical), RN A zol (B iotecx Laboratories), [35S]m ethionine (ICN 
B iom edicals), [ a - 32P]ATP, H ybond N+, photographic film  (A m ersham ), E N 3H A N C E (NEN), 
SDS (Fluka Chem ie), PhastSystem , FPLC system, M onoQ , Superose 12 colum n, D EA E 
Sepharose CL-4B (Pharm acia B iotech), secondary antibody conjugates (Dakopatts), 
Im m obilon-P m em brane (M illipore), M ultiM ark prestained m arker (Novex) and 
chondroitinase A BC from  P roteus vulgaris  (Seikagaku).
41
Product Nucleotides Primer set
1 41-628 atggggtggcgggcgccgg (f)
tcatgggaactggggcactgtgc (r)
2 543-1252 tcatctccagcggctctgt (f)
ttacatgcagccaaactcgtc (r)
3 985-1560 tgagctagactgtggccccc (f)
tcaggggcctgctcgttgtgg (r)
Construction of transfer vectors Table 1. Primers used for introduction of translation stop
Three transfer vectors w ere codons into sequences of human perlecan. All sequences 
constructed designated pVL1393-P1 are in 5' to 3' direction; underlined residue indicates mismatch 
(encoding am ino acids 1-196 o f  in mutagenic primer. Nucleotide numbering corresponds to 
hum an perlecan), pV L1393-P12a the cDNA sequence available from GenBank by accession 
(am ino acids 1-404) and pV L1393- number X62515 [1].
P12ab (1-506). The initiation codon is 
supplied by the insert, and the open 
reading fram e is placed out o f the 
original polyhedrin reading fram e to 
avoid aberrant initiation. To introduce 
translation term ination codons, 
m utagenic prim ers (Table 1) w ere 
used w ith clones H pe2 and P5 [1] as
tem plate and V ent® polym erase. The PC R  products w ere inserted into the SrfI cloning site o f 
pC R -Script according to  the suppliers protocol. Transform ants (prepared according to  [27]) 
w ere screened to contain the unique B am H I-site at the 5'-, and the N otI-site at the 3'- 
orientation from  the cD N A  fragm ents. The cD N A  sequences w ere checked com pletely 
by sequencing (ABI apparatus type 37717) The BamHI-NotI fragment containing PCR product 1 (Table 
1) was subcloned into pVL1393, yielding pVL1393-P1. The Xcml-Notl fragment containing the major 
3' part of PCR product 2 (Table 1) was subcloned into pVL1393-P1, yielding pVL1393-P12a. The 
DralH-Notl fragment containing the major 3' part of PCR product 3 (Table 1) was subcloned into 
pVL1393-P12a, yielding pVL1393-P12ab.
Tissue culture and isolation of recombinant baculoviruses
The general tissue culture m ethods w ere adapted from  [23]. Spodop tera frug iperda  SF21 cells 
w ere cultured at 27°C in TN M -FH  m edium  supplem ented w ith 10% fetal bovine serum. 
Except w here otherw ise stated, m onolayer cultures w ere used. R ecom binant viruses w ere 
derived from  BacPA K 6 by liposom e-m ediated cotransfection. The culture supernatant w as 
harvested 4 days after cotransfection and individual plaques w ere obtained by a soft-agar 
overlay method. W ell-isolated plaques w ere picked and left to diffuse overnight in 500 |il 
norm al m edium  at 4°C. Pure plaques w ere propagated by infecting 5 105 SF21 cells in a 35 
m m  dish w ith 100 |il o f  the plaque pick and harvesting the m edium  4 days after infection. For 
further propagation o f  baculovirus strains during a m axim um  o f  tw o passages, suspension 
cultures o f  50 ml w ere inoculated w ith 5 105 cells/m l and incubated until logarithm ic growth. 
Cells w ere then infected w ith a m ultiplicity o f  0.1 and harvested 96 h post infection, at which 
tim e the cell densities had reached a plateau o f about 2 1 0 6 cells/m l. Cell densities w ere 
m onitored in a hem ocytom eter (Burker). V irus stocks w ere titrated by plaque assays. For 
expression o f  recom binant proteins, cells w ere infected at sem iconfluence w ith a m ultiplicity 
o f  5 and harvested at 50-60 h post infection.
Genome analysis of baculovirus expression vectors
Independently isolated baculovirus strains w ere analyzed for correct integration locus and 
purity. Baculovirus genom ic D N A  w as isolated from  non-occluded virions as described [28]. 
Shortly, the m edium  w as cleared from  cells (15 m in at 300x g) and non-occluded virions w ere 
collected by ultracentrifugation for 1 h at 100,000x g. The virions w ere incubated overnight at 
37°C in presence o f  0.1 m g/m l proteinase K  and 1% SDS. The D N A  w as further purified 
follow ing standard procedures [29] and stored at 4°C. A fter endonuclease P s tI  digestion, 1 |ig 
o f  fragm ented virus D N A  w as applied to  each lane o f a 0.35%  agarose gel and separated 
overnight at 4°C. Southern b lot transfer to  a H ybond N+ m em brane w as perform ed overnight 
by capillary force. The filter w as hybridized at 42°C w ith a 520 bp cD N A  fragm ent 
hom ologous to  dom ain I o f  hum an perlecan (dom ain I), and w ashed under m edium  stringent
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conditions (75 m M  N aCl containing 7.5 m M  sodium  citrate and 0.1%  SDS, pH  7.0 at 42°C). 
For autoradiography, a photographic film  w as developed after 4 days exposure.
[35S]methionine incorporation and autoradiography
This procedure w as adapted from  ref. [23]. A  suspension culture o f  insect cells w as grow n to 
a cell density o f 5 105 cells/m l and infected w ith  recom binant baculovirus w ith a m ultiplicity 
o f  10. Forty-eight h after infection, 1.5 ml o f  cell suspension w as centrifuged (5 m in at 500x 
g, 24°C) and the cells w ere resuspended in 1.5 ml o f  m ethionine-deficient G race’s medium. 
The cells w ere further incubated for 60 min; all incubations w ere at 27°C under frequent 
inversion. The cells w ere collected and incubated for 60 m in in 1.5 ml o f  m ethionine-deficient 
G race’s m edium  supplem ented w ith 50 |iC i/m l [35S]m ethionine (specific activity >1000 
Ci/m m ol). The labeling m ixture w as rem oved and cells w ere w ashed tw ice w ith NaCl/P; (140 
m M  NaCl, 2.7 m M  KCl, 10 m M  N a2H PO 4, 1.8 m M  K H 2P O 4, pH  7.5). Finally, the cells w ere 
incubated for 90 m in in 200 |il N aC l/P; and centrifuged (5 m in 500x g). The supernatant was 
stored at -80°C. D ue to  the host shut-off in the baculovirus infection cycle, the supernatant 
contains a lim ited set o f  extracellular proteins, synthesized at 50 h post infection and labeled 
w ith [35S]m ethionine. Proteins w ere analyzed by SD S-PA G E (12.5 % ) and processed for 
autoradiography w ith E N 3H A N C E according to the m anufacturer’s instructions.
Size exclusion and ion exchange chromatography
For size exclusion chrom atography, a Superose 12 colum n (height 30 cm, Vt =23.7 ml, V 0= 
7.6 ml as determ ined for blue dextran-2000) w as calibrated w ith m olecular w eight m arker 
proteins and contained 208 plates average in the range o f  14 to  440 kDa. Sam ple volum e w as 
200 |il, flow  rate 0.5 m l/m in and elution w as perform ed in N aC l/P; containing 0.01%  Brij35 
and 0.01%  N aN 3.
For ion exchange chrom atography, sam ple volum es varying from  200 |il to 10 ml w ere 
applied to  a M onoQ  colum n w ith a bed volum e o f  1 ml. A  linear gradient from  0 to  1 M  NaCl 
in 10 m M  Tris (pH  6.8), 0.1%  Z w ittergent 3 -1 2  and 0.01%  N aN 3 w as used for elution w ith a 
flow  rate o f  0.5 m l/min. A liquots o f  each sam ple w ere dissolved in U ltim aG old scintillation 
m ix (Packard) and counted for 4 m in in a liquid scintillation analyzer.
Chondroitinase ABC treatment
Sam ples w ere incubated w ith 0.5 U /m l chondroitinase ABC (protease-free) for 16 h at 37°C 
in 0.1 M  Tris (pH  8.0) containing 0.025%  N aN 3. Control reactions w ere included containing
0.1 m g/m l chondroitin sulfate in presence and absence o f  chondroitinase ABC. The efficiency 
o f  the deglycosylation w as m easured by a 1,9-dim ethyl-m ethylene blue assay [30].
Immunological methods
For im m unoblotting and E L ISA  procedures w e follow ed standard m ethods [31] using 95J10, 
a perlecan-specific m Ab that w as previously raised in recom binant E. coli (paper in 
preparation). In sum m ary, recom binant perlecan-(24-404)-fragm ent w as produced in the 
bacterial pG EX  expression system  [32] and treated w ith throm bin. The recom binant fragm ent 
w as used for production o f  m A bs in m ice according to  previously described procedures [33]. 
H ybridom a cell lines w ere screened in ELISA  against the recom binant fusion protein and in 
indirect im m unofluorescence studies on hum an kidney cortex sections. The glom erular 
staining pattern observed w ith 95J10 m atched the results obtained w ith the anti-perlecan mAb 
7B5 [3]. Im m unological detection w as based on chem ilum inescent (im m unoblotting) or 
chrom ogenic (ELISA ) reactions driven by horse radish peroxidase.
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Basic FGF binding assay
Quantities o f  24, 100, 250 and 500 ng bFG F and B SA  w ere dissolved in 100 |il 50 m M  
carbonate buffer (pH  9.6) and transferred into 96-wells plates incubated overnight at 4°C for 
coating. A fter thorough w ashing, the w ells w ere incubated w ith 2.5 |ig o f  the perlecan-(1 - 
404)-fragm ent in NaCl/P; containing 3%  BSA, partially purified by exchange chrom atography 
(fractions eluted betw een 0.4 and 0.6 M  N aC l from  M onoQ). A fter thorough w ashing with 
NaCl/Pi, bound (1-404)-fragm ent w as detected as in the above described ELISA.
Additional methods
G lycosam inoglycan electrophoresis w as perform ed according to  [34]. Protein concentrations 
w ere m easured by the Bradford m ethod as BSA.
R e s u l t s
Isolation of recombinant baculovirus strains
To allow  expression o f  perlecan fragm ents in Spodoptera  fru g ip erd a  SF21 insect cells, three 
recom binant baculovirus strains w ere generated as follows. Truncated cD N A  fragm ents w ere 
prepared encoding am ino acids (1 -196), (1 -404 ) and (1 -506 ) o f  hum an perlecan. The cDN A 
fragm ents w ere inserted into the transfer vector pVL1393. The integrity o f  the cDN A 
constructs w as confirm ed by restriction enzym e analysis and the com plete coding regions and 
non-translated borders w ere verified by sequence analysis.
In the pV L1393-derived transfer vectors, the cD N A  inserts are flanked by regions that are 
hom ologous to A cN PV  sequences surrounding the polyhedrin gene. These flanking sequences 
allow  hom ologous recom bination, resulting in substitution o f  the w ildtype polyhedrin gene by 
the cD N A  constructs o f  interest. To counterselect against non-recom binant virus replication, 
w e em ployed a parental virus specially designed for this purpose, BacPA K6. A  soft-agar 
overlay plaque assay yielded only polyhedrin-negative plaques. W ell-isolated plaques w ere 
picked to  isolate recom binant baculovirus strains. PC R  am plification techniques w ere used for 
a prim ary screening o f  the virus strains (data not shown).
For m ore thorough investigation, the baculovirus isolates w ere propagated and genom ic D N A  
(134 kb circular) w as purified and digested w ith P s tI  endonuclease (Figure 1A). The P s tI  
digestion pattern can discrim inate betw een different loci o f  integration because an additional 
restriction site is introduced jux taposing  the inserted cD N A  sequence. Consequently, the 
polyhedrin-containing P s tI  fragm ent (arrow  a in Figure 1A) o f  w ildtype A cN PV  is further 
degraded into sm aller products in recom binant strains (arrow  b in Figure 1A). The observed 
fragm ent sizes w ere in full concordance w ith the expected values, calculated from  the 
nucleotide sequences o f A cN PV  (G enB ank #L22858) and o f  the introduced cDN A 
constructs. Furtherm ore, the presence o f  perlecan cD N A  in these subfragm ents w as 
dem onstrated by Southern blotting w ith a probe hom ologous to  an internal fragm ent o f 
dom ain I (arrow  b in Figure 1B). From  these data w e conclude that perlecan cD N A  constructs 
encoding (1-196)-, (1 -404)- and (1-506)-fragm ent w ere successfully introduced into the 
polyhedrin locus o f the baculovirus genome.
Transcription and expression of perlecan fragments
To confirm  the presence o f  recom binant m RNA , a N orthern hybridization w as perform ed 
w ith a cD N A  probe specific for dom ain I o f  hum an perlecan (data not shown). N o m R N A  w as 
detected in w ildtype, w hereas high levels w ere produced in recom binant baculovirus-infected 
SF21 cells. As discussed below , the size o f  the m R N A  observed for the perlecan-(1-196)- 
fragm ent w as substantially larger than expected (approxim ately 4 kb). Transcription w as 
observed at 36 and 64 h post infection but not at 0 or 12 h, w hich corresponds w ith the
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Figure 1 A) Restriction enzyme analysis of wildtype (lane 1) and recombinant (lanes 2-4) baculovirus 
strains and B) Southern hybridization confirming the insertion of perlecan cDNA constructs into the 
polyhedrin locus of the baculovirus genome. Lane 1: wildtype AcNPV; lane 2: recombinant AcNPV encoding 
perlecan-(1 196)-polypeptide; lane 3: AcNPV encoding perlecan-(1 404)-polypeptide; lane 4: AcNPV encoding 
perlecan-(1 506)-polypeptide; lane 5: linearized pVL1393-P1 plasmid DNA as positive control for hybridization. 
Genomic DNA was digested with PstI and fragments were separated by electrophoresis on a 0.35% agarose 
gel (A). The same gel was used for Southern blot transfer and hybridization with a domain I-specific probe 
against human perlecan (B). Arrows indicate (a) wildtype Pstl-D fragment carrying the polyhedrin-locus; (b) 
recombinant PstI fragments carrying the inserted cDNA constructs.
characteristics o f  late-phase baculovirus prom oters.
Production o f  the recom binant perlecan fragm ents w as studied by m etabolic labeling with 
[35S]m ethionine. B est results w ere obtained by labeling at 50 h post infection, w hen only a 
lim ited set o f  virus-encoded proteins is secreted from  baculovirus-infected cell cultures. The 
supernatant w as harvested and analyzed w ithout further m anipulation by SD S-PAG E and 
autoradiography (Figure 2). Com parison o f  recom binant and w ildtype baculovirus-encoded 
proteins revealed the presence o f  recom binant perlecan-(1-404)-fragm ent and -(1 -506)- 
fragm ent. In contrast, no additional band w as visible in case o f  the (1-196)-fragm ent. The (1­
404)- and (1-506)-fragm ent m igrate in SD S-PAG E as m olecules o f  approxim ately 53 and 62 
kD a respectively, as estim ated by standard curve interpolation. Based on the prim ary amino 
acid sequences, m olecular m asses o f the core proteins are predicted as 42 and 53 kD a 
respectively, taking rem oval o f  the signal peptides into account. To investigate the integrity o f 
the tw o produced proteins, im m unological studies w ere perform ed w ith the m Ab 95J10 
(raised against dom ain I and IIa o f  hum an perlecan expressed in E. coli). W estern b lo t analysis
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Figure 2. Extracellular protein production by baculovirus- 
infected insect cells after metabolic labeling with 
[35S]methionine. Spodoptera frugiperda SF21 cells were 
infected with wildtype AcNPV (lane 1), AcNPV encoding 
perlecan-(1 196)-fragment (lane 2), (1 404)-fragment (lane 3), 
or (1 506)-fragment (lane 4). Arrows a and b indicate (1 506)- 
and (1 404)-fragment respectively. Molecular mass markers are 
indicated on the left. The labeled supernatants were harvested 
and analyzed by SDS-PAGE (12.5%) and autoradiography.
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Figure 3. Western blot detection of 
recombinant perlecan fragments using 
mAb 95J10. SF21 cells were infected with 
wildtype AcNPV (lane 1), AcNPV encoding 
perlecan-(1 404)-fragment (lane 2) or (1 
506)-fragment (lane 3). Marker proteins are 
indicated on the left.
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showed that the (1 -404)- and (1-506)-fragm ent are im m unologically  related to  hum an 
perlecan (Figure 3). As a control, the 95J10 epitope w as not detected in insect cells infected 
w ith w ildtype A cN PV  (lane 1) or recom binant A cN PV  encoding the (1-196)-fragm ent (not 
shown). C onsistent results w ere found in EL ISA  (data not shown). The obtained yield w as 
betw een 1 and 5 m g o f  recom binant protein per 109 cells.
Purification of recombinant perlecan fragments
[35S]m ethionine labeled supernatants (Figure 2, lane 3 and 4) w ere used to  investigate the 
behavior o f  the (1 -404)- and (1-506)-fragm ent on chrom atographic media. For size exclusion 
chrom atography, a Superose 12 colum n w as utilized. Individual fractions w ere collected and 
aliquots w ere separated by SDS-PAGE. R adioactive proteins w ere visualized by 
autoradiography (Figure 4). Both the (1 -404)- and (1-506)-fragm ent (not shown) eluted at 
K av = 0 .23-0 .29 , w hereas these bands did not appear in case o f  the (1-196)-fragm ent or after 
infection w ith w ildtype A cN PV  (data not shown).
A n essentially pure fraction o f  [35S]m ethionine labeled (1 -404)-fragm ent obtained by gel 
perm eation (Figure 4, lane 2) w as applied onto a M onoQ  anion exchange colum n to study its 
binding characteristics. The recom binant protein strongly bound to  the m atrix at pH  6.8. A  
linear salt gradient w as used for elution and radioactivity o f  the fractions w as quantified by 
liquid scintillation counting (Figure 5). The protein eluted from  the colum n at a concentration 
o f  0.4 to  0.5 M  NaCl. A  sim ilar procedure w as follow ed w ith non-radioactive (1 -404)- 
fragm ent, using im m unological detection procedures (Figure 6). In this case, the (1 -404)- 
fragm ent w as incubated w ith D E A E Sepharose (a m atrix carrying the same active groups as 
M onoQ). A fter elution w ith a N aC l gradient increasing stepw ise from  0.0 to  1.0 M , all 
fractions w ere analyzed by an EL ISA  procedure using 95J10. C onsistent w ith the previous 
results, the m ajority o f  the protein w as detected in the fraction containing 0.4 M  NaCl.
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Figure 4. Purification of the perlecan-(1-404)-fragment by size 
exclusion chromatography. Crude culture supernatant obtained after 
metabolic labeling with [35S]methionine (lane 1) was applied onto a 
Superose 12 column under non-denaturing conditions. Individual fractions 
(lanes 2 9) were analyzed by 12.5% SDS-PAGE and autoradiography. Kav 
values are noted for each fraction. The arrow indicates the (1 404)- 
fragment. Molecular mass markers are indicated on the right ( MultiMark 
prestained marker).
Characterization of glycosaminoglycan residues
The binding characteristics o f  the (1 -404)-fragm ent to  anion exchange beads suggest that 
exposed negative charges are present on the m olecule. W e therefore studied the glycosylation 
characteristics o f  the (1-404)-fragm ent produced by baculovirus-infected insect cells. A fter 
treatm ent w ith chondroitinase ABC (protease-free), its b inding capacity to  D E A E Sepharose 
w as abolished (Figure 6) and the protein w as found in the flow -through. Further evidence for
Fraction num ber
Figure 5. Anion exchange chromatography of 
perlecan-(1 404)-fragment. [35S]methionine 
labeled (1 404)-fragment, purified by size 
exclusion chromatography as shown in Figure 4 
(lane 2), was applied onto a MonoQ anion 
exchange column. The radioactive protein strongly 
bound to the matrix at pH 6.8 and eluted in a linear 
NaCl gradient at a concentration of 0.4-0.5 M.
the presence o f  chondroitin sulfate residues on 
the (1-404)-fragm ent is shown in Figure 7. 
G lycosam inoglycans w ere extracted from  the 
recom binant proteoglycan by alkaline borohy- 
dride treatm ent and analyzed by agarose gel 
electrophoresis. A  single band w as visible that 
co-m igrated w ith chondroitin sulfate. The 
above data suggest that the (1-404)-fragm ent 
produced by recom binant AcN PV, is glycosyl­
ated w ith one or m ore chondroitin sulfate 
residues. The proteoglycan-like properties o f 
the (1-404)-fragm ent conform  w ith its ability 
to bind basic fibroblast grow th factor (Table 2). 
This w as dem onstrated by coating increasing 
quantities o f  bFG F on ELISA  plates, 
incubating w ith culture supernatant o f 
baculovirus-infected insect cells, and 
determ ining the am ount o f  im m obilized (1 -  
404)-fragm ent in an ELISA -like procedure 
w ith m Ab 95J10. This interaction betw een the
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Figure 6. Ion exchange chromatography of 
intact and chondroitinase ABC-digested 
perlecan-(1 404)-fragment. Closed circles: 
intact (1 404)-fragment; open circles: (1 404)- 
fragment digested with protease-free 
chondroitinase ABC. The proteins were eluted 
from DEAE-Sepharose beads using a stepwize 
NaCl gradient. Aliquots of each fraction were 
analyzed in duplo by an ELISA using the 
perlecan-specific mAb 95J10. The relative 
concentrations of (1 404)-fragment are given in 
absorbance units at 492 nm.
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Figure 7. Characterization of glycosaminoglycans 
extracted from recombinant perlecan-(1 404)- 
fragment. Lanes 1: 5 ng marker glycosaminoglycans 
containing heparan sulfate (HS), dermatan sulfate (DS) 
and chondroitin sulfate (CS). Lanes 2 and 3: 
glycosaminoglycans extracted from recombinant (1 404)- 
fragment (five-fold diluted and undiluted, respectively). 
Glycosaminoglycans were separated by agarose gel 
electrophoresis and stained with combined Azure A / 
silver [34].
(1-404)-fragm ent and bFG F is inhibited in presence o f  free glycosam inoglycans, heparan 
sulfate being a stronger com petitor than chondroitin sulfate (Table 3). This is not surprising 
since bFG F has been reported to  have a higher affinity for heparan sulfate than for chondroitin 
sulfate. The results indicate that the binding o f  the (1-404)-fragm ent to  im m obilized bFG F is 
m ediated by the glycosam inoglycan m oieties o f  the recom binant proteoglycan.
D is c u s s io n
No recombinant protein is synthesized by BEVs encoding the perlecan-(1 196)-fragment
The inability o f  A cN PV -infected insect cells to  produce the recom binant perlecan-(1-196)- 
fragm ent is poorly understood. The possibility o f  a fram e shift or point m utation in the cDN A 
construct w as excluded by sequence analysis. Baculoviruses carrying the cD N A  construct 
encoding the (1-196)-fragm ent w ere convincingly shown to contain the insert correctly in the 
polyhedrin locus, and the size o f  the cD N A  fragm ent w as confirm ed by PCR. These results 
clearly indicate that the recom binant virus offers an intact open reading fram e. Transcription 
analysis by N orthern blotting showed that an unexpectedly long m R N A  (approx. 4 kb) was 
present, induced betw een 12 and 36 h post-infection. H ow ever, no recom binant protein was 
produced.
One possible explanation for the deficiency in recom binant (1-196)-fragm ent production is 
the inefficient use o f  the polyadenylation signal. In late phases o f  baculovirus infection, 
transcription is m ediated by a virus-encoded R N A  polym erase [35], and not all factors that 
influence term ination o f transcription by this enzym e are know n [36]. For the A cN PV  
polyhedrin gene, m ultiple transcripts (1.2, 3.4 and 4.9 kb in size) have been observed w ith a 
com m on 5' end [37, 38]. Therefore the elongated m R N A  might result from “read-through” 
transcription, and we speculate that this may cause instability of the mRNA.
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Table 2. The recombinant perlecan-(1-404)- 
fragment binds to immobilized bFGF. Increasing 
quantities of bFGF or BSA were coated on ELISA 
plates. Wells were incubated with supernatant from 
(1-404)-fragment-producing cells, washed, and 
bound fragment was measured by ELISA with mAb 
95J10, given in absorption units at 492 nm.
Amount coated BSA bFGF 
(ng)______________ (A492) (A492)
Q Q.225 Q.225
24 Q.226 Q.2Q2
1QQ Q.225 Q.639
25Q Q.225 1.69Q
5QQ Q.226 3.254
A nother reason for the lack o f  (1-196)- 
expression could be the activity o f  an additional 
late-phase prom oter positioned approxim ately 2 
kb dow nstream  o f  the polyhedrin coding 
sequence [37]. This prom oter drives the 
transcription o f  a 3.2 kb m R N A  in the opposite 
orientation, com prising the antisense strand o f 
the inserted cDNA. Since the probe used for 
N orthern hybridization w as double-stranded, the 
observed signal m ay represent the “ anti sense” 
transcript. In w ildtype AcNPV, the level o f  this 
transcript is dow n-regulated by transcription 
from  the polyhedrin prom oter [37]. Possibly the 
consensus generated in this B E V  influences the 
balance betw een sense and antisense 
transcription, in favor o f  the antisense product.
Successful expression and purification of (1 
404)- and (1 506)-fragment
The recom binant perlecan-(1-404)-fragm ent 
and (1-506)-fragm ent, com prising dom ains I 
and II o f  hum an perlecan, w ere successfully 
synthesized in the baculovirus expression 
system. This w as shown by m etabolic labeling 
(Figure 2) and im m unological assays w ith the 
m Ab 95J10 (Figure 3). The signal peptide 
(originating from  hum an perlecan cDN A) was 
recognized and the proteins w ere transported to 
the extracellular com partm ent. D uring 
electrophoresis on a 12.5% SD S-polyacryla- 
m ide gel, the [35S]m ethionine labeled recom bi­
nant proteins m igrate as 53 and 62 kD a 
respectively, w hich is 10 kD a larger than the calculated m ass o f  their core proteins. As argued 
below , this difference can be explained by post-translational m odifications, since the 
electrophoretic m obility o f  glycosylated proteins does not correlate to  m olecular m ass in a 
linear logarithm ic m anner. In contrast, elution on a gel perm eation colum n calibrated w ith 
g lobular m arker proteins takes place at K av = 0 .23-0 .26  w hich coincides w ith an apparent 
m ass o f  180-250 kDa. This discrepancy illustrates that m olecular w eight determ inations based 
on relative m obility should be considered very carefully, especially w hen proteoglycans are 
involved. The yield o f  betw een 1 and 5 m g recom binant protein per 109 cells is in agreem ent 
w ith the results obtained w ith other recom binant proteins [23].
Table S. Free glycosaminoglycans compete for 
binding of perlecan-(1-404)-fragment to bFGF. A
constant amount of bFGF (250 ng) was coated on 
ELISA plates. Binding of (1-404)-fragment was 
assayed in presence of increasing concentrations 
of free HS or CS. Bound fragment was measured 
as absorbance units at 492 nm.
Competitor
(MQlml)
HS
(A492)
CS
(A492)
Q 1.69Q 1.69Q
Q.25 Q.675 1.564
1 Q.159 1.149
5 Q.Q58 Q.573
25 Q.Q66 Q.159
1QQ Q.Q23 Q.213
Identification of glycosaminoglycans as chondroitin sulfate
The presence o f  chondroitin sulfate glycosam inoglycans on baculovirus-derived perlecan -(1 - 
404)-fragm ent is supported by the follow ing findings. Firstly, the (1-404)-fragm ent strongly 
binds to  the anion exchange m atrices D EA E-Sepharose CL-4B and M onoQ. The observed 
elution pattern resem bles the characteristic behavior o f  proteoglycans previously isolated 
from  basem ent m em branes [39, 40]. Secondly, the binding capacity o f the (1-404)-fragm ent 
to  anion exchange colum ns is abolished by chondroitinase A BC treatm ent. Furtherm ore, 
glycosam inoglycans isolated from  the (1-404)-fragm ent w ere convincingly identified as 
chondroitin sulfate (Figure 7) by agarose gel electrophoresis. Finally, the (1-404)-fragm ent
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binds to  im m obilized bFG F (Table 2). This interaction is inhibited in presence o f  free 
glycosam inoglycans (Table 3), suggesting that b inding o f the (1-404)-fragm ent is m ediated 
through its side chains.
A lthough the interaction betw een bFG F and the (1-404)-fragm ent provides evidence for 
attachm ent o f  glycosam inoglycans, it can hardly be com pared to  the binding event that occurs 
in the basem ent m em brane. The binding o f  bFG F in  vivo  is know n to require specific 
oligosaccharide sequences that are present solely in heparan sulfate and heparin [13, 41], 
involving a dissociation constant o f  10-8 to  10-9 M  [16]. In our ELISA -based binding assay the 
affinity m ust be lower, since free chondroitin sulfate acts as a potent com petitor. W e therefore 
conclude that baculovirus-derived (1-404)-fragm ent binds to im m obilized bFG F w ith 
relatively low  affinity through its chondroitin sulfate chains.
The appearance o f chondroitin sulfate residues on the perlecan-(1-404)-fragm ent is 
unexpected since the predom inant in  vivo  form  o f perlecan carries heparan sulfate chains. 
Some efforts have been m ade to  elucidate the factors influencing glycosylation o f 
proteoglycans. The com position o f  glycosam inoglycan chains has been found to  depend 
firstly on the am ino acid sequence o f  the core protein [42]. The prim ary structure o f  perlecan 
dom ain I perm its both attachm ent o f  heparan sulfate and chondroitin sulfate [11]. A  second 
determ inant for glycosylation is the cell type in w hich the proteoglycan is synthesized. H ybrid 
heparan/chondroitin sulfate form s o f  perlecan have been observed in Engelbreth-H olm - 
Swarm  tum or cells [43], in cultured hum an glom erular visceral epithelial cells [44] and 
chinese ham ster ovary cells [11]. D espite these data, the exact determ inants for the type o f 
glycosylation rem ain unclear.
Application of recombinant fragments of human perlecan
Expression o f  perlecan fragm ents in the baculovirus system  provides an im portant tool to 
study the functions o f  this proteoglycan in a dom ain-specific manner. In the present study we 
described the expression and purification o f  perlecan-(1-404)- and -(1-506)-fragm ent, 
com prising the tw o N -term inal dom ains o f  perlecan. G iven the spatial separation o f the 
structural dom ains as visualized by electron m icroscopy [45], it is likely that the (1 -506)- 
fragm ent will have identical properties as the corresponding globule in the w hole perlecan 
m olecule. The included dom ains are likely candidates to play a role in lipoprotein 
m etabolism . D om ain II o f perlecan shows strong hom ology w ith the ligand binding dom ain o f 
the low -density lipoprotein receptor [1, 2]. A  synergic action has been proposed for the 
com bined binding o f  lipoprotein together w ith lipoprotein lipase, a com plex that could be 
stabilized by a favorable configuration o f  heparan sulfate in the proxim ity o f  the low -density 
lipoprotein receptor like dom ain [20, 22]. These and other hypothetical functions o f  the N - 
term inal core dom ains o f  perlecan will be assessed in the future.
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Lipoprotein binding by the core protein of human perlecan
chapter three S u m m a r y  Perlecan is a  proteoglycan of virtually all extracellular 
m atrices including those  of the vascular system . Domain I of 
perlecan may be glycosylated with heparan  sulfate (HS), chondro­
itin sulfate or derm atan sulfate. The primary structure of domain II is 
similar to that of the low-density lipoprotein receptor. In this study 
w e p resen t in vitro evidence for a  possible role of perlecan in 
lipoprotein adhesion  to the extracellular matrix. Two recom binant 
fragm ents of hum an perlecan (one comprising domain I and IIa, the 
o ther dom ain I, IIa and IIb) w ere produced in the y east Pichia  
p a sto ris  at high level (G.5 and 2.4 g/l respectively). The fragm ents 
w ere devoid of glycosam inoglycans a s  shown by anion exchange 
chrom atography and insensitivity to heparitinase and chondroit- 
inase ABC. Both fragm ents and a  similar recom binant protein 
produced in E. coli show ed affinity for the hum an lipoproteins VLDL 
and IDL (together in one fraction), LDL and Lp(a), w hereas HDL 
w as not bound. Addition of exogenous HS did not significantly 
influence the interaction. In contrast to the glycosam inoglycan-free 
perlecan fragm ents, a  similar fragm ent produced a s  a  chondroitin 
sulfate proteoglycan by insect cells w as not functional in lipoprotein 
binding. The results sug g est that the core protein of hum an perle­
can functions a s  a  lipoprotein binding site in the extracellular matrix, 
and that this activity may be m odulated by its glycosylation char­
acteristics.
In t r o d u c t io n
Heparan sulfate proteoglycans of the cell surface are essential factors in receptor-mediated 
internalization of lipoprotein particles. Internalization by the low-density lipoprotein (LDL) 
receptor requires a dual interaction of apolipoprotein B-100 (apoB-100) with HS and the 
receptor. Both interactions were localized to site B of apoB-100 (residues 3359-3369), which 
is not present in apo-B48 [1,2]. In analogy, the internalization of remnant lipoproteins 
requires a dual binding of apolipoprotein E to HS and the LDL receptor related protein (LRP) 
[3]. Lipoproteins also bind to the extracellular matrix, where they also associate with glyco­
saminoglycans [4-6]. However, the participation of core protein structures in this process has 
not been described yet.
Perlecan is a widely expressed extracellular proteoglycan that is present in all vascular 
basement membranes [7]. The core protein of human perlecan has a molecular mass of 467 
kDa and is composed of five functional domains [8,9]. Domain I (residues 24-196) offers 
three sites for glycosaminoglycan attachment [10]. Despite the designation of perlecan as a 
heparan sulfate (HS) proteoglycan, this domain may also be glycosylated with other glycosa­
minoglycans such as chondroitin sulfate and dermatan sulfate [11-14]. The type of glycosyla­
tion may importantly alter the functional properties of perlecan. For example, the angiogenic 
and mitogenic activity of perlecan depends on the activation of fibroblast growth factors by 
interaction with HS residues [15,16]. Also lipoprotein lipase was shown to bind HS [17,18]. 
For a more complete survey of the many functions of HS, several excellent reviews are 
available [19-22]. Domain IIa (residues 197-404) is similar in primary structure to the apoB- 
100 binding site of the low-density lipoprotein (LDL) receptor [8,9]. The LDL receptor-like
T o Index
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domain is flanked on the C-terminal side by a single Ig-like loop, designated domain IIb 
(residues 405-506). This loop is similar to the 21 Ig-like repeats that occur in domain IV.
The presence of the LDL receptor-like domain led us to hypothesize that the lipoprotein 
binding sites in the extracellular matrix might reside on perlecan. Here, we tested this 
hypothesis using recombinant proteins comprising domains I and II of human perlecan. To 
take a possible contribution of domain IIb into account, we produced different recombinant 
constructs that either excluded or included this Ig-like loop. In addition, we compare recom­
binant proteins produced by different expression systems to reveal functional differences 
induced by post-translational modifications. The results suggest that perlecan may be a 
functional binding site for lipoproteins in the extracellular matrix.
M a t e r ia l s  a n d  m e t h o d s  
Antibodies
Monoclonal antibody 95J10 was raised against human perlecan-(24-404)-fragment produced 
as a fusion protein with glutathione-S-transferase in Escherichia coli [23]. This antibody does 
not cross-react with perlecan from other species, other basement membrane components, 
glycosaminoglycans, glutathione-S-transferase or proteins from E. coli cell lysate [24].
Generation of recombinant Pichia pastoris clones
Recombinant yeast clones expressing perlecan fragments were generated following proce­
dures supplied with the Pichia pastoris  expression kit (Invitrogen, Leek, The Netherlands). 
Perlecan cDNA fragments were excised from the plasmids pVL1393-P12a and pVL1393- 
P12ab [25]. The plasmids were digested with NcoI, treated with the Klenow fragment of DNA 
polymerase I, purified and subsequently NotI-digested. The two fragments (1.2 and 1.5 kb) 
were ligated into the SnaBI and NotI sites of the pPIC9K vector (Invitrogen) [26]. The 
resulting vectors pPIC9K-P12a and pPIC9K-P12ab were transformed into the E. coli strain 
DH5a for propagation. The integrity of the plasmids was confirmed by restriction enzyme 
analysis and by sequencing on a ABI377-type automated sequence analyzer (ABI Prism). The 
plasmids were linearized by digestion with SalI and electroporated into P. pastoris  GS115 
spheroblasts. After integration of the expression cassette into the P. pastoris  genome, 
recombinant colonies were selected by growth on histidine-deficient media. Clones containing 
multiple copies of the expression cassette were identified by determining the maximum 
concentration of G418 allowing growth [26].
Characterization of recombinant fragments produced in P. pastoris
For expression of recombinant perlecan-(24-404)-fragment and perlecan-(24-506)-fragment 
the selected clones were grown at 30°C in BMMY medium (86.8 mM KH2PO4, 13.2 mM 
K2HPO4, 20 g/l peptone, 13.4 g/l yeast nitrogen base, 10 g/l yeast extract, 0.5 % methanol and
0.4 mg/l biotin, pH 6.0) while shaking at 225 rpm. Alternative media used for optimization 
were BMM (86.8 mM KH2PO4, 13.2 mM K2HPO4, 13.4 g/l yeast nitrogen base, 0.5 % 
methanol, 0.4 mg/l biotin, pH 6.0) and MM (13.4 g/l yeast nitrogen base, 0.5 % methanol, 0.4 
mg/l biotin, pH 6.0). Medium was harvested after 0, 5, 20, 28, 44, 51, 72 or 100 h, centrifuged 
for 3 min at 10,000 x g and stored at -80°C until analysis.
Ion exchange chromatography was performed using 1-ml columns of DEAE Sepharose 
(Pharmacia) with 50 mM Tris pH 7.0 as equilibration and wash buffer. For elution, a gradual 
increase of NaCl to a final concentration of 2 M was applied. All fractions were analyzed for 
presence of recombinant fragments by dot blotting. To this end, 1 |il of each supernatant was 
spotted onto a nitrocellulose membrane and allowed to air-dry. After blocking for 1 h with 3%
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BSA in PBS containing 0.1% Tween-20, the membrane was incubated for 1 h at 22°C with 
MAb 95J10 (10 |ig IgG/ml in PBS containing 1.5% BSA and 0.2% Tween-20), washed, and 
incubated for 1 h at 22°C with alkaline phosphatase-conjugated goat-anti-mouse serum 
(diluted 1:1000 in PBS containing 1.5% BSA and 0.2% Tween-20). The membrane was 
washed again and incubated in a solution of 0.33 mg/ml p-nitro blue tetrazolium, 0.165 mg/ml 
bromo-chloro-indolylphosphate, 100 mM NaCl, 5 mM MgCl2 and 100 mM TrisHCl pH 9.5 
for 20 min at 22°C.
To estimate produced yields, quantitative ELISA was performed as described elsewhere [24] 
except that serial two-fold dilutions of the yeast culture medium were coated for 16 h at 4°C, 
starting from a 20-fold dilution as the highest concentration of supernatant. A calibration 
curve with standard amounts of affinity purified bacterial fusion protein was taken on the 
same plate and all samples were analyzed in duplicate.
Recombinant perlecan fragments from other expression systems
Recombinant human perlecan-(24-404)-fragment was expressed as a fusion protein in E. coli 
and purified by affinity chromatography as described previously [23]. This protein did not 
contain glycosaminoglycan residues. The expression, characterization and purification of 
perlecan-(1-404)-fragment by baculovirus-infected insect cells was also described previously 
[25]. This fragment was secreted into the cell culture medium and contained chondroitin 
sulfate residues. For this study we harvested the culture medium at 64 h after infection of the 
insect cells.
Isolation of lipoproteins from human plasma
Lipoprotein fractions and lipoprotein-deficient serum (LPDS) were isolated by density- 
gradient ultracentrifugation as described [27]. In short, 2.0 ml of fresh human plasma was 
transferred to a SW40 polycarbonate ultracentrifuge tube and mixed with 0.770 g KBr. 
Subsequently, 2 ml of high-density buffer (2.65 M KBr, 195 mM NaCl and 0.27 mM EDTA, 
d=1.225 g/ml), 4 ml of medium-density buffer (1.14 M KBr, 84 mM NaCl and 0.27 mM 
EDTA, d=1.100 g/ml) and 4 ml of low-density buffer (0.27 mM EDTA; d=1.006 g/ml) were 
layered on top of the surface without mixing. After centrifugation for 22 h at 40,000 rpm and 
20°C in a SW40 swing-out rotor and a Beckmann L7-55 ultracentrifuge, individual lipopro­
tein fractions were aspirated: VLDL/IDL (together on the surface), LDL, Lp(a) and 
HDL/LPDS (together at the bottom). The bottom fraction was desalted by size exclusion 
chromatography using Sephadex G-10 resin (Pharmacia Biotech, Roosendaal, The Nether­
lands), the density adjusted to 1.21 g/ml, and HDL (d< 1.21) and LPDS (d>1.21) were 
separated by ultracentrifugation for 24 h at 20°C in a fixed-angle TFT 45.6 rotor. All lipo­
proteins except the VLDL/IDL fraction were dialyzed against 160 mM NaCl, 10 mM EDTA 
and 10 mM NaHPO4 (pH 7.4) during 24 h at 4°C. The samples were supplemented with 5% 
saccharose for cryoprotection and stored at -20°C until use. Protein content was assayed by 
the Lowry method with BSA as standard. Cholesterol was determined using the CHOD-PAP 
reagent (Boehringer Mannheim, Germany) following the manufacturer's instructions.
Glycosidase digestion
For chondroitinase treatment, culture media containing recombinant proteins from P. pastoris 
were added to two volumes of a 0.2 M TrisHCl buffer containing 0.05% NaN3 at pH 8.0. This 
mixture was incubated for 2 h at 37°C in presence of 0.3 U/ml chondroitinase ABC (Seika- 
gaku Corp., Tokyo, Japan). For heparitinase digestion, the recombinant proteins were 
dialyzed for 20 h at 4°C against heparitinase-buffer (0.1 M sodium acetate, 10 mM CaCl2, pH 
7.0). Heparitinase (Seikagaku) was added to a final concentration of 0.05 U/ml and the 
mixture was incubated for 3 h at 43°C. To monitor the reaction progress, 2 mg/ml HS (from
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bovine kidney, Sigma) was added to the dialysate and treated the same way. For application in 
lipoprotein binding studies, perlecan-(24-404)-fragment and perlecan-(24-506)-fragment 
were diluted in PBS to 60 and 80 |ig/ml respectively. The absence of proteolytic activity in 
these mixtures was ascertained by SDS-PAGE analysis before and after the incubation. 
Lipoproteins and LPDS were diluted to 125 |ig/ml protein in 0.1 M sodium acetate and 20 
mM CaCl2 (pH 7.0). One ml was incubated for 3 h at 43 °C with 10 mU heparitinase.
Determination of glycosaminoglycan content
To measure the glycosaminoglycan content, 400 |il of samples were mixed with 1 ml of 
Farndale's reagent (0.2% (w/v) sodium formiate, 0.2% (v/v) formic acid and 0.0016% (w/v) 
1,9-dimethyl-methylene blue in water, pH 3.5) [28]. The optical density was measured at 525 
nm. A calibration curve was constructed using 400 |il of HS standard dilutions (range 2.5 to
25 |ig/ml in heparitinase-buffer). Glycosaminoglycan concentrations were calculated by 
interpolation of a linear regression curve (correlation coefficient >0.998; n=20).
Lipoprotein binding studies
Lipoproteins were diluted to 25 |ig/ml on protein basis in coating buffer (50 mM carbonate, 
pH 9.6) and 100 |il was incubated for 16 h at 4°C in ELISA wells (Nunc maxisorp). The wells 
were then blocked for 30 min at 22°C with 10 mg/ml bovine serum albumin in coating buffer, 
washed twice with PBS, and incubated for 1 h at 37°C with 100 |il culture supernatant from 
the selected P. pastoris clone diluted in PBS to a final concentration of 60 |ig/ml (perlecan- 
(24-404)-fragment) and 80 |ig/ml (perlecan-(24-506)-fragment). In some cases heparitinase 
was added as described above. After washing 5 times with PBS, the wells were incubated for
1 h at 22°C with 95J10 (10 |ig IgG/ml in PBS), washed again 5 times, and further processed 
according to standard protocols [29] using a peroxidase-conjugated goat-anti-mouse antise­
rum (1:2500 in PBS containing 1%BSA, Dakopatts). The produced optical density was read at 
492 nm.
R e s u l t s
Optimization of expression of perlecan fragments in P. pastoris
Two fragments of human perlecan were expressed as recombinant proteins in the yeast P. 
pastoris. The first fragment comprised domain I and IIa of perlecan, including amino acids 
24-404. The second fragment comprised domain IIb in addition, including amino acids 24­
506. We will refer to these constructs as perlecan-(24-404)-fragment and perlecan-(24-506)- 
fragment respectively. The original signal sequence of human perlecan (amino acids 1-21) 
was replaced by a yeast signal sequence to induce secretion of the recombinant proteins into 
the culture medium.
To optimize the expression levels of both constructs, we characterized the recombinant yeast 
clones for the number of expression cassettes per cell. The cassette also contains a G418 
resistance marker, and the resistance towards increasing concentrations of G418 was previ­
ously demonstrated to correlate in a linear way with the amount of integrations. For 118 
clones containing the expression cassette for perlecan-(24-404)-fragment, 119 clones 
containing that for perlecan-(24-506)-fragment, and 48 clones containing the empty expres­
sion cassette, we measured the maximum concentration of G418 at which growth occurred. 
The results are listed in Table 1. Growth of the host strain was observed at a maximum 
concentration of 0.25 g/l G418. Five clones encoding the (24-404)-fragment and seven clones 
encoding the (24-506)-fragment that were able to grow in presence of 4.0 g/l G418 were 
selected for further examination.
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Table 1. Screening of P. pastoris clones fo r the number of integrated 
copies of the expression cassettes encoding A) perlecan-(24 404)- 
fragment, B) perlecan-(24 506)-fragment or C) the empty cassette as a 
control. The induced resistance towards G418 was used as a marker. For 
each concentration of G418 tested, the number of clones for which this was
a b c d e f g h
1 
2 
3
4
5
6
7
8
9
10 
11 
12
13
14
Figure 1. Influence of the time of harvest on the yield of recombinant ”  
perlecan fragments produced by P. pastoris. Perlecan-like immunore- 15 # 
activity was detected in 1-pl aliquots of supernatant from recombinant
clones spotted onto nitrocellulose membrane. Clones 1 5 encode the (24 404)-fragment, clones 6 12 encode 
the (24 506)-fragment, and clones 13 14 carry the empty expression cassette as a negative control. On the 
bottom, supernatant containing perlecan-(1 404)-fragment from baculovirus-infected insect cells was spotted as 
a positive control (nr. 15). The time of harvest was 0, 5, 20, 28, 44, 51, 72, and 99 h (a h).
G418 Number of resistant clones
(g/l) A B C
0.25 21 21 9
0.50 1 3 0
0.75 0 3 1
1.00 2 7 1
1.50 42 12 11
2.00 47 58 23
4.00 5 15 3
total 118 119 48
• * *  *  •
m «  *  *  *
•  * •  *  *  *
*  •  • • *  *  m
*  • •
*  *  *
» * #  * #  *
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For optimal results we also determined how the yield of the recombinant proteins was 
influenced by the time of harvest. At various time points after inoculation, we measured the 
presence of recombinant proteins by immunoblotting with a monoclonal antibody directed to 
the N-terminal region of human perlecan [23]. Perlecan-(24-404)-fragment and perlecan-(24- 
506)-fragment became readily detectable from 5 h incubation on (Figure 1). The immunore- 
activity increased markedly during the first 28 to 44 h. As a control, recombinant P. pastoris 
clones that contain the empty expression cassette produced no detectable perlecan-like 
immunoreactivity.
Next, we compared the expression levels obtained by use of various growth media. A single 
yeast clone was cultured in three different media (named MM, BMM and BMMY medium) 
for expression of perlecan-(24-404)-fragment. The culture media were analyzed after 40 h by 
western blotting with an anti-perlecan monoclonal antibody. The use of BMMY medium gave 
clearly the highest yields (approximately 5-fold higher than MM and BMM; data not shown).
Characterization of the recombinant fragments
Culture media of five P. pastoris  clones expressing perlecan-(24-404)-fragment and seven 
clones expressing perlecan-(24-506)-fragment were analyzed by western blotting (Figure 2). 
All analyzed clones produced perlecan-like immunoreactivity, whereas no detectable staining 
was observed for clones that carried the empty expression cassette. For the (24-404)-fragment 
multiple bands were stained, of which the major band corresponded with the predicted 
molecular mass, 42 kDa. The other band displayed a lower electrophoretic mobility, suggest­
ing different post-translational modification characteristics or a higher molecular mass (e.g. 
by read-through translation in a percentage of cases). As expected for the (24-506)-fragment 
the major band corresponded with the predicted molecular mass (53 kDa) and no prominent 
additional bands were visible. The yields were 2.4 g/l for perlecan-(24-404)-fragment and 0.5 
g/l for perlecan-(24-506)-fragment, respectively.
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Figure 2. Characterization of recombinant perlecan-(24 404)-fragment and perlecan-(24 506)-fragment 
by western blotting with an anti-perlecan monoclonal antibody. Eight pl of culture medium was applied in 
each lane. Lanes 1 5: different P. pastoris clones expressing perlecan-(24 404)-fragment. Lanes 7 13: 
different clones expressing perlecan-(24 506)-fragment. Lanes 6 and 14: supernatant from two P. pastoris 
clones with multiple insertions of the empty expression cassette as a negative control.
The smeared appearance of the (24-404)-fragment and the (24-506)-fragment on western 
blots suggested that some type of glycosylation of the recombinant proteins occurred. 
However, smears observed for glycosaminoglycan-containing proteoglycans are normally 
more prominent. The mobility of both recombinant proteins was not altered after heparitinase 
or chondroitinase ABC digestion. Furthermore, the fragments did not bind to DEAE Sepha- 
rose in anion exchange chromatography. As proteoglycans are known to firmly bind to this 
matrix under the used conditions (up to 2.0 M NaCl is required for elution), this indicates that 
glycosaminoglycan chains are absent.
Interaction of lipoproteins with recombinant domain I and II of human perlecan
To investigate the functionality of perlecan domain II as a lipoprotein receptor, lipoproteins 
were isolated from human plasma. The preparations were analyzed for protein and cholesterol 
content (Table 2). Standard amounts were coated into ELISA wells. Subsequently, binding of 
perlecan fragments to these preparations was analyzed by incubating the wells with culture 
medium, followed by immunodetection. The results are summarized in Figure 3.
Both the perlecan-(24-404)-fragment and the (24-506)-fragment produced by P. pastoris 
showed affinity for VLDL/IDL, LDL and Lp(a) (Figure 3A, B). The highest signal was 
observed for LDL. When the fragments were incubated in LDL-coated wells, the generated 
absorbance exceeded that of directly coated 
fragment. In contrast to this, no binding to 
HDL or LPDS was observed. Also perlecan- 
(24-404)-fragment expressed as a fusion 
protein in E. coli had affinity for VLDL/IDL,
LDL and Lp(a) (Figure 3C). Also in this case, 
the highest absorbance levels were observed 
in LDL-coated wells.
In contrast to the adhesive properties of 
recombinant fragments from P. pastoris  and 
E. coli, perlecan-(1-404)-fragment produced 
by the baculovirus expression system did not 
bind to any of the analyzed lipoprotein
Table 2. Protein and cholesterol content of 
lipoprotein fractions isolated from human 
plasma._____________________________________
Fraction Protein Cholesterol 
____________ (mg/ml)______ (mM)
VLDL/IDL 1.08 3.6
LDL 0.25 0.6
Lp(a) 0.64 0.8
HDL 2.08 1.0
LPDS 51.2 0.1
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BSA VLDL LDL Lp(a) HDL LPDS + 
/IDL
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1.5  - ■ 
1
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D
BSA VLDL LDL Lp(a) HDL LPDS + 
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Figure 3. Binding of recombinant fragments of human perlecan to lipoproteins isolated from human 
plasma. (A) Perlecan-(24 404)-fragment produced in P. pastoris, (B) perlecan-(24 506)-fragment produced in P. 
pastoris, (C) perlecan-(24 404)-fragment produced as bacterial fusion protein, and (D) perlecan-(1 404)- 
fragment produced by baculovirus-infected insect cells were incubated in ELISA wells coated with 2.5 pg BSA, 
VLDL/IDL, LDL, Lp(aP, HDL or LPDS. The mean value of two independent measurements is shown. As a posi­
tive control (+), the used concentration of each recombinant fragment was directly coated into the wells.
4
0
fractions (Figure 3D). The same concentration of this recombinant protein produced a full- 
scale detection signal when directly coated into the wells. These results suggest that domains I 
and II of perlecan may bind lipoproteins when the fragment is devoid of glycosaminoglycans, 
but this affinity is absent when it is associated with chondroitin sulfate. For this reason, we 
investigated the influence of glycosaminoglycan interactions in more detail.
Influence of glycosaminoglycans on 
lipoprotein binding
Since the apoB-100 component of 
lipoproteins is known to contain glycosa- 
minoglycan binding sites, we analyzed the 
lipoprotein fractions for glycosaminogly- 
can content (Table 3). The VLDL/IDL, 
LDL and Lp(a) preparations contained 
significant amounts of glycosaminoglycan 
(approximately 21, 26 and 54 ng per |ig of 
protein, respectively). HDL and LPDS 
were free of glycosaminoglycans. To 
differentiate between different types of 
glycosaminoglycan, the lipoproteins were 
treated with heparitinase. This enzyme
Table 3: Glycosaminoglycan content of the lipoprotein 
fractions before and after treatment w ith heparitinase
Two individual measurements are given.__________
Fraction Glycosaminoglycan (ng/pg protein) 
- HT + HT
VLDL/IDL 21.021.0 15.0 16.5
LDL 25.5 27.7 0.7 0.7
Lp(a) 53.2 54.0 0.01.5
HDL 0.01.5 0.00.7
LPDS 0.00.0 0.00.7
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Table 4. Reduced binding of recombinant perlecan fragments produced in P. 
pastoris to lipoprotein fractions VLDL/IDL, LDL and Lp(a) as coated sub­
strates after heparitinase (HT) treatment. Binding activities are given as optical 
density units.____________________________________________________________
Perlecan-(24- Perlecan-(24-506)-
S ubstra te  404)-fragm ent fragm ent
- HT + HT - HT + HT
A492 A492 A492 A492
BSA 0.06 0.06 0.07 0.06
VLDL/IDL 0.48 0.18 1.14 0.40
LDL 0.78 0.42 1.80 0.85
Lp(a) 0.69 0.29 1.46 0.66
recognizes and hydrolyzes specific disaccharide structures in the HS chain, which are not 
present in chondroitin sulfate, dermatan sulfate, keratan sulfate or hyaluronate. A HS chain 
may be degraded completely or in part, depending on the frequency of occurrence of these 
structures. Glycosaminoglycans in LDL and Lp(a) were completely degraded by heparitinase, 
demonstrating that they contain HS as the only glycosaminoglycan type (Table 3). The 
glycosaminoglycan content of VLDL/IDL was reduced partially by heparitinase, leaving 77% 
of the material intact. This fraction therefore contains HS, which may be of a different 
composition, partly inaccessible for the enzyme, or accompanied by other glycosaminoglycan 
types.
To reveal a possible involvement of HS in the interaction of lipoproteins with the perlecan 
core protein fragments, we analyzed the effect of heparitinase on binding. When recombinant 
fragments were applied to the lipoprotein-coated wells in the presence of heparitinase, the 
observed binding was importantly reduced (Table 4). This was demonstrated for both 
recombinant proteins from P. pastoris. Thus, binding of lipoproteins to the perlecan core 
protein fragment is potentiated by the presence of endogenous HS. When the concentration of 
HS was increased by exogenous addition, the binding of perlecan-(24-404)-fragment to 
VLDL/IDL, LDL and Lp(a) was not influenced significantly (Figure 4). The perlecan 
fragment still did not bind to HDL or LPDS, indicating that their inability to bind the perlecan
HS (mg/ml)
Figure 4. Influence of exogenous HS on the binding of perlecan-(24 404)-fragment to d ifferent lipopro­
tein fractions. After coating the native lipoproteins or BSA as control, wells were incubated with the perlecan- 
(24 404)-fragment from P. pastoris in presence of increasing concentrations of HS. Binding of the fragment 
was quantitated by ELISA as optical density units at 492 nm.
CHAPTER THREE 6 3
fragments is not due to the lack of HS in these fractions.
D is c u s s io n
The availability of recombinant fragments containing domains I and II of human perlecan 
offers opportunities to study their functions in a well-defined way. Extraction of perlecan 
from tissues is complicated due to the strong interactions with many other components of the 
basement membrane, implicating a high risk for contamination. The purification procedure is 
time-consuming and therefore prone to proteolytic degradation and low recovery. The use of 
recombinant protein fragments circumvents these problems. The P. pastoris  expression 
system allows the stable and high-level eukaryotic expression of proteins. In contrast to the 
baculovirus expression system [25], glycosaminoglycan synthesis on the recombinant 
fragments was not supported by P. pastoris. None of the three used host systems produced the 
perlecan fragments as a HS proteoglycan.
The lipoprotein-binding activity of perlecan can be assigned to the core protein, since the 
binding was observed for recombinant fragments from P. pastoris  and E. coli, both devoid of 
glycosaminoglycan residues. The involvement of the core protein is also confirmed by the 
inability of soluble HS to compete with the fragments for binding. The binding site is located 
within domains I and IIa. The subdomain IIb is apparently not essential for lipoprotein 
binding. Given the high similarity of domain II with the LDL receptor it can be speculated, 
that this domain is most likely responsible for the interaction.
Comparing the perlecan-binding activity among individual lipoproteins, the results suggests 
that apoB-100 may be the involved ligand. All lipoprotein fractions that bound the recombi­
nant perlecan fragments contain apoB-100, whereas the non-binding fractions lack this 
component. The highest binding activity was observed for LDL, that contains apoB-100 as the 
only protein component. However the differences cannot be merely explained by apoB 
content: VLDL/IDL (that contains relatively little apoB) showed a high affinity in this 
respect. Neither was a direct correlation with the HS content of the lipoproteins apparent. To 
confirm if apoB-100 acts as a ligand and to localize the involved binding site, further 
experimental evidence is required.
Glycosaminoglycans appear to play a modulating role in the binding of lipoproteins to the 
core protein of perlecan. HS or HSPG binds to lipoproteins in vivo, as shown by the co­
purification of HS with VLDL/IDL, LDL and Lp(a) from human plasma. ApoB could be 
involved, since this apoprotein has HS affinity [1, 2]. We also showed that treatment of these 
lipoproteins with heparitinase reduced binding activity to the perlecan fragments. This 
suggests that endogenous HS potentiates binding, assuming that the lipoproteins remained 
native during the heparitinase treatment. The presence of endogenous HS explains that extra 
HS does not influence binding of lipoproteins. But how is lipoprotein binding affected when 
HS is covalently attached to domain I of perlecan? When glycosylated with chondroitin 
sulfate, the perlecan-(1-404)-fragment showed no affinity for lipoproteins. HS attachment 
may act synergistic and enhance lipoprotein binding to the core protein. Alternatively, the 
presence of HS residues on domain I could inhibit lipoprotein binding if the supramolecular 
conformation required for such a dual binding is unfavorable.
In conclusion, we demonstrated that the core protein of human perlecan has lipoprotein 
binding activity in vitro . This phenomenon may contribute to regulate the retention of 
lipoproteins in the extracellular matrix in a glycosylation-dependent way. As increased 
lipoprotein adhesion to the subendothelial matrix is considered to be a causal event in the 
development of atherosclerosis, these data may contribute to a better understanding of the 
mechanism involved.
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chapter four S u m m a r y  H eparan sulfate proteoglycans (HSPGs) are  essential 
com ponents of the glom erular b asem en t m em brane (GBM) that 
carry a  strong anionic charge. A w ell-characterized extracellular 
H S P g  is perlecan, ubiquitously exp ressed  in basem ent 
m em branes. A cDNA construct encoding domain I and II of hum an 
perlecan w as exp ressed  a s  a  fusion protein with glutathione S- 
transferase. This fusion protein w as used  to genera te  the novel 
monoclonal antibody 95J10. W e com pared the staining pattern of 
95J10 with that of M215, a  previously prepared mAb that 
recognizes HSPG isolated from hum an GBM. In kidney cortex, the 
anti-perlecan mAb 95J10 show ed a  strong staining of the 
m esangium , Bowm an's capsule, the tubular basem en t m em brane 
and stained the GBM only slightly. In contrast, M215 predominantly 
stained the GBM in a  linear fashion. Im m unoelectron m icroscopy 
supported th e se  results showing concentrations of perlecan in 
som e regions of the GBM, w hereas the yet unidentified M215- 
antigen w as hom ogenously distributed throughout the GBM. Also 
in other hum an tissues, both antibodies also produced a  clearly 
different staining pattern. Furtherm ore a  polyclonal antiserum  
recognizing HSPG isolated from the GBM did not recognize 
perlecan from the EHS tumor. T h ese  results provide evidence for 
the p resence  of ano ther HSPG in the GBM that is immunologically 
distinct from perlecan. The ab sen ce  of perlecan splice variants in 
the kidney su g g ests  that this com ponent is encoded by a  different 
gene  than perlecan. Given its m arked expression in the GBM, this 
com ponent could be a  determining factor in the m aintenance of 
selective glom erular permeability.
In t r o d u c t io n
The glomerular basement membrane (GBM) is a specialized extracellular matrix located at 
the interface of the glomerular visceral epithelium and the vascular endothelium. The GBM 
provides a rigid structure that supports the tissue to withstand high local blood pressure, its 
mechanical strength being enhanced by the highly organized interplay of its biopolymer 
components [e.g. collagen IV, laminin, nidogen and heparan sulfate proteoglycans (HSPGs)] 
[1]. Another crucial function of the GBM is to regulate the passage of proteins depending on 
their molecular size and charge [2]. The impermeability of the GBM for anionic 
macromolecules is assigned to the presence of HSPGs anchored within it. The electrostatic 
charge of these HSPGs can be visualized by electron microscopy using cationic ferritin [2] or 
heparan sulfate (HS)-specific mAbs [3]. The significance of this mechanism was 
demonstrated by perfusing rat kidney with heparitinase, which resulted in leakage of anionic 
tracer proteins [4]. A similar effect was observed when the kidney was perfused with anti-HS 
mAbs [5]. Alterations in the HS content of the GBM causing nephrotic syndrome are involved 
in, for example, minimal change nephropathy, glomerulonephritis, diabetic nephropathy, and 
Denys-Drash syndrome [6-8].
T o Index
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For biochemical characterization, HSPGs were extracted from isolated glomeruli [9], from 
epithelial cell lines [10] or from the mouse Engelbreth-Holm-Swarm sarcoma [11-13]. 
Extraction of HSPG from basement membranes is complicated due to its strong interactions 
with other components. In addition, their analysis is confused by their smeared appearance on 
protein gels and their sensitivity to proteolysis. The first basement membrane proteoglycan 
characterized was termed perlecan, with reference to its beads-on-a-string-like appearance in 
rotary shadowing electron microscopy [14]. It consists of a 467 kDa core protein carrying five 
functional domains and three HS chains attached in close proximity to its N-terminus [15-17]. 
Human perlecan is expressed by a single gene, named HSPG2 and located on the short arm of 
chromosome 1 [18-20]. Several observations have suggested the presence of additional 
basement membrane HSPGs: low-density forms (representing perlecan) and high-density 
forms characterized by relatively small core proteins (18-143 kDa) [21, 22]. However, it was 
demonstrated that these high-density proteoglycans are immunologically related to perlecan, 
suggesting that they are generated by proteolytic processing [23].
Previous immunofluorescence studies performed with various polyclonal and monoclonal 
antibodies yielded inconsistent results, with particular differences in the staining intensity of 
the GBM [3, 9, 11, 24, 25]. For the generation of mAbs, prokaryotic expression offers a large 
advantage over proteoglycan extraction from basement membranes, because the risk of co­
immunization with contaminating HSPG species is eliminated. Furthermore, recombinant 
protein expression allows the development of domain-specific antibodies. We have 
synthesized domains I and II of human perlecan as a bacterial fusion protein and generated the 
monoclonal antibody 95J10. In this study, we compare the expression pattern in human 
tissues for 95J10 and M215, a mAb that was previously raised against isolated human GBM- 
HSPG [3]. The results provide evidence for the presence of a yet unidentified HSPG in the 
GBM, which appears to be immunologically distinct from perlecan.
E x p e r im e n t a l  p r o c e d u r e s  
Materials
The following were obtained from the indicated sources: pGEX4T-3 expression vector, 
glutathione-conjugated Sepharose 4B (Pharmacia Biotech); reduced glutathione (Boehringer 
Mannheim), pCR-Script cloning vector, SrfI (Stratagene Cloning Systems); isopropyl-B-D- 
thiogalactoside, T4 DNA ligase, NcoI, BamHI (Life Technologies); Vent polymerase, NotI, 
XcmI (New England Biolabs); thermal cycler apparatus (Perkin Elmer); automated sequencer 
(Applied Biosystems); thrombin, phenylmethylsulfonyl fluoride, ribonuclease A (Sigma 
Chemical Co.), 2-iodoacetamide (Merck); N-ethylenemaleimide, EDTA (Fluka Chemie); 
benzamidine hydrochloride (Janssen Chimica); 6-aminohexanoic acid (Aldrich Chemical); 
Tween-20 (ICN Biomedicals); Immobilon-P, ultrafiltration units (Millipore); goat-anti-mouse 
peroxidase conjugate (Dakopatts); sheep-anti-mouse fluorescein isothiocyanate conjugate 
(Cappel, Oss, The Netherlands); [g-32P]ATP, ECL detection kit (Amersham).
Construction of the expression vector pGEX4T3-P12a
A prokaryotic expression vector encoding amino acids 24-404 of human perlecan was pre­
pared as follows. Two PCR products were generated from cDNA clone Hpe2 [16] using Vent 
polymerase for proofreading activity. The primer sets were: 5'- 
TCATCTCCAGCGGCTCTGT-3' (forward P1), 5'-TCATGGGAACTGGGGCACTGTGC-3' 
(reverse P1), 5'-TCATCTCCAGCGGCTCTGT-3' (forward P2) and 5'-TTACATGCAGCC- 
AAACTCGTC-3' (reverse P2, this primer introduces an in-frame stop codon immediately 
behind amino acid 404). The two PCR products were inserted into the SrfI cloning site of 
pCR-Script [26, 27] and screened to detect the unique NotI-site at the 3'-end of the cDNA
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fragments. The P2 fragment was then ligated to the P1 fragment by use of the Xcm I restriction 
site, and introduced into pGEX4T-3 [28] using the N coI and N otI cloning sites. The fidelity of 
amplification and ligation procedures was checked by sequence analysis. The resulting 
expression vector was named pGEX4T3-P12a.
Expression and purification of recombinant perlecan-(24 404)-fragment
Expression of the recombinant perlecan-(24-404)-fragment was performed as described [28], 
except that the cell pellet was resuspended in 125 ml ice-cold NaCl/P; (140 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.5), 1% Triton-X100, 10 mM N- 
ethylmaleimide, 5 mM EDTA, 10 mM 6-amino-hexanoic acid, 5 mM 2-iodoacetamide, 1 mM 
phenylmethylsulfonyl fluoride and 1 mM benzamidine-HCl. Cell lysis and affinity 
purification of the recombinant fusion protein were performed in the presence of 1% Triton- 
X100, which was essential for optimal yields. In contrast, the yield could not be improved by 
other modifications of the procedure such as the use of sarkosyl for solubilization [29], 
growth at 30°C [30] or treatment with Mg2+ and ATP prior to affinity chromatography [31]. 
Affinity-purified fusion protein was incubated with 1.7 NIH U/ml human thrombin (specific 
activity approximately 4000 NIH U/mg) and incubated for 60 min at 22°C. To exhaustively 
remove the glutathione-S-transferase (GST) fragment from the thrombin-digested mixture, 
the mixture was dialysed against NaCl/Pi to remove free glutathione and passed through a 
glutathione-conjugated Sepharose 4B column (1 ml) at room temperature. The flow-through 
was concentrated by ultrafiltration against a 10-kDa cutoff membrane to a final concentration 
of 0.63 mg/ml (determined by the Bradford method with BSA as reference) [32].
Antibodies
The anti-perlecan mAb 95J10 was prepared as follows. Mice were immunized and boosted 
with 20 mg purified perlecan-(24-404)-fragment per injection (this preparation was 
completely devoid of GST). Hybridoma cell lines were screened by ELISA with an 
independently isolated batch of recombinant fusion protein. Twelve positive clones were 
examined in indirect immunofluorescence studies for their capacity to stain human renal 
basement membranes. A mAb designated 95J10 was selected that showed strong glomerular 
staining. The mAb also reacted in western blot analysis with the fusion protein and with 
perlecan-(1-404)-fragment expressed by baculovirus-infected insect cells [33], which 
indicated that it also recognizes the antigen in a denatured conformation. No cross-eactivity of 
mAb 95J10 with Escherichia coli proteins or GST was observed by ELISA and western 
blotting. Experimental animal care, cell fusion, and generation of the monoclonal hybridoma 
cell line 95J10 were performed by Diabor Ltd., Oulu, Finland.
Other antibodies used were R254 (a rat mAb against mouse perlecan; a generous gift of Dr. J. 
van den Born), M215 (a mouse mAb against the core protein of HSPG isolated from human 
GBM [3]), and K42 (a rabbit antiserum recognizing HSPG from the human and murine GBM 
[9]).
Immunological methods
SDS-PAGE and immunoblot analyses were carried out following standard procedures [30]. 
All samples were denatured by boiling in presence of 2-mercaptoethanol prior to loading onto 
a homogeneous 5% polyacrylamide gel. Immunofluorescence and tissue distribution studies 
were performed with adult human tissue specimens obtained during autopsy, snap-frozen in 
liquid nitrogen, and stored at -80°C until use. Cryostat sections of 2 mm were attached to 
glass slides and treated with acetone for 10 min at 4°C for fixation. mAb M215 or 95J10 were 
applied as undiluted hybridoma supernatant. After 1 h incubation at 22°C, specimens were 
submerged five times in fresh NaCl/Pi for washing. Bound primary antibody was detected by
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Figure 1. Western blot detection of 
recombinant fusion protein with a GST- 
specific monoclonal antibody. Lane 1, 
crude cell extract of bacteria carrying the 
plasmid pGEX4t3; lane 2, crude cell 
extract of bacteria carrying the plasmid 
pGEX4t3-P12a; lane 3, affinity purified 
preparation of the fusion protein; lane 4: 
thrombin-digested fusion protein; lane 5: 
perlecan-(24-404)-fragment obtained from 
thrombin-digested fusion protein; lane 6, 
GST fragment obtained from thrombin- 
digested fusion protein. The positions of 
marker proteins are given on the left. 
Arrows on the right indicate the fusion 
protein in lane 2 and 3 (FP) and the GST 
fragment in lane 4 and 6.
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Figure 2. SDS-PAGE analysis of 
recombinant protein produced by 
recombinant E. coli. Recombinant 
protein was extracted from E. coli, purified 
by glutathione affinity chromatography and 
digested with thrombin. Proteins were 
separated by SDS-PAGE (12.5% 
polyacrylamide) and stained with 
Coomassie brilliant blue. M, marker lane; 
molecular mass indications are given on 
the left (kDa). The contents of lanes 3 6 
are as described in Figure 1.
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incubating with fluorescein-isothiocyanate-conjugated sheep-anti-mouse immunoglobulins 
(30 min at 22°C in the dark). After thorough washing with fresh NaCl/P;, the preparations 
were examined with a Leitz fluorescence microscope. For immunoelectron microscopy, 
kidney cortex slices were fixed with periodate-lysine and paraformaldehyde, immersed in 2.3 
M sucrose for cryprotection and snap-frozen in liquid nitrogen. Staining of peroxidase- 
conjugated antibody complexes was performed following standard protocols [34] and the 
sections were postfixed in Epon 812. Thin sections were examined with a Jeol 1200 EX 
electron microscope.
Northern hybridization
A multiple human tissue northern blot (Clontech Laboratories Inc.) was treated according to 
the supplier's protocol with an antisense probe homologous to exon 3 of perlecan (5'- 
AAGTCCCCGCTGCCCAGGTCCCCACTGCCCAGGTCGT-3') [20]. This exon is a 
prerequisite for the presence of the HS chains. After hybridization, the filter was washed 3 x
15 min under stringent conditions (15 mM NaCl, 1.5 mM sodium citrate, 0.1% SDS, pH 7.0 
at 50°C) and exposed for autoradiography for 91 h.
R e s u l t s
Expression of perlecan domains I and II as a fusion protein with GST
A cDNA construct was prepared encoding domain I and II of human perlecan, fused to the 
carboxyl end of GST from Schistosoma japonicum  [28]. For localization of the recombinant 
protein, we tested the cell lysate, the culture supernatant, and the inclusion bodies isolated 
from the bacteria. The recombinant protein was found exclusively in the cell lysate. Crude 
cell extracts were analyzed by SDS-PAGE and immunoblotting with an anti-GST mAb 
(Figure 1), confirming the presence of a recombinant fusion protein. Although the fusion 
protein was expressed at a level of 1.3 ± 0.3 mg/l crude culture (mean ± SD, n=4), only 120 
mg/l could be recovered by affinity chromatography. The affinity-purified fraction did not 
appear as a single band on SDS-PAGE, but contained multiple proteins as shown in lane 3 
(Figure 1). The largest of these proteins appeared as a strong band, which corresponded to the 
predicted molecular mass of 68 kDa. The observed additional bands and the low final yield 
suggest sensitivity of the fusion protein to proteolysis.
The GST fragment was removed from the hybrid protein utilizing an engineered recognition 
site for thrombin cleavage, and an additional round of affinity chromatography. Coomassie 
brilliant blue staining of the recombinant perlecan-(24-404)-fragment identified two bands of
26 and 19 kDa in size respectively (Figure 2, lane 5). The staining signal is weak compared to 
the GST fraction (Figure 2, lane 6), which indicated a relatively low protein concentration. 
These results likely reflect proteolytic degradation of the fusion protein, also observed in lane 
3 (Figure 1 and 2). The final preparation, completely devoid of GST as shown in Figure 1 
(lane 5), was used to generate the monoclonal antibody mAb 95J10.
HSPG distribution in the human kidney
In indirect immunofluorescence studies on human kidney cortex, mAb 95J10 displayed a 
bright staining of the mesangium, Bowman’s capsule, the tubular basement membrane, and 
peritubular capillaries (Figure 3B). The overall staining of the GBM was weak and visible 
only along fragments of the glomerular capillaries. In the arteriole, an intense staining was 
observed in intima, media and adventitia (Figure 3A). The staining was especially pronounced 
at the luminal border. The staining was compared with that of another mAb designated M215. 
This mAb was obtained by immunization with HSPG purified from isolated human GBM, 
and is directed against an epitope of the core protein [3]. mAb M215 showed a strong linear
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Figure 3. Immunofluorescence detection of heparan sulfate proteoglycans in the human renal cortex.
Cryosections were stained for perlecan (A, B) and non-perlecan GBM-HSPG (C, D) using the mAbs 95J10 and 
M215, respectively. The asterisk in A indicates the tunica media of the arteriole; the arrow in B indicates 
Bowman s capsule; the arrowhead in C indicates autofluorescence typically originating from the elastica interna 
of the arteriole. Magnifications are 150x (A,C) and 400x (B, D).
staining of the GBM in immunofluorescence studies (Figure 3D), along with a less intense but 
also linear staining of all other renal basement membranes (Bowman’s capsule, the tubular 
basement membrane and the basement membranes of the peritubular capillaries). mAb M215 
did not stain the mesangial matrix. In contrast to 95J10, vascular staining of M215 was 
restricted to the endothelial border (Figure 3C).
The ultrastructural distribution of HSPGs in the GBM was analyzed by immunoelectron 
microscopy with both mAbs (Figure 4). The anti-perlecan mAb 95J10 stained the GBM along 
some fragments of the capillary wall, whereas other regions were not stained at all (Figure 
4A). In all cases, the staining was clustered at the endothelial side of the basal lamina (Figure 
4C). Besides the local accumulation of perlecan in the GBM, an elevated expression was seen 
in the mesangial matrix (Figure 4A). M215, however, produced a homogenous staining along 
the entire length of the GBM (Figure 4B and D). The clustered appearance of perlecan, and 
the linear distribution of non-perlecan GBM-HSPG, agree with the results from 
immunofluorescence studies.
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Figure 4. The ultrastructural localization of HSPGs in the glomerular basement membrane. Human kidney 
cortex was stained for perlecan (A, C) and non-perlecan GBM-HSPG (B, D) using mAbs 95J10 and M215 and 
was examined by immunoelectron microscopy. The arrowhead in A shows elevated levels of perlecan in the 
mesangial matrix. The arrowhead in C shows a typical condensation of perlecan on the endothelial side of the 
GBM. The arrowhead in D shows the homogenous linear distribution of non-perlecan GBM-HSPG. Magnifications 
5000x (A, B) and 15 000x (C, D).
HSPG distribution in human tissues
Adjacent sections of human tissues were stained for perlecan (mAb 95J10) and non-perlecan 
GBM-HSPG (mAb M215). We especially focused on tissues that clearly displayed different 
staining patterns in indirect immunofluorescence studies using both mAbs. Figure 5 shows 
typical results in skin, pancreas, artery, tongue, and cerebrum. Both antibodies stained the 
epidermal basement membrane in the skin (Figure 5A and F). In addition, mAb 95J10 stained 
the capillaries more intensely than M215. In the pancreas, mAb 95J10 (Figure 5B) displayed a 
strong staining of the sinusoids, the islets of Langerhans, and the capillaries whereas mAb 
M215 (Figure 5G) only stained the capillaries. In arteries, 95J10 (Figure 5C) stained the 
media and adventitia with vaso vasorum, reflecting the basement membrane distribution 
surrounding the smooth muscle cells. In contrast, the staining by mAb M215 was confined to 
the vasa vasorum (Figure 5 H). In cryosections from human tongue, mAb 95J10 (Figure 5D) 
strongly recognized the endomysium that surrounds the skeletal muscle fibers, the capillaries, 
an artery, nerve fibers with a myelin sheath, and perineurium (bundles are surrounded by 
connective tissue). In contrast, mAb M215 stained only the capillaries (Figure 5I). In 
cerebrum, 95J10 strongly stains veins in the cerebral cortex, the arteries, and the capillaries.
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Figure 5. Indirect immunofluorescence staining of HSPGs in various human tissues. Cryosections were 
stained with mAb 95J10 (A E) or mAb M215 (F J). A and F, skin (arrow indicates epidermal basement 
membrane). B andG, pancreas (in B arrow indicates sinusoids and arrowhead indicates capillary. In G, arrow 
indicates capillary). C and H, artery (M, media; A, adventitia). D and I, tongue (arrow indicates skeletal muscle 
fibers; arrowhead indicates capillary; N, nerve fibers). E and J, cerebrum (in E arrow indicates vein and asterisk 
indicates artery; in J, arrow indicates capillary). Magnifications were 100x (C, E, H, J), 150x (A, D, F, I) and 400x 
(B, G).____________________________________________________________________________________________
In the same tissue, mAb M215 only stains the capillaries (Figure 5J). In all cases, the 
specificity of the staining was checked by parallel incubations without the primary antibody. 
The results obtained by immunohistochemistry suggest the occurrence of two different GBM- 
associated HSPG species. Could the observed differences be based on different epitope 
accessibilities in vivo? To exclude this possibility, preparations of HSPG isolated from the 
human GBM and from the mouse EHS tumor were analyzed by western blotting (Figure 6). 
The EHS tumor is known to produce large amounts of perlecan. Using a rabbit polyclonal 
antiserum (K42) that recognizes both murine and human GBM-HSPG [9], no staining of 
EHS-HSPG was detected. Staining with mAb M215 gave identical results (data not shown). 
As a control for the transfer of EHS-HSPG to the blot, an identical treatment with a rat mAb 
against mouse perlecan resulted in a marked staining of EHS-HSPG. mAb 95J10 could not be
K42 R254
(--------------- \  \
M 1 2 1 2  1 2
A B
Figure 6. Comparative immunoblot analysis of HSPGs from glomerular basement membrane and EHS 
tumor. Equal quantities of HSPG isolated from the human GBM (lanes 1) and from the mouse EHS tumor (lanes 
2) were separated by SDS-PAGE (5% polyacrylamide). Both HSPGs were analyzed by silver staining (A) and 
immunoblotting (B). For immunoblotting, we used K42 (a rabbit pAb that recognizes GBM-HSPG from mouse and 
man; left part of B) and R254 (a rat mAb that recognizes mouse perlecan; right part of B).
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used for this purpose, since it is specific for human perlecan. The specificity of antiserum K42 
for GBM-HSPG, without any cross-reaction with perlecan, confirms that the two HSPG 
species are immunologically unrelated.
Perlecan splice variants occur in brain, placenta and skeletal muscle but not in kidney
Elucidation of the perlecan gene structure showed the theoretical possibility of alternative 
splicing [16, 17, 20]. Interestingly, the occurrence of splice variants would result in the 
expression of perlecan isoforms. We therefore investigated the occurrence of perlecan splice 
variants by northern blotting (Figure 7). The full size messenger RNA (approximately 14 kb) 
was detected in heart, placenta, skeletal muscle, kidney and pancreas, but was hardly or not at 
all present in brain, lung, and liver. Interestingly, a smaller size mRNA species was detected 
in brain (2.5-2.6 kb), placenta (1.9 kb and 6.4-6.7 kb) and skeletal muscle (3.1-3.3 kb). The 
significance of these molecules is not clear. In the kidney however, we could not distinguish 
any splice variants.
D is c u s s io n
As the presence of strongly anionic 
HSPGs is important to maintain the 
selective permeability of the GBM, the 
identification of perlecan as a 
basement membrane-associated HSPG 
has provoked many investigators to 
study perlecan expression levels 
during nephropathy. We used a novel 
mAb designated 95J10, directed 
against amino acids 22-404 of human 
perlecan, to analyze the distribution of 
perlecan in the glomerulus in more 
detail. The staining pattern of 95J10 in 
indirect immunofluorescence is in 
agreement with other studies 
performed with mAbs raised against 
recombinant fragments from domain 
III of perlecan [24, 25], and with a 
polyclonal antiserum against perlecan 
from the EHS-tumor [11]. However, 
the exact localization of perlecan in 
the GBM can hardly be deduced from 
immunofluorescence microscopy 
studies. Our results from immuno- 
electron microscopy indicate that perlecan is present in the GBM, but only on the endothelial 
side. Moreover, perlecan is distributed in a non-homogenous pattern and many segments of 
the GBM were not stained by 95J10. Therefore, charge-selective properties of the GBM can 
not be ascribed to the anionic charge of perlecan alone.
The expression pattern of perlecan is in marked contrast to that observed with M215, a 
previously described mAb against HSPG isolated from the GBM [3]. This HSPG is less 
widely distributed than perlecan, as shown by indirect immunofluorescence on multiple 
human tissues. In the kidney, this antibody predominantly stained the GBM in a linear 
manner. Similar results were obtained with other monoclonal and polyclonal antibodies raised
1 2 3 4 5 6 7 8
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Figure 7. Northern blot analysis of mRNA from various 
human tissues. PolyA-rich mRNA isolated from heart (1), 
brain (2), placenta (3), lung (4), liver (5), skeletal muscle (6), 
kidney (7), and pancreas (8) was hybridized with a perlecan- 
specific probe and washed stringently. The bottom panel 
shows a control hybridization with a R-actin-specific probe to 
indicate differences in total mRNA content.
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against GBM-HSPG, and with a mAb that recognizes an epitope on the HS chain [5, 8, 9]. 
The homogenous distribution of this HSPG within the GBM was confirmed by 
immunoelectron microscopy.
Our results indicate that two immunologically unrelated HSPG species are present in the 
GBM. This conclusion is based on the following considerations. Firstly, the anti-HSPG 
antibodies 95J10 and M215 show a clearly different distribution in human tissues. Comparing 
the staining patterns of 95J10 and M215, it is of importance that both antibodies are directed 
against the core proteins. The exact composition of the glycosaminoglycan residues is not 
solely dependent on the nature of the core protein but is also influenced by the cellular 
environment in which they are synthesized and modified. Secondly, we demonstrated that a 
polyclonal antiserum against GBM-HSPG does not cross-react with perlecan. Thirdly, 
observations from other groups also support the presence of multiple extracellular HSPG 
species in the glomerulus. In one of these investigations, proteoglycan synthesis was studied 
in cultures of three cell types from calf glomeruli. Epithelial cells excreted immunologically 
distinct HSPG components (Mr approximately 300 kDa) as compared to endothelial and 
mesangial cells which produced a perlecan-type HSPG (molecular weight 500 kDa) [35]. 
Another study supported the synthesis of perlecan-like HSPG by cultured rat mesangial cells 
[36]. And finally, partial amino acid sequences of HSPG isolated from bovine and human 
kidney also supported the presence of HSPG species that are unrelated to perlecan [37, 38]. 
After hybridization of kidney mRNA, only the full length perlecan transcript could be 
distinguished (Figure 7). Although minor differences in mRNA length cannot be detected by 
this method, such small rearrangements could not explain the altered immunoreactivity 
towards mAbs with different domain specificities (this study and [24, 25]). Heparan sulfate- 
carrying splice isoforms of perlecan could not be missed through the choice of the probe, 
because the corresponding exon is required for the presence of HS chains [20]. Therefore, the 
production of multiple HSPGs in the GBM is not mediated by alternative splicing of perlecan. 
This indicates that a different gene is involved.
The availability of the recombinant perlecan-(24-404)-fragment and the novel mAb 95J10 
could be of value in determining the functional properties of the individual domains of the 
perlecan core protein. The ultrastructural localization of perlecan in the GBM suggests that its 
role in the maintenance of selective glomerular permeability is more modest than was initially 
assumed. The presence of an additional HSPG, that is unrelated to perlecan, may indicate a 
new direction for investigating the structural basis of charge-selective GBM permeability. The 
unidentified HSPG that is highly expressed in the GBM may play an important role in renal 
function.
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Agrin is a major heparan sulfate proteoglycan in the human 
glomerular basement membrane
chapter five S u m m a r y  Agrin is a  heparan  sulfate proteoglycan (HSPG) that is 
highly concentrated  in the synaptic basal lamina at the 
neurom uscular junction (NMJ). Agrin-like immunoreactivity is also 
detected  outside the NMJ. Here, w e show that agrin is a  major HSPG 
com ponent of the hum an glom erular b asem en t m em brane (GBM). 
This in addition to perlecan, a  previously characterized HSPG of 
basem en t m em branes. Antibodies against agrin and against an 
unidentified GBM-HSPG produced a  strong staining of the GBM and 
the NMJ, different from that observed  with anti-perlecan antibodies. 
In addition, anti-agrin an tisera  recognized purified GBM-HSPG and 
com peted with an anti-GBM-HSPG monoclonal antibody (mAb) in 
ELISA. Furthermore, both antibodies recognized a  molecule that 
migrated in SDS-PAGE as  a  sm ear and had a  m olecular m ass  of 
approxim ately 2 0 0 -2 1 0  kDa after deglycosylation. In immuno- 
electron m icroscopy agrin show ed a  linear distribution along the 
GBM and w as p resen t throughout the width of the GBM. This w as 
again different from perlecan, which w as exclusively presen t on the 
endothelial side of the GBM and distributed in a  nonlinear m anner. 
Quantitative ELISA show ed that, com pared with perlecan, the agrin- 
like GBM-HSPG show ed a  sixfold higher molarity in crude glomerular 
extract. T hese  results show that agrin is a  major com ponent of the 
GBM, indicating that it may play a  role in renal ultrafiltration and cell- 
matrix interaction.
INTRODUCTION
The glomerular basement membrane (GBM) is a highly organized network of extracellular 
proteins such as collagen IV (a3, a 4  and a5), laminins (a5, a1 , ß2, gl), nidogen/entactin and 
heparan sulfate proteoglycans (HSPGs) [1]. Closely associated with the vascular endothelium 
and the podocyte it provides mechanical support to both cell layers, and modulates the access 
of plasma molecules to the primary urine depending on their molecular size, shape and 
charge. The charge-selectivity is partly ascribed to the presence of HSPGs which provide the 
GBM with an electrostatic charge, resulting in a decreased permeability for anionic 
macromolecules such as albumin [2].
Since the characterization of perlecan as a HSPG component of basement membranes [3], this 
compound has been studied extensively as a candidate factor in the development of 
albuminuria. Perlecan consists of five functional domains composing a core protein of 467 
kDa, carrying three heparan sulfate chains attached to the unique N-terminal domain [3,4]. To 
date however, the involvement of perlecan in renal ultrafiltration is questionable. W ell- 
defined monoclonal antibodies (mAbs) against the perlecan core protein [3,5,6] showed a 
clearly different distribution from antibodies directed against isolated GBM-HSPG and 
epitopes on the heparan sulfate chains [7-9], indicating the presence of additional HSPG 
species in the GBM. A possible role for agrin in the kidney was suggested by the possibility 
to stain neuromuscular junctions (NMJs) with anti-GBM-HSPG antibodies [10], the 
identification of agrin as a HSPG [11] and the production of tryptic peptides from bovine 
tubular basement membrane HSPGs with a high sequence similarity compared with rat agrin 
[12].
T o Index
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In rat and mouse, the agrin core protein has an approximate molecular mass of 210 kDa 
[13,14]. Agrin induces the clustering of acetylcholine receptors (AChRs) and aggregation of 
sodium channels during the development of the neuromuscular junction [15-17]. The AChR 
clustering activity varies for different isoforms that are produced by the use of alternative 
splice sites [18-20]. Agrin isoforms active in AChR clustering are expressed by neurons, 
while muscle cells and many other tissues appear to express isoforms inactive in this process 
[21-23]. In this study we show that agrin is a major HSPG of the human GBM. This finding 
may give new clues for investigating the structure of the GBM in the normal and diseased 
kidney.
E x p e r im e n t a l  p r o c e d u r e s  
Antibodies
Characteristics of the used antibodies are as follows. Anti-agrin pAb 707 was raised in rabbit 
against full-length chick agrin from recombinant source [24]. Mouse mAb M215, mAb M138 
and rabbit polyclonal antibody (pAb) K42 were raised against human HSPG isolated from the 
GBM [7,9]. These three antibodies identically stain human tissues in immunofluorescence. 
pAb K42 crossreacts with this antigen in rat and mouse tissues. The mouse mAb 95J10 is 
directed against a core protein epitope within domains I and II of human perlecan [6]. 
Crossreactivity with various human basement membrane components was negligible, as 
determined by ELISA (Table 1), including collagen type I from human placenta, collagen 
type IV from human placenta, 
heparan sulfate, chondroitin 
sulfate B (Sigma, St. Louis,
MO, USA), and fibronectin 
from human plasma 
(Boehringer Mannheim, Ger­
many). The mouse mAbs Agr- 
33 and Agr-131 (StressGen 
Biotechnologies, Victoria,
Canada) are directed against 
spatially separated epitopes on 
the core protein of rat agrin 
[25]. They do not crossreact in 
immunofluorescence on human 
tissues (unpublished observa­
tions).
Indirect immunofluorescence
Adult human kidney cortex tissue obtained from post-trauma donors was snap-frozen in 
polybrene, cooled with liquid nitrogen. Two-mm sections were stored at -80°C until use. 
Skeletal muscle tissue was obtained from adult rat hamstrings and frozen in polybrene 
immediately after dissection. Six-mm sections were prepared as above. 
Immunohistochemistry was performed as described elsewhere [10], using FITC-conjugated 
goat-anti-mouse and goat-anti-rabbit as the secondary antibodies (Dakopatts, Copenhagen, 
Denmark). For identification of neuromuscular synapses in skeletal muscle sections, 
rhodamine-conjugated a-bungarotoxin was added to the secondary antibody mixture at a final 
dilution of 1:400. In double immunofluorescence studies, mAbs were detected by goat-anti- 
mouse immunoglobulins coupled to Texas Red (Sanbio, Uden, The Netherlands).
Table 1. Crossreactivity of antibodies 95J10, M215 and K42 with 
human basement membrane components as determined by 
ELISA. One pg of each component was coated. Immunoreactivity 
was measured as absorption units at 492 nm.____________________
Component mAb 95J10 mAb M215 pAb K42
Collagen I 0.05 0.05 0.04
Collagen IV 0.04 0.04 0.05
Fibronectin 0.04 0.04 0.04
Albumin 0.04 0.04 0.19
Heparan sulfate 0.04 0.04 0.05
Chondroitin sulfate 0.04 0.04 0.05
Heparin 0.04 0.04 0.04
Purified GBM-HSPG 0.16 2.41 1.40
Purified GST-P12a 2.07 0.05 0.05
Blanco 0.04 0.04 0.04
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Immuno-electron microscopy
Incubations were performed at 22°C, unless otherwise indicated. Kidney cortex slices were 
immersed for 3 h with PLP fixative (a mixture of periodate-lysine and 2% paraformaldehyde), 
rinsed with PBS (pH 7.4), cryoprotected in 2.3 M sucrose for 45 min and snap-frozen in liquid 
nitrogen. Twenty-five-mm cryostat sections were incubated with pAb 707 diluted 1:100 in 
PBS containing 1% BSA for 18 h at 4°C and then washed three times for 30 min with PBS. 
This was also done with mAb 95J10 (diluted 1:5) and mAb M215 (diluted 1:10). After 
rinsing, the sections were incubated for 90 min with the appropriate peroxidase-conjugated 
secondary antibody (goat-anti-rabbit immunoglobulins: Dakopatts; rabbit-anti-mouse 
immunoglobulins: BioSys) diluted 1:70 in PBS containing 1% BSA. After three 30-min 
washes in PBS, the sections were preincubated for 10 min in PBS containing 0.05% 
diaminobenzidine. Subsequently, the sections were stained for 10 min with the same medium 
containing 0.03 % hydrogen peroxide. For immunogold labeling, goat-anti-rabbit and goat- 
anti-mouse immunoglobulins coupled to colloidal gold of 1 nm (Nanoprobes, Stony Brook, 
NY) were diluted 50-fold in PBS containing 1 % BSA. The sections were incubated for 90 
min at 22°C, then washed three times for 30 min in distilled water, and the gold signal was 
enhanced using HQ silver (Nanoprobes) for 5 min. After washing in distilled water for 18 h at 
4°C the sections were postfixed in 1% osmium for 20 min at 22°C, dehydrated and embedded 
in Epon 812. Thin sections were prepared on a Reichert ultratome and examined in a Jeol 
1200 EX electron microscope.
Preparation of glomerular extract
Glomeruli were isolated from human kidney cortex by the sieving method [26] and 
resuspended in 20 volumes 4 M guanidine HCl, 0.2% (w/v) Zwittergent 3-12, 50 mM sodium 
acetate, 10 mM EDTA, 10 mM N-ethylmaleimide, 10 mM 6-aminohexanoic acid, 5 mM 2- 
iodoacetamide, 1 mM phenylmethylsulfonyl fluoride and 1 mM benzamidine HCl (pH 6.0). 
The suspension was incubated for 16 h at 4°C for extraction, and centrifuged for 25 min at 
10,000 x g to remove insoluble material.
Enzyme-linked immunosorbent assay
For quantitative determination of HSPGs by ELISA, crude glomerular extract was diluted 40­
fold in coating buffer [27]. Perlecan levels were measured with 95J10 as the primary 
antibody, using a recombinant fragment comprising domains I and II of human perlecan [6] as 
standard. In the case of M215, purified GBM-HSPG [7] was used as standard. To correct for 
the efficiency of coating, known amounts of the standards were added to the diluted extract 
before coating. Regression lines were computed for the calibration curves, which were linear 
functions of the amount of internal standard. The concentration of each HSPG in the crude 
glomerular extract was calculated as the average of five individual measurements.
For semi-quantitative ELISA, wells were uniformly coated with 0.5 mg/well purified GBM- 
HSPG. Protein concentrations were determined according to the Bradford method with BSA 
as standard [28]. Competition ELISA was performed by using a mixture of pAb 707 (serial 
dilution) and mAb M138 (0.2 mg/ml) as the primary antibody. Subsequently, bound mAb was 
measured using a peroxidase-conjugated goat-anti-mouse serum (1:2000, Dakopatts) as 
above.
Nitrous acid treatment and immunoblotting
Five mg GBM-HSPG [7] was dissolved in 100 ml nitrous acid solution, freshly prepared by 
dissolving 5% (w/v) NaNO2 in 1.5 M hydrochloric acid. This mixture was incubated for 80 
min at 22°C. Subsequently, the core proteins were precipitated in the presence of 75 % 
ethanol. SDS-PAGE and immunoblotting were carried out according to described procedures
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Figure 1. Indirect immunofluorescence staining of 
glomeruli w ith anti-HSPG antibodies. (A, B)
Combined immunofluorescence staining of a single 
section with pAb 707 (against agrin, A) and mAb 
M215 (against the core protein of GBM-HSPG, B). 
(C) pAb K42 (against GBM-HSPG). (D) mAb Agr-33 
(against the core protein of rat agrin). E: mAb 95J10 
(against perlecan) . Sections were prepared from 
human (A, B, C, E) or rat (D) kidney cortex. Bar, 37.5 
Dm (in A and B) or 5o Dm (in C E).
[27]. All samples were denatured prior to electrophoresis through 3-20% polyacrylamide, 
using Multimark as a molecular size marker (Novex, San Diego, USA).
R e s u l t s
Immunofluorescence microscopy
The presence of agrin in the glomerulus was investigated by indirect immunofluorescence. 
Cryosections of human renal cortex were stained with antibodies against agrin, perlecan and 
“GBM-HSPG”, a previously described HSPG isolated from the human GBM [7]. Combined 
staining with anti-agrin pAb 707 (Figure 1A) and mAb M215 against GBM-HSPG (Figure 
1B) gave identical results. This consisted of a strong linear staining of the GBM, together with 
a weak linear staining of tubular basement membranes. Similar results were obtained with 
four independent anti-agrin antisera, and all corresponding pre-immune sera were negative 
(not shown). The observed staining pattern closely resembled that observed with the pAb
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Figure 2. D istribution of agrin (top panel) and GBM-HSPG (bottom panel) in rat skeletal muscle. (A, C)
Staining by rhodamine-a-bungarotoxin indicates the acetylcholine receptor clusters in the neuromuscular junction. 
(B, D) Indirect immunofluorescence using the anti-agrin mAb Agr-33 (B) and anti-GBM-HSPG pAb K42 (D). Bars, 
50 mm.
K42, directed against HSPG isolated from the GBM (Figure 1C). To confirm that the 
glomerular staining was not an artifact due to crossreactivity of the pAb, two mAbs Agr-33 
(Figure 1D) and Agr-131 (not shown) against rat agrin were used to stain rat kidney cortex. 
Both antibodies produced a strong staining of the GBM, and a very weak staining of the 
tubular basement membrane. In comparison with anti-agrin and anti-GBM-HSPG staining, 
the anti-perlecan antibody produced a clearly different staining pattern (Figure 1E). The above 
results indicate that agrin is present in the GBM.
Because agrin is concentrated at the NMJ, we next compared staining patterns of anti-agrin 
and anti-GBM-HSPG antibodies in rat skeletal muscle sections. Junctions were identified by 
staining with rhodamine-a-bungarotoxin, recognizing the acetylcholine receptor clusters on 
the postsynaptic membrane (Figure 2A). Staining of the same section with mAb Agr-33 
(directed against rat agrin) resulted in a strong signal localized at the synaptic cleft of the 
neuromuscular junction (Figure 2B). All junctions identified by rhodamine-a-bungarotoxin 
staining showed a strong immunofluorescence. In addition, extrajunctional patches were
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observed that were strongly 
stained by Agr-33 but not by rho- 
damine-a-bungarotoxin. Further­
more, a weak staining of base­
ment membranes surrounding the 
muscle fibers was present. Com­
parably, sections stained by rho- 
damine-a-bungarotoxin (Figure 
2C) were immunostained with 
anti-GBM-HSPG pAb K42 
(Figure 2D). In agreement with 
Agr-33, K42 stained all 
neuromuscular junctions together 
with some focal accumulations 
outside the junction and the weak 
staining of the basement 
membrane that surrounds the 
muscle fibers.
Immuno-electron microscopy
To study the distribution of basement membrane HSPGs at the ultrastructural level, immuno- 
electron microscopy was performed on human kidney cortex. The distribution of agrin (top 
panel), perlecan (middle panel) and the GBM-HSPG recognized by M215 (bottom panel) is 
shown in Fig. 3. Using anti-agrin pAb 707, a strong linear staining was seen along the full 
length of the GBM (Fig. 3A-C). The whole width of the GBM was stained, but the signal was 
markedly stronger at both edges of the GBM. This localization at both the endothelial and 
epithelial side of the GBM was confirmed by immunogold labeling (Fig. 3C). We could also 
observe a faint staining of the mesangial matrix. The anti-perlecan mAb 95J10 produced a 
strong staining at the interface of the mesangium and the capillary endothelium (Fig. 3D-F). 
The overall GBM staining was mild, and restricted to the endothelial side in a non-linear 
pattern. Also by immunogold labeling, perlecan staining was found exclusively on the 
endothelial side of the GBM. With mAb M215, a strong linear staining was observed 
throughout the whole length and width of the GBM (Fig. 3 G-I). Immunogold labeling also 
demonstrated that the M215-epitope was present throughout the GBM. Occasionally, a mild 
staining of the mesangial matrix was observed. The linear distribution of the agrin-like HSPG 
along the GBM corresponds with the homogenous linear staining by immunofluorescence in 
this and previous studies (Figure 1B) [7-9,29]. Also the ultrastructural distribution of perlecan 
corresponds with the staining observed in immunofluorescence, characterized by a 
discontinuous staining of the capillaries and a relatively strong staining of the mesangium and 
Bowman’s capsule (Figure 1E) [3,5,30].
Immunoreactivity of anti-agrin pAb 707 with purified GBM-HSPG
The described results show a colocalization of agrin-like and GBM-HSPG-like 
immunoreactivity in both the GBM and the neuromuscular junction. Given the unknown 
identity of the purified GBM-HSPG and the identification of agrin as a HSPG, we asked
< -------------------------------------------------------------------------------------------------------------------------
Figure 3. Immuno-electron m icroscopy of human glomeruli w ith anti-agrin antiserum 707 (A C); anti- 
perlecan mAb 95J10 (D F) and anti-GBM-HSPG mAb M215 (G I). Immunolocalization was visualized by 
peroxidase staining (A, B, D, E, G and H) or by colloidal gold particles (C, F and I). Standard bar sizes are 2 mm 
(A, D, G) and 0.25 mm (B, C, E, F, H, I) respectively.
A492
Figure 4. Recognition of GBM-HSPG by serially diluted 
anti-agrin antiserum (open squares) or pre-immune 
serum (open circles) in ELISA. Similarly, binding of a 
mouse mAb M138 was measured in presence of serially 
diluted anti-agrin antiserum as a competitor (solid squares).
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whether both proteoglycans could 
be identical. To address this, 
isolated GBM-HSPG was coated 
into microtiter wells. Antisera 
raised against agrin showed a 
strong reaction with this 
proteoglycan, whereas the corre­
sponding pre-immune sera were 
negative (Figure 4, open squares 
and circles). In addition we tested 
the capability of anti-agrin 
anti serum to compete in ELISA 
with four different mAbs against 
human GBM-HSPG (including 
M215 and M l 3 8, all recognizing 
the same core protein). The 
binding of three mAbs was not 
blocked. Since the anti-agrin 
antiserum was raised against chick 
agrin, this suggests that the corre­
sponding epitopes of human agrin 
are not immunogenic or absent in 
chick agrin. However, the binding 
of M138 to native GBM-HSPG 
was inhibited by anti-agrin (Figure 
4, solid squares). These results 
show that the isolated GBM- 
HSPG is recognized by both anti- 
GBM-HSPG and anti-agrin 
antibodies.
Western blot analysis of isolated 
GBM-HSPG was performed with 
antibodies against agrin and 
GBM-HSPG (Figure 5). All 
antibodies recognized a large 
proteoglycan with a char­
acteristically smeared appearance 
and similar molecular mass. The 
antigen was sensitive to nitrous 
acid treatment, indicating the 
presence of heparan sulfate 
residues. The nitrous acid-treated 
core protein was recognized by all 
antibodies and displayed a 
molecular mass of approximately 
200-210 kDa. Besides this 
prominent band, two additional bands were weakly stained by M215 and M138. These bands 
are presumably degradation products, and could also be visualized with pAb 707 after 
prolonged exposure (not shown).
- 250
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Figure 5. Western b lo t analysis of intact (top) and nitrous acid 
treated GBM-HSPG (bottom). Proteoglycans were denatured and 
separated by SDS-pAg E (3-20%). Antibodies used were pAb 707 
(lane 1), mAb M215 (lane 2) and mAb M138 (lane 3). Positions of 
marker proteins are indicated on the right.
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Quantitative detection of HSPGs in isolated glomeruli
The strong staining of agrin in immunofluorescence 
and immuno-electron microscopy suggests that it is 
highly concentrated in the GBM. To determine the 
relative contribution of each molecule to the total 
HSPG content of the glomerulus, quantitative 
ELISA was performed with 95J10 and M215. A 
standard curve for 95J10 was constructed using an 
affinity-purified recombinant fragment comprising 
domains I and II of human perlecan [6]. For M215, 
the purified GBM-HSPG preparation was used as 
standard. The results (Table 2) show that the agrin- 
like HSPG is present in sixfold molar excess over 
perlecan.
D is c u s s io n
In this study we have used pAb 707 against chick agrin [24] to investigate the presence of 
agrin in the human glomerulus. To this end, we first confirmed that the pAb retains a high 
specificity for agrin in mouse, rat and human tissues. Comparing the distribution of agrin and 
GBM-HSPG by immunofluorescence, we found an exact colocalization in both the 
glomerulus and the neuromuscular junction. Consistently, the pAb 707 recognized the HSPG 
isolated from the human GBM in a direct ELISA assay. The antiserum could also inhibit the 
binding of mAb M138 to GBM-HSPG in a competition ELISA assay. This demonstrates that 
one of the epitopes recognised by pAb 707 is identical or proximate to the M138 epitope, 
known to be located on the core protein [9]. Finally, the estimated molecular mass of the core 
protein (200-210 kDa) corresponds to that of rat agrin [11, 13] as shown by immunoblot 
analysis. These data suggest that the unidentified HSPG component of the GBM is identical to 
agrin. Nevertheless, small differences are seen by immuno-electron microscopy with pAb 707 
and mAb M215. The anti-agrin antibody is particularly bound to the endothelial and epithelial 
side of the GBM, whereas M215 binding was observed throughout the width of the GBM. 
This difference, also confirmed by immunogold labeling, might be related to different access 
of both antibodies to the lamina densa. Alternatively, the corresponding epitopes may be 
shielded by interactions of agrin in the lamina densa.
The quantitation of the agrin-like GBM-HSPG and perlecan in extract from isolated glomeruli 
could be misleading in two ways. Firstly, the standard used for quantitation by M215 cannot 
be considered absolutely contaminant-free, even though it was extensively purified. Although 
no contaminants were observed by visual inspection of SDS-PAGE analyses, a trace amount 
of perlecan was detected by ELISA (Table 1). Likewize, the presence of trace amounts of 
hypothetical other HSPG species can not be excluded. And secondly, the relative 
concentrations of both HSPGs in whole glomeruli are not necessarily identical to those in the 
GBM. Considering that perlecan is also present in Bowman=s capsule (Figure 1E), the 
relative abundance of the agrin-like HSPG within the GBM is presumably even higher.
Which functions could agrin serve in the human GBM ? Although many aspects of the 
structure and function of agrin isoforms have been studied in detail, the presence of agrin in 
the mammalian kidney and GBM was not yet described. One study reported the occurrence of 
agrin-like proteins in the tubular structures of chick kidney, and showed that these molecules 
have only little AChR-clustering activity [21]. This suggests a distinct function for agrin in 
the GBM. We speculate on three possible functions. First, the presence of agrin contributes to 
the incorporation of polyanions into the GBM. The ultrastructural localization of the different
Table 2. HSPG levels in extract from 
isolated human glomeruli, determined by 
quantitative ELISA with mAbs 95J10 and
M215 (n=5).
Antibody used HSPG concentration
95J10 0.46 ± 0.08 |j M
M215 2.86 ± 0.14 j M
9 4  CHAPTER FIVE
HSPGs within the GBM does not support a key role for perlecan in determining selective 
permeability. The contribution of agrin may be crucial regarding its homogenous presence in 
the GBM (Figure 3) and its abundance in isolated glomeruli (Table 2). Hence, agrin could be 
essential to maintain charge-selectivity during ultrafiltration.
Second, agrin may provide a cytoskeletal link for the GBM through its interaction with a -  
dystroglycan [33] and laminin [34]. While a-dystroglycan appears not to be the receptor 
involved in AChR clustering [18, 35], it has been shown to be important for the development 
of kidney epithelial cells [36, 37]. Whereas the a-dystroglycan-binding region of agrin is 
mapped to the C-terminal half of the molecule, an N-terminal fragment of 130 amino acids 
was shown to bind to laminin-1, -2 and -4 [34]. Binding of agrin to laminin can also be 
expected in the GBM since its laminin composition resembles that of the NMJ, including the 
chains a1 , ß2 and g1 [38, 39].
A third possible function of agrin in the GBM is suggested by the presence of nine Kazal-type 
protease inhibitor domains [13]. Agrin inhibits the proteases trypsin, chymotrypsin and 
plasmin [23], and therefore it may stabilize the structure of the extracellular matrix.
In contrast to the early expression of agrin in synaptogenesis, the onset of expression in the 
GBM may be delayed to later stages of development. Agrin-deficient mutant mice show 
aberrations in the development of neuromuscular junctions and die short before birth. At this 
stage, no prominent kidney malformations were mentioned [40]. This relates to the abundance 
of agrin mRNA in the early development of the rat nervous system, in later stages (E15-P1) 
accompanied by lower but significant mRNA levels in the kidney [41]. Important alterations 
in proteoglycan composition are known to occur during development and maturation of the 
GBM [8, 42]. Agrin is likely to be one of the components involved in these changes.
From this study we conclude that agrin is a major HSPG component of the human GBM. This 
finding has drastic implications for the investigation of structural and functional properties of 
the GBM. Changes in agrin structure and content may be important for glomerular function 
and play a role in various types of glomerulopathy. The structure of the agrin isoform which is 
present in the GBM and its relevance for cell-matrix interactions are subjects for further 
investigation.
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chapter six S u m m a r y  Agrin is a  heparan  sulfate proteoglycan involved in the 
developm ent of the neurom uscular junction during em bryogenesis.
In addition to this well-characterized function, agrin m ay have 
functions in other tissu es , and during other s tag es  in developm ent.
In this study we present the cDNA seq u en ce  that encodes hum an 
agrin, and dem onstrate  a  high agrin content in adult basem ent 
m em branes. The N-terminal domain of hum an agrin is highly similar 
to that of chick agrin, suggesting a  similar function in laminin binding. 
The p resence  of four sG X G  tetrapeptide seq u en ces  supports 
serine-linked glycosylation of the core protein, two sites being 
particularly favorable for heparan  sulfate attachm ent. The SEA 
m odule (previously assoc iated  with O-glycosylation) is also strongly 
conserved betw een species. Com parison of agrin mRNA levels in 
fetal and adult hum an tissues show ed a  rem arkable upregulation in 
adult kidney and lung. T hese  high transcription levels corresponded 
with the accum ulation of agrin in the alveolar and glomerular 
basem en t m em branes. The data  provide new directions for 
investigating the role of agrin in its different physiological 
environm ents, including the b asem en t m em branes of the 
neurom uscular junction, kidney and lung.
In t r o d u c t io n
Agrin is a heparan sulfate proteoglycan (HSPG) of basement membranes (BMs). It induces 
aggregation of acetylcholine receptors (AChRs) at the neuromuscular junction (NMJ) [1, 2]. 
Its primary structure was previously reported for electric ray, rat, mouse and chick [3-6]. The 
agrin gene was shown to encode multiple isoforms through alternative splicing at three sites, 
designated x, y  and z. These splice variants differ greatly in function [6-9]. During the 
formation of the NMJ (the contact site of a motoneuron and a skeletal muscle cell), agrin 
isoforms expressed by motoneurons induce the clustering of AChRs within the postsynaptic 
membrane. Isoforms expressed by the muscle cell do not have a clustering activity [6, 10-12]. 
Agrin-related proteins are also expressed in non-neural tissues, suggesting functions in 
addition to neuromuscular synapse development [1, 13-16]. The many molecular interactions 
described for agrin make this feasible. Agrin was shown to bind laminin [17, 18] and a -  
dystroglycan [19, 20]. a-Dystroglycan is a peripheral membrane receptor associated with the 
dystrophin glycoprotein complex [20]. Thus, agrin may anchor the BM to the cytoskeleton 
and be involved in signal transduction. Furthermore, agrin was recently identified as a major 
HSPG of the glomerular BM [21]. Here it could participate in the charge-selective 
ultrafiltration process. Agrin could be involved in the storage, activation, inhibition or 
presentation of various growth factors, and modulate their effect in a tissue-dependent 
manner.
The human agrin gene was previously mapped to chromosome 1 [5], but the cDNA structure 
is unknown. To obtain cDNA clones encoding full-length agrin, we used expressed sequence 
tag information from public databases [18, 22]. Here, we report the cDNA sequence of human 
agrin, and provide data concerning its distribution in human tissues.
T o Index
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Materials
Human skeletal muscle poly(A)-rich RNA was purchased from Clontech (Palo Alto, CA, 
USA). RNAzolB was from Campro Scientific (Veenendaal, The Netherlands). Oligo(dT) 
cellulose columns were from New England Biolabs (Beverly, MA, USA). Superscript II, 
oligonucleotides and biochemicals for RACE procedures (rapid amplification of cDNA ends) 
were from Life Technologies (Breda, The Netherlands). Long-distance polymerase chain 
reactions were performed using the Expand PCR system (Boehringer Mannheim, Mannheim, 
Germany) according to the manufacturer's instructions. This system uses a mixture of Taq and 
Pwo polymerase [23]. For subcloning of the PCR products the pGEM-T vector was used 
(Promega, Madison, USA).
Molecular cloning of human agrin cDNA
Human glomerular RNA was isolated from kidney cortex tissue using established sieving 
methods [24] and extraction in RNAzolB. Poly(A)-rich RNA was obtained by standard 
procedures [25]. In addition to this RNA preparation, commercially available poly(A)-rich 
RNA from human skeletal muscle was used. Full length cDNA synthesis was performed 
using Superscriptll with both oligo(dT) and random primers. This reaction mixture was 
incubated for 60 min at 42°C. The resulting cDNA preparations were used as template for 
long-distance PCR reactions.
The oligonucleotides used to amplify each cDNA clone (designated Cs1 through Cs4) are 
listed in Table 1. The position of each clone is indicated in Figure 1A. Clones Cs1 and Cs2 
were derived from human glomerular cDNA; Cs3 and Cs4 from skeletal muscle cDNA. The 
design of the primers was based on sequence information from public databases. Relevant 
accession numbers are M64780 (rat cDNA), M94271, U35613 (chick cDNA), M92654 
(mouse genomic DNA), L01423 (marine ray cDNA), S44195, H11951 and U84406 (human 
expressed sequence tags) [3-6, 16, 18, 22]. The procedures used for RACE experiments are 
described elsewhere [26]. The resulting PCR products were cloned into the pGEM-T vector 
and propagated in E. coli strain JM109.
Sequence analysis
Automated sequence analysis was carried out using an ABI377-type apparatus (ABI Prism, 
Warrington, Great Britain). The reported cDNA structure is based on high-quality double­
stranded sequence information. Labeling reactions were performed with Amplitaq polymerase 
using the Dye Terminator Sequencing system (ABI Prism) in a GeneAmp 9600 thermal cycler 
(Perkin Elmer Cetus, Gouda, The Netherlands). Multiple independent clones were sequenced
Table 1: Oligonucleotides used for amplification of cDNA clones encoding human agrin. The clones Cs1 
and Cs2 were amplified by a single PCR, whereas clones Cs3 and Cs4 were generated using a second 
reaction with nested primers. Universal primers for RACE procedures used were according to the supplier's 
protocol [26]. All primers are listed in 5' to 3' direction.________________________________________________
Clone (size) forward primer reverse primer
Cs1
5? cgagacctgtggagatgccgtg gttggtgttgacgggcacggtggaacgcagc
Cs2
Is?CO gccgcgtgcgtcctgcccg ctggtcacacgggccctg
Cs3
5?LO gagaaggcactgcagagcaaccactttgaactgagc 3'-RACE anchored d(T) primer
gctgcgttccaccgtgcccgtcaacaccaac 3'-RACE anchor primer
Cs4
5? 5'-RACE anchored d(G) primer ctgcccgggcctcctcgatc
5'-RACE anchor primer cacggcatctccacaggtctcg
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from purified plasmid DNA as template. PCR products from RACE experiments were 
sequenced from purified PCR product as template, isolated using the Qiaquick protocol 
(Qiagen, Hilden, Germany).
Computational chemistry was performed on the CAOS/CAMM network (University of 
Nijmegen, The Netherlands) by using the following programs. Signal sequence and cleavage 
site predictions were calculated with the SignalP program [27]. MOTIFS was used to identify 
amino acid sequence patterns described in the PROSITE dictionary. PEPSTATS was used to 
calculate the molecular mass of the core protein. The BLASTP algorithm was used to detect 
similarity with known amino acid sequences [28].
Hybridization procedures
A master blot, containing poly(A)-rich RNA isolated from various human tissues, and a 
human multiple tissue northern blot were purchased from Clontech. The quantity of mRNA 
spotted for each tissue onto the master blot was normalized using eight different housekeeping 
gene transcripts as probes (ribosomal protein S9, ubiquitin, 23-kDa highly basic protein, 
hypoxanthine guanine phosphoribosyl transferase, tubulin, b-actin, phospholipase and 
glyceraldehyde-3-phosphate dehydrogenase). A probe homologous to human agrin was 
prepared by random primed labeling [25]. The filters were washed under stringent conditions 
(0.1 x SSPE, 0.5% SDS at 55°C) and analyzed by autoradiography. The signals on the master 
blot were quantified with a phosphorimager (BioRad, Veenendaal, The Netherlands), 
subtracted with the average background density, and integrated over the spot area with the 
Molecular Analyst software package (BioRad Laboratories, Veenendaal, The Netherlands).
Immunofluorescence
Cryosections from inflated human lung tissue and kidney cortex were prepared as previously 
described [29, 30]. Skeletal muscle cryosections were prepared from human diaphragm. To 
stain agrin we used a rabbit antiserum raised against full-length recombinant chick agrin [16], 
a kind gift of Dr. M.A. Ruegg, Dept. of Anatomy, University of Basel, Switzerland. We 
previously showed that this antibody retains specificity for human agrin [21]. 
Immunofluorescence staining and microscopic analysis were performed as described 
previously [21].
RESULTS
Molecular cloning and domain structure of human agrin
Using long-distance polymerase chain reactions in conjunction with 5'- and 3'- RACE 
strategies [26], we obtained four cDNA clones encoding human agrin. The positions of the 
clones are indicated in Figure 1A. The clones together comprise a cDNA sequence of 7032 
nucleotides (Figure 2), providing an open reading frame ending at position 6081. The extreme 
5' terminus of the cDNA sequence is incomplete, and starts 30 nucleotides upstream from the 
predicted signal peptide cleavage site [18, 27]. The mature core protein comprises 2016 amino 
acids (212 kDa). The agrin core protein is composed of multiple modules, depicted in Figure
IB. The degree of similarity with agrins from other species is given for each domain in Figure
IC. The overall conservation is strong, with high similarities observed especially for the 
laminin-binding domain and the SEA module. Since the core protein structure was previously 
reviewed in detail for other species, we will discuss the domain organization only briefly.
The N-terminus of the mature polypeptide is formed by a module named NtA, that was 
experimentally shown to have a laminin-binding function in chick agrin [18]. Nine follistatin- 
like domains are present, sharing similarity with many other Kazal-type protease inhibitors 
including pancreatic trypsin inhibitor, follistatin, ovoinhibitor, thrombin inhibitor and elastase
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Figure 1. A) Position of individual cDNA clones encoding human agrin. B) Schematic representation of the 
domain structure of agrin. Arrows indicate putative glycosaminoglycan attachment sites. C) The degree of 
similarity between human agrin and agrins from other species, calculated as the percentage of identical amino 
acids (nd: no data). D) Symbols and nomenclature for individual domains are as described by [37].
inhibitor. In most cases the similarity was limited to the conserved PVCGSDGVTY pattern 
(underlined in Figure 2). In the case of the elastase inhibitor, a high similarity with the fifth 
follistatin-like domain extended to the specificity-determining region just upstream from this 
conserved pattern. However, the functionality of the protease inhibitor-like domains is still 
unclear, and the value of these predictions remains to be investigated. The 8th and 9th 
follistatin-like domains are separated by two LE repeats with similarity to the laminin-type 
epidermal growth factor (EGF) repeats. These elements most likely form a rod-like structure 
comparable to those observed on the short arms of laminins [31].
The central part of the agrin molecule is composed of two S/T-rich domains, characterized by 
their extremely high proline, threonine and serine content. The first domain contains 25% 
proline, 18% threonine and 16% serine; the second domain 22%, 16% and 9% respectively. 
Both domains are devoid of cysteine residues. The degree of conservation of the S/T-rich 
domains between human and rat agrin is relatively low (49% and 65% amino acid identity), 
but the prolines are particularly conserved. The SEA module is a pattern of secondary 
structure found in sperm protein, enterokinase, agrin, MUC1 (a mucin-like glycoprotein) and 
perlecan. Since all these molecules are components of the extracellular matrix and occur in 
heavily glycosylated environments, the SEA module is suggested to be involved in O- 
glycosylation [32]. Four potential attachment sites for glycosaminoglycans (double underlined 
in Figure 2) were detected by ProSite analysis, matching the consensus sequence SGXG [33]. 
Finally, the C-terminal region of agrin contains four EGF-like repeats and three laminin-G- 
like domains.
----------------------------------------------------------------------------------------------------------------------------►
Figure 2. Primary structure of human agrin. First line, cDNA sequence with nucleotide numbering at the right 
and left. Second line, deduced amino acid sequence. Domain borders are indicated by arrowheads below the 
amino acid sequence. The conserved regions of follistatin-like domains are underlined. To indicate possible sites 
for glycosaminoglycan attachment, SGXG motifs are bold-underlined and SG dipeptides are boxed. Putative sites 
for alternative splicing (x, y and z) are indicated in parentheses, and the 9-amino acid insert in splice site x is 
dotted-underlined. This sequence is available from GenBank under accession number AF016903.
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1 gccgcgtgcgtcctgcccggagccggcgggacatgcccggagcgcgcgctggagcggcgcgaggaggaggcgaacgtggtg 81
1 a a c v l p g a g g a T C P E R A L E R R E E E A N V V 27
signal peptide (partial) A laminin-binding domain
82 ctcaccgggacggtggaggagatcctcaacgtggacccggtgcagcacacgtactcctgcaaggttcgggtctggcggtac 162
28 L T G T V E E I L N V D P V Q H T Y S C K V R V W R Y 54
163 ttgaagggcaaagacctggtggcccgggagagcctgctggacggcggcaacaaggtggtgatcagcggctttggagacccc 243
55 L K G K D L V A R E S L L D G G N K V V I [¿^¡J_g_g D P 81
244 ctcatctgtgacaaccaggtgtccactggggacaccaggatcttctttgtgaaccctgcacccccatacctgtggccagcc 324
82 L I C D N Q V S T G D T R I F F V N P A P P Y L W P A 108
325 cacaagaacgagctgatgctcaactccagcctcatgcggatcaccctgcggaacctggaggaggtggagttctgtgtggaa 405
109 H K N E L M L N S S L M R I T L R N L E E V E F C V E 135
406 gataaacccgggacccacttcactccagtgcctccgacgcctcctgatgcgtgccggggaatgctgtgcggcttcggcgcc 486
136 D K P G T H F T P V P P T P P D A A C  R G M L C G F G A 162
follistatin-like domain 1
487 gtgtgcgagcccaacgcggaggggccgggccgggcgtcctgcgtctgcaagaagagcccgtgccccagcgtggtggcgcct 567
163 V C E P N A E G P G R A S C V C K K S P C P S V V A P 189
568 gtgtgtgggtcggacgcctccacctacagcaacgaatgcgagctgcagcgggcgcagtgcagccagcagcgccgcatccgc 648
190 V C G S D A S T Y S N E C E L Q R A Q C S Q Q R R I R 216
649 ctgctcagccgcgggccgtgcggctcgcgggacccctgctccaacgtgacctgcagcttcggcagcacctgtgcgcgctcg 729
217 L L S R G P C G S R D P AC S N V T C S F G S T C A R S 243
follistatin-like domain 2
730 gccgacgggctgacggcctcgtgcctgtgccccgcgacctgccgtggcgcccccgaggggaccgtctgcggcagcgacggc 810
244 A D G L T A S C L C P A T C R G A P E G T V C G S D G 270
811 gccgactaccccggcgagtgccagttcctgcgccgcgcctgcgcccgccaggagaatgtcttcaagaagttcgacggccct 891
271 A D Y P G E C Q F L R R A C A R Q E N V F K K F D G P 297
892 tgtgacccctgtcagggcgccctccctgacccgagccgcagctgccgtgtgaacccgcgcacgcggcgccctgagatgctc 972
298 C D P ^ C  Q G A L P D P S R S C R V N P R T R R P E M L 324
follistatin-like domain 3
973 ctacggcccgagagctgccctgcccggcaggcgccagtgtgtggggacgacggagtcacctacgaaaacgactgtgtcatg 1053
325 L R P E S C P A R Q A P V C G D D G V T Y E N D C V M 351
1054 ggccgatcgggggccgcccggggtctcctcctgcagaaagtgcgctccggccagtgccagggtcgagaccagtgcccggag 1134
352 G R [ S " G [ A A R G L L L Q K V R [ S "G [ Q C Q G R D Q C ^ P  E 378
1135 ccctgccggttcaatgccgtgtgcctgtcccgccgtggccgtccccgctgctcctgcgaccgcgtcacctgtgacggggcc 1215
379 P C R F N A V C L S R R G R P R C S C D R V T C D G A 405
follistatin-like domain 4
1216 tacaggcccgtgtgtgcccaggacgggcgcacgtatgacagtgattgctggcggcagcaggctgagtgccggcagcagcgt 1296
406 Y R P V C A Q D G R T Y D S D C W R Q Q A E C R Q Q R 432
1297 gccatccccagcaagcaccagggcccgtgtgaccaggccccgtccccatgcctcggggtgcagtgtgcatttggggcgacg 1377
433 A I P S K H Q G P C D Q A P S P A C L G V Q C A F G A T 459
follistatin-like domain 5
1378 tgtgctgtgaagaacgggcaggcagcgtgtgaatgcctgcaggcgtgctcgagcctctacgatcctgtgtgcggcagcgac 1458
460 C A V K N G Q A A C E C L Q A C S S L Y D P V C G S D 486
1459 ggcgtcacatacggcagcgcgtgcgagctggaggccacggcctgtaccctcgggcgggagatccaggtggcgcgcaaagga 1539
487 G V T Y G S A C E L E A T A C T L G R E I Q V A R K G 513
1540 ccctgtgaccgctgcgggcagtgccgctttggagccctgtgcgaggccgagaccgggcgctgcgtgtgcccctctgaatgc 1620
514 P C D R a C G Q C R F G A L C E A E T G R C V C P S E C 540
*  follistatin-like domain 6
1621 gtggctttggcccagcccgtgtgtggctccgacgggcacacgtaccccagcgagtgcatgctgcacgtgcacgcctgcaca 1701
541 V A L A Q P V C G S D G H T Y P S E C M L H V H A C T 569
1702 caccagatcagcctgcacgtggcctcagctggaccctgcgagacctgtggagatgccgtgtgtgcttttggggctgtgtgc 1782
568 H Q I S L H V A S A G P C E T AC G D A V C A F G A V C 594
follistatin-like domain 7
1783 tccgcagggcagtgtgtgtgtccccggtgtgagcaccccccgcccggccccgtgtgtggcagcgacggtgtcacctacggc 1863
595 S A G Q C V C P R C E H P P P G P V C G S D G V T Y G 621
1864 agtgcctgcgagctacgggaagccgcctgcctccagcagacacagatcgaggaggcccgggcagggccgtgcgagcaggcc 1944
622 S A C E L R E A A C L Q Q T Q I E E A R A G P C E Q A 648
1945 gagtgcggttccggaggctctggctctggggaggacggtgactgtgagcaggagctgtgccggcagcgcggtggcatctgg 2025
649 E C G [ S "G [ G J S G I I S G I E D G D a C E Q E L C R Q R G G I W 675
follistatin-like domain 8
2026 gacgaggactcggaggacgggccgtgtgtctgtgacttcagctgccagagtgtcccaggcagcccggtgtgcggctcagat 2106
676 D E D S E D G P C V C D F S C Q S V P G S P V C G S D 702
2107 ggggtcacctacagcaccgagtgtgagctgaagaaggccaggtgtgagtcacagcgagggctctacgtagcggcccaggga 2187
703 G V T Y S T E C E L K K A R C E S Q R G L Y V A A Q G 729
2188 gcctgccgaggccccaccttcgccccgctgccgcctgtggcccccttacactgtgcccagacgccctacggctgctgccag 2268
730 A C R G P T F A P L P P AV A P L H C A Q T P Y G C C Q 756
LE domains
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2269 gacaatatcaccgcagcccggggcgtgggcctggctggctgccccagtgcctgccagtgcaacccccatggctcttacggc 2349
757 D N I T A A R G V G L A G C P S A C Q C N P H G S Y G 783
2350 ggcacctgtgacccagccacaggccagtgctcctgccgcccaggtgtggggggcctcaggtgtgaccgctgtgagcctggc 2430
784 G T C D P A T G Q C S C R P G V G G L R C D R C E P G 810
2431 ttctggaactttcgaggcatcgtcaccgatggccggagtggctgtacaccctgcagctgtgatccccaaggcgccgtgcgg 2511
811 F W N F R G I V T D G R | S G | C T P C S C D P Q G A V R 837
2512 gatgactgtgagcagatgacggggctgtgctcgtgtaagcccggggtggctggacccaagtgtgggcagtgtccagacggc 2592
838 D D C E Q M T G L C S C K P G V A G P K C G Q C P D G 864
2593 cgtgccctgggccccgcgggctgtgaagctgacgcttctgcgcctgcgacctgtgcggagatgcgctgtgagttcggtgcg 2673
865 R A L G P A G C E A D A S Al P A T C A E M R C E F G A 891
follistatin-like domain 9
2674 cggtgcgtggaggagtctggctcagcccactgtgtctgcccgatgctcacctgtccagaggccaacgctaccaaggtctgt 2754
892 R C V E E | S G | S A H C V C P M L T C P E A N A T K V C 918
2755 gggtcagatggagtcacatacggcaacgagtgtcagctgaagaccatcgcctgccgccagggcctgcaaatctctatccag 2835 
919 G S D G V T Y G N E C Q L K T I A C R Q G L Q I S I Q 945
2836 agcctgggcccgtgccaggaggctgttgctcccagcactcacccgacatctgcctccgtgactgtgaccaccccagggctc 2916
946 S L G P C Q E A V A P S a T H P T S A S V T V T T P G L 972
A S/T-rich domain 1
2917 ctcctgagccaggcactgccggccccccccggcgccctccccctggctcccagcagtaccgcacacagccagaccacccct 2997
973 L L S Q A L P A P P G A L P L A P S S T A H S Q T T P 999
2998 ccgccctcatcgcgacctcggaccactgccagcgtccccaggaccaccgtgtggcccgtgctgacggtgccccccacggca 3078
1000 P P S S R P R T T A S V P R T T V W P V L T V P P T A 1026
3079 ccctcccctgcacccagcctggtggcgtccgcctttggtgaatctggcagcactgatggaagcagcgatgaggaactgagc 3159
1027 P S P A P S L V A S A F G E | S G | S T D G S S D E E L | 1053
3160 ggggaccaggaggccagtgggggtggctctggggggctcgagcccttggagggcagcagcgtggccacccctgggccacct 3240 
1054 D Q E A | S G | G L E P L E G S S V A T P G P P 1080
3241 gtcgagagggcttcctgctacaactccgcgttgggctgctgctctgatgggaagacgccctcgctggacgcagagggctcc 3321
1081 V E R A S C Y N S A L G C C S D G K T P S L D A E G S 1107
3322 aactgccccgccaccaaggtgttccagggcgtcctggagctggagggcgtcgagggccaggagctgttctacacgcccgag 3402
1108 N C a P A T K V F Q G V L E L E G V E G Q E L F Y T P E 1134
A SEA module
3403 atggctgaccccaagtcagaactgttcggggagacagccaggagcattgagagcaccctggacgacctcttccggaattca 3483
1135 M A D P K S E L F G E T A R S I E S T L D D L F R N S 1161
3484 gacgtcaagaaggatttccggagtgtccgcttgcgggacctggggcccggcaaatccgtccgcgccattgtggatgtgcac 3564
1162 D V K K D F R S V R L R D L G P G K S V R A I V D V H 1188
3565 tttgaccccaccacagccttcagggcacccgacgtggcccgggccctgctccggcagatccaggtgtccaggcgccggtcc 3645
1189 F D P T T A F R A P D V A R A L L R Q I Q V S R R R S 1215
3646 ttgggggtgaggcggccgctgcaggagcacgtgcgatttatggactttgactggtttcctgcgtttatcacgggggccacg 3726
1216 L G V R R P L Q E H V R F M D F D *W F P A F I T G A T 1242
.........(site" Xj..................
3727 tcaggagccattgctgcgggagccacggccagagccaccactgcatcgcgcctgccgtcctctgctgtgacccctcgggcc 3807
1243 | S "G | A I A A G A T A R A T T A S R L P S S A V T P R A 1269
S/T-rich domain 2
3808 ccgcaccccagtcacacaagccagcccgttgccaagaccacggcagcccccaccacacgtcggccccccaccactgccccc 3888
1270 P H P S H T S Q P V A K T T A A P T T R R P P T T A P 1296
3889 agccgtgtgcccggacgtcggcccccggccccccagcagcctccaaagccctgtgactcacagccctgcttccacgggggg 3969
1297 S R V P G R R P P A P Q Q P P K P A C D S Q P C F H G G 1323
EGF-like repeat 1
3970 acctgccaggactgggcattgggcgggggcttcacctgcagctgcccggcaggcaggggaggcgccgtctgtgagaaggtg 4050
1324 T C Q D W A L G G G F T C S C P A G R G G A V C a E K V 1350
A laminin-
4051 cttggcgcccctgtgccggccttcgagggccgctccttcctggccttccccaccctccgcgcctaccacacgctgcgcctg 4131
1351 L G A P V P A F E G R S F L A F P T L R A Y H T L R L 1377
G-like domain 1
4132 gcactggaattccgggcgctggagcctcaggggctgctgctgtacaatggcaacgcccggggcaaggacttcctggcattg 4212
1378 A L E F R A L E P Q G L L L Y N G N A R G K D F L A L 1404
4213 gcgctgctagatggccgcgtgcagctcaggtttgacacaggttcggggccggcggtgctgaccagtgccgtgccggtagag 4293
1405 A L L D G R V Q L R F D T G | S " G | P A V L T S A V P V E 1431
4294 ccgggccagtggcaccgcctggagctgtcccggcactggcgccggggcaccctctcggtggatggtgagacccctgttctg 4374
1432 P G Q W H R L E L S R H W R R G T L S V D G E T P V L 1458
4375 ggcgagagtcccagtggcaccgacggcctcaacctggacacagacctctttgtgggcggcgtacccgaggaccaggctgcc 4455
1459 G E S P | S ^"G | T D G L N L D T D L F V G G V P E D Q A A 1485
(siteyj
4456 gtggcgctggagcggaccttcgtgggcgccggcctgagggggtgcatccgtttgctggacgtcaacaaccagcgcctggag 4536
1486 V A L E R T F V G A G L R G C I R L L D V N N Q R L E 1512
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4537 cttggcattgggccgggggctgccacccgaggctctggcgtgggcgagtgcggggaccacccctgcctgcccaacccctgc 4617
1513 L G I G P G A A T R G |Sjj_gJ_V_£ E C G D H Pi C L P N P C 1539
EGF-like repeat 2
4618 catggcggggccccatgccagaacctggaggctggaaggttccattgccagtgcccgcccggccgcgtcggaccaacctgt 4698
1540 H G G A P C Q N L E A G R F H C Q C P P G R V G P T C 1566
4699 gccgatgagaagagcccctgccagcccaacccctgccatggggcggcgccctgccgtgtgctgcccgagggtggtgctcag 4779
1567 A D E K S P C Q P N P iC H G A A P C R V L P E G G A Q 1593
EGF-like repeat 3
4780 tgcgagtgccccctggggcgtgagggcaccttctgccagacagcctcggggcaggacggctctgggcccttcctggctgac 4860
1594 C E C P L G R E G T F C A Q T A I S " G I Q D G |S G I P F L A D 1620
laminin-G-like domain 2
4861 ttcaacggcttctcccacctggagctgagaggcctgcacacctttgcacgggacctgggggagaagatggcgctggaggtc 4941
1621 F N G F S H L E L R G L H T F A R D L G E K M A L E V 1647
4942 gtgttcctggcacgaggccccagcggcctcctgctctacaacgggcagaagacggacggcaagggggacttcgtgtcgctg 5022
1648 V F L A R G P I S G I L L L Y N G Q K T D G K G D F V S L 1674
5023 gcactgcgggaccgccgcctggagttccgctacgacctgggcaagggggcagcggtcatcaggagcagggagccagtcacc 5103
1675 A L R D R R L E F R Y D L G K G A A V I R S R E P V T 1701
5104 ctgggagcctggaccagggtctcactggagcgaaacggccgcaagggtgccctgcgtgtgggcgacggcccccgtgtgttg 5184
1702 L G A W T R V S L E R N G R K G A L R V G D G P R V L 1728
5185 ggggagtccccggttccgcacaccgtcctcaacctgaaggagccgctctacgtagggggcgctcccgacttcagcaagctg 5265
1729 G E S P V P H T V L N L K E P L Y V G G A P D F S K L 1755
5266 gcccgtgctgctgccgtgtcctctggcttcgacggtgccatccagctggtctccctcggaggccgccagctgctgaccccg 5346
1756 A R A A A V S I S G I F D G A I Q L V S L G G R Q L L T P 1782
5347 gagcacgtgctgcggcaggtggacgtcacgtcctttgcaggtcacccctgcacccgggcctcaggccacccctgcctcaat 5427 
1783 E H V L R Q V D V T S F A G H P A C T R A I S G I H P C L N 1809
EGF-like repeat ' 4
5428 ggggcctcctgcgtcccgagggaggctgcctatgtgtgcctgtgtcccgggggattctcaggaccgcactgcgagaagggg 5508 
1810 G A S C V P R E A A Y V C L C P G G F I S G I P H C iE K G 1836
laminin-
5509 ctggtggagaagtcagcgggggacgtggataccttggcctttgacgggcggacctttgtcgagtacctcaacgctgtgacc 5589 
1837 L V E K S A G D V D T L A F D G R T F V E Y L N A V T 1863
G-like domain 3
5590 gagagcgagaaggcactgcagagcaaccactttgaactgagcctgcgcactgaggccacgcaggggctggtgctctggagt 5670 
1864 E S E K A L Q S N H F E L S L R T E A T Q G L V L W IS | 1890
(site z)
5671 ggcaaggccacggagcgggcagactatgtggcactggccattgtggacgggcacctgcaactgagctacaacctgggctcc 5751 
1891 IGI K A T E R A D Y V A L A I V D G H L Q L S Y N L G S 1917
5752 cagcccgtggtgctgcgttccaccgtgcccgtcaacaccaaccgctggttgcgggtcgtggcacatagggagcagagggaa 5832 
1918 Q P V V L R S T V P V N T N R W L R V V A H R E Q R E 1944
5833 ggttccctgcaggtgggcaatgaggcccctgtgaccggctcctccccgctgggcgccacgcagctggacactgatggagcc 5913 
1945 G S L Q V G N E A P V T G S S P L G A T Q L D T D G A 1971
5914 ctgtggcttgggggcctgccggagctgcccgtgggcccagcactgcccaaggcctacggcacaggctttgtgggctgcttg 5994 
1972 L W L G G L P E L P V G P A L P K A Y G T G F V G C L 1998
5995 cgggatgtggtggtgggccggcacccgctgcacctgctggaggacgccgtcaccaagccagagctgcggccctgccccacc 6075 
1999 R D V V V G R H P L H L L E D A V T K P E L R P C P T 2025
6076 ccatgagctggcaccagagccccgcgcccgctgtaattattttctatttttgtaaacttgttgctttttgatatgattttc 6156
2026 P •
6157 ttgcctgagtgttggccggagggactgctggcccggcctcccttccgtccaggcagccgtgctgcagacagacctagtgct 6237
6238 gagggatggacaggcgaggtggcagcgtggagggctcggcgtggatggcagcctcaggacacacacccctgcctcaaggtg 6318
6319 ctgagcccccgccttgcactgcgcctgccccacggtgtccccgccgggaagcagccccggctcctgaatcaccctcgctcc 6399
6400 gtcaggcgggactcgtgtcccaaaaaggaaggggctgctgaggtctgatggggcccttcctccgggtgaccccacagggcc 6480
6481 tttccaagcccctatttgagctgctccttcctgtgtgtgctctggaccctgcctcggcctcctgcgccaatactgtgactt 6561
6562 ccaaacaatgttactgctgggcacagctctgcgttgctcccgtgctgcctgcgccagccccaggctgctgaggagcagagg 6642
6643 ccagaccagggccgatctgggtgtcctgaccctcagctggccctgcccagccaccctggacatgaccgtatccctctgcca 6723
6724 caccccaggccctgcgaggggctatcgagaggagctcactgtgggatggggttgacctctgccgcctgcctgggtatctgg 6804
6805 gcctggccatggctgtgttcttcatgtgttgattttatttgacccctggagtggtgggtctcatctttcccatctcgcctg 6885
6886 agagcggctgagggctgcctcactgcaaatcctccccacagcgtcagtgaaagtcgtccttgtctcagaatgaccaggggc 6966
6967 cagccagtgtctgaccaaggtcaaggggcaggtgcagaggtggcagggatggctccgaagccagaa 7032
Transcription of human agrin in fetal and adult tissues
Although many studies involving agrin are related to neuromuscular development, the expres­
sion of agrin is more widespread [1, 13, 14, 21]. We compared the transcription levels of 
agrin mRNA in fetal and adult human tissues, using the 4.1 kb cDNA clone Cs1 as a homolo­
gous probe. For quantitation, we used a dot blot containing carefully normalized quantities of 
poly(A)-rich RNA from a wide range of human tissues. The most prominent hybridization 
signals originated from adult kidney and lung (Figure 3). Agrin mRNA levels were also 
higher than average in adult liver and the thyroid gland. Besides this, low amounts of agrin
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mRNA were detected in all 
other tissues. These signals 
are likely specific, since 
they were identical after 
hybridization with a differ­
ent probe (clone Cs2). Most 
likely, the detected mRNA 
originates from the vascu­
larization of these tissues. 
This possibility is supported 
by the detection of agrin- 
like immunoreactivity in 
capillaries of many tissues 
[30, 34]. In fetal stages, 
agrin mRNA was detected 
at low levels in all tissues 
tested, but slightly higher 
amounts were observed in 
kidney and lung (Figure 3). 
To analyze the lengths of 
agrin mRNAs in kidney and 
lung, northern blot analyses 
were performed. Hybridiza­
tion with clone Cs2 visual - 
ized only a single mRNA 
band, 7.6 -  7.8 kb in size. In 
addition to this full length 
transcript, a relatively short 
transcript was identified 
when clone Cs1 was used as 
probe. The approximate 
length of this transcript was 
5 kb. The fact that this 
molecule does not hybridize 
to Cs2 indicates that it is 
truncated at the 5' end.
Expression of human agrin in kidney, lung and skeletal muscle
To compare the different agrin mRNA levels with protein expression, we analyzed the 
distribution of agrin immunoreactivity in adult human tissues by indirect 
immunofluorescence. Consistent with their high m RNA levels, a strong staining was 
observed in lung and kidney. In lung, agrin immunoreactivity was located in the alveolar as 
well as the capillary BMs (Figure 5A). Between the alveolar epithelium and the capillary 
endothelium, both BMs fuse. Also the capillaries of fetal and adult brain contained agrin-like 
immunoreactivity (data not shown). In the kidney (Figure 5B), anti-agrin immunostaining was 
prominent in the glomerular BM, together with a less intense staining of the tubular BM, 
Bowman's capsule and vascular walls. In skeletal muscle, clusters of agrin-like antigenicity 
were observed in the NMJ (Figure 5D). To identify junctions, a combined staining with 
rhodamine-conjugated a-bungarotoxin was performed (Figure 5C). Besides this intense
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Figure 3. Comparison of agrin mRNA levels in human tissues. RNA
isolated from various fetal and adult human tissues was hybridized with 
clone Cs1. Relative agrin mRNA levels were calculated in arbitrary units 
(A). The corresponding autoradiograph is shown (B). The quantity of RNA 
spotted onto this commercial blot (Clontech) was normalized by 
hybridization with probes for eight different housekeeping mRNAs. Adult 
kidney RNA was pooled from 3 male/female Caucasian donors, ages 42­
63. Adult lung RNA was pooled from 2 male/female Caucasians, ages 23 
and 42. Fetal RNA was pooled from 14 or more Caucasians, ages 17-28 
weeks.
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Figure 4. Northern blot analysis of 
human agrin mRNA in adult lung and 
kidney. After hybridization with clone Cs2 
as a probe, a single band was observed in 
lung (lane 1) and kidney (lane 2) 
corresponding with an mRNA length of 7.6­
7.8 kb. In addition, a relatively short 
transcript was observed in both tissues after 
hybridization with clone Cs1 (lane 3: lung; 
lane 4: kidney). The positions of molecular 
mass markers are indicated on the left.
107
t
Figure 5. Immunofluorescence detection of agrin in cryosections of human lung (A), 
kidney (B), and skeletal muscle (D). To identify neuromuscular junctions, in (C), the same 
section as shown in (D) was stained with a-bungarotoxin. The arrow in (A) indicates a capillary. 
Arrowheads in (C) and (D) indicate two typical neuromuscular junctions. Bar, 25 pm.
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staining, a weak staining of the BM surrounding the skeletal muscle cells was observed. 
These staining characteristics agree with previously reported data on rat, chick and mouse 
skeletal muscle [4, 13]. In summary, the results indicate that the high transcription levels in 
lung and kidney result in the accumulation of agrin in the alveolar and glomerular BM.
D is c u s s io n
Size and composition of human agrin
The cDNA sequence presented in this study lacks approximately 42 nucleotides of the signal 
sequence, assuming a similar signal peptide length compared to chick agrin. Thus, the 
predicted size of human agrin mRNA is 7.1 kb or larger, depending on the size of the 5' non­
coding region. This corresponds with the largest transcripts present in lung and kidney, as 
shown in Figure 4. After cleavage of the signal peptide, the calculated molecular mass of the 
human agrin core protein is 212 kDa. This agrees with previous estimations of 220-250 kDa, 
based on SDS-PAGE experiments after removal of the glycosaminoglycan chains [1, 7, 15]. 
The agrin core protein is substituted with heparan sulfate chains [1]. In previous studies on 
chick agrin, it was demonstrated that the proteoglycan comigrates with proteins of 
approximately 400 kDa as a diffuse band, characteristic for heavily glycosylated proteins [1]. 
As shown in Figure 2, the presented primary structure offers several sites for 
glycosaminoglycan attachment. The first potential O-glycosylation site is located near the N- 
terminal boundary of the fifth follistatin-like domain. This site contains a SGGSGSG 
sequence, of which the SGSG repeat unit was identified as a site that strongly supports 
glycosaminoglycan attachment, with preference for heparan sulfate rather than chondroitin 
sulfate [35]. The second possible attachment site that precedes the SEA module is most 
favorable, as far as the requirements for glycosaminoglycan attachment are known, for 
modification with heparan sulfate residues [1, 33, 35, 36]. This site is located in a strongly 
acidic cluster with acidic residues at -2  and -4  relative to the putative serine acceptor site (see 
Figure 2). Three additional SG dipeptides are present in this cluster and could also be 
glycosylated, given their position relative to acidic residues. Other SGXG patterns are placed 
in a less favorable context for substitution with HS chains, and therefore a function of these 
sites in glycosaminoglycan attachment is less likely as far as can be predicted. Thus, 
glycosaminoglycan attachment may be confined to the central region of the human agrin core 
protein (arrows in Figure 1B).
Age- and tissue-dependence of agrin expression
The role of neuronal agrin in embryogenesis is evident from numerous studies, and it is 
known that concentrations of agrin remain present in the adult NMJ. This correlates with the 
minor hybridization signals in skeletal muscle (Figure 3), because NMJs comprise only a 
minute part of the total tissue mass. However, the significance of agrin in non-neural tissues is 
not yet clear. In this study, we found a strong upregulation of agrin transcription in adult 
kidney and lung. This leads to the accumulation of agrin-like immunoreactivity in the BMs of 
these tissues, as shown by indirect immunofluorescence. In adult lung, the localization of 
agrin was primarily confined to the capillary and alveolar BM. In kidney most 
immunoreactivity was located in the glomerular BM, but the tubular BM was also stained.
Our results from northern blotting suggest that the agrin gene may produce a 5'-truncated 
transcript, encoding an isoform that carries heparan sulfates, but lacks the laminin-binding 
domain. In line with these ideas, relatively small agrin-like molecules were previously 
reported to occur [13, 37].
The composition of the reported cDNA at the known splice sites was as follows. At site x, 
located near the SEA module, a 9 amino acids insert (DWFPAFITG) was found as indicated
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in Figure 2. At the y  and z site, all analyzed clones were devoid of any inserts. The absence of 
a basic tetrapeptide at the y  site indicates that this agrin isoform has a low heparin-binding 
activity [9, 19]. At the z site, an insert is required for the acetylcholine receptor-clustering 
activity of neuronal agrin isoforms. The presented primary structure thus predicts a low 
acetylcholine receptor clustering activity for agrin from kidney and skeletal muscle, which is 
in agreement with previous experiments [13]. In a recent review, Ruegg and Bixby 
demonstrated high amounts of agrin-like protein in adult kidney and lung, which lack inserts 
at the y  and z site [38]. All findings indicate that agrin isoforms are not only involved in 
embryonic development, but may exert additional functions in mature tissues.
Significance of agrin expression for renal and pulmonary function
The glomerular, alveolar and neuromuscular BMs have in common that they are fused BMs 
assembled by two different cell types, located on opposite sides of the BM. The collagen fibril 
network in these matrices is mainly composed of collagen IV chains a3, a4  and a5 , whereas 
the a1 and a2  chains predominate in most other BMs [39]. Also the laminin composition is 
mutually comparable and different from other BMs, with the presence of the laminin b2 chain 
(S-laminin) as the most distinct characteristic [39-42].
In the glomerular BM, agrin likely acts as a permselectivity modulator. The importance of 
HSPGs in this structure was demonstrated by perfusing rat kidney with heparitinase, resulting 
in an increased permeability for anionic macromolecules, and hence albuminuria [43]. The 
contribution of agrin to the polyanionic charge of the glomerular BM may be essential for this 
mechanism [44]. A filtration-associated function was also suggested for agrin expressed in 
capillaries, especially those that act as a blood-brain barrier [34].
In the alveolar BM, the relevance of HSPGs was established by previous studies. Intratracheal 
instillation of elastase induced a decrease in alveolar HSPG content, followed by pulmonary 
emphysema [45]. A similar effect was observed after instillation of b-D-xyloside, an inhibitor 
of proteoglycan synthesis [30]. The function of agrin isoforms in the alveolar BM could be 
related to the inhibition of proteases [14]. The anti-proteolytic activity of agrin is particularly 
interesting because the disruption of the balance between proteolysis and protease inhibition 
is considered a causal factor in the pathogenesis of pulmonary emphysema [46].
Future directions
Up to date, agrin and perlecan are the only identified HSPGs associated with BMs. Both 
genes are clustered on the short arm of human chromosome 1 [5, 47, 48]. The presence of 
additional BM HSPG species is not unlikely [49]. The molecular cloning of cDNA encoding 
human agrin offers new starting points for the investigation of its functional properties. The 
high expression of agrin in the differentiated alveolar and glomerular BM suggests that agrin 
may be a mediator in pulmonary and renal function. Since HSPGs are known to play an 
important role in pulmonary emphysema and nephrotic syndrome, agrin may be involved in 
the pathogenesis of these disorders. In future research, we intend to focus on the role of agrin 
in various types of nephrotic syndrome. In addition, we will investigate the exact composition 
of agrin splice variants present in the human glomerular and alveolar BM.
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Functional analysis of human renal agrin
chapter seven S u m m a r y  The p resence  of agrin in the glomerular basem ent 
m em brane (GBM) su g g ests  that, in addition to its role in the 
developm ent the neurom uscular junction, this heparan  sulfate 
proteoglycan may have other functions in the kidney. To a s s e s s  
th e se  functional properties, w e produced 19 recom binant fragm ents 
of hum an kidney agrin a s  fusion proteins with glutathione S- 
transferase. The purified fusion proteins w ere used  to localise the 
epitope of 25 monoclonal antibodies, raised against HSPG purified 
from hum an GBM and tubular b asem en t m em brane (TBM). 
Epitopes w ere found in the N-terminal through central region of the 
agrin core protein, a  region near the ninth follistatin-like domain 
proving particularly immunogenic. Functional analy ses of the 
fragm ents show ed that the fifth follistatin-like domain had a 
relatively high plasm in-inhibiting activity. Furthermore, the N- 
terminal fragm ent AGR1 had laminin-binding activity. This activity 
w as utilised to analyse  agrin-laminin interactions in the GBM. AGR1 
adhered  to the g B m  in hum an kidney cortex tissue and also to 
extracellular matrix produced by cultured hum an podocytes and 
glom erular endothelial cells. Agrin expression w as exclusively 
detected  in matrix produced by podocytes. The results indicate that 
agrin has multiple functions in the GBM, ranging from the 
incorporation of heparan  sulfate to p ro tease  inhibition and cell- 
matrix interaction.
In t r o d u c t io n
Agrin, known as a heparan sulfate proteoglycan (HSPG) is well-characterized as a component 
of the neuromuscular junction with a synapse-organizing function [1-3]. Much is known 
about structural-functional relationships in this regard. Agrin induces the clustering of 
acetylcholine receptor molecules on the postsynaptic membrane [4-6]. This activity is 
exclusive for neuronal agrin isoforms, and depends on differential splicing at the z  site (called 
B in chick agrin) [7-10]. Muscle agrin isoforms also influence the differentiation of 
presynaptic structures, such as the formation of synaptotagmin clusters in the neuron [11]. 
Agrin is translocated to the extracellular matrix and immobilized there by its laminin-binding 
domain [12, 13].
Besides its role in synaptogenesis, agrin seems to have additional functions. For example 
agrin interacts with a-dystroglycan, a cell surface glycoprotein that is linked to the 
dystrophin-associated glycoprotein complex and the cytoskeleton [14-17]. The 212 kDa core 
protein contains many large domains that appear to be redundant for neuronal function, in 
particular the follistatin-like domains, laminin-like EGF repeats, serine/threonine-rich regions 
and SEA module. In fact, a 45 kDa C-terminal fragment of neuronal agrin is sufficient to 
induce clustering of acetylcholine receptors [7]. Also the role of the heparan sulfate (HS) 
residues linked to the central region of the core protein is unknown. These considerations 
suggest that additional functions of this multifunctional molecule are yet to be revealed.
The localization of agrin in non-neural tissues, including kidney, may contribute to the 
recognition of such functions [18-20]. We previously purified HSPG from human glomerular 
and tubular basement membrane (GBM and TBM) and generated a large panel of monoclonal 
antibodies (mAbs) [21, 22]. This HSPG appeared to be immunologically related to agrin and 
accumulates in high amounts in the GBM [23]. Since HSPGs are essential to maintain the
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charge-selective permeability of the GBM during renal ultrafiltration [24-27], this suggests a 
crucial function for agrin’s HS residues. In this study, we describe the expression of a large 
group of recombinant agrin fragments and demonstrate that the mAbs against GBM-HSPG 
recognize the agrin core protein. The recombinant proteins were also utilized to investigate 
the functions of agrin with special regard to the GBM, including inhibition of protease activity 
and binding to laminin. And finally, we describe the cellular origin of agrin expression in the 
human GBM.
MATERIALS a n d  m e t h o d s
Production and characterization of recombinant fusion proteins
For synthesis of recombinant fragments of human agrin as fusion proteins with glutathione-S- 
transferase (GST) from Schistosoma japonicum , we used the pGEX expression system 
(Pharmacia Biotech, Roosendaal, The Netherlands). The borders of each recombinant agrin 
fragment were defined by engineering mutagenic primers so that a BamHI- and an EcoRI 
restriction site were introduced at the 5’- and 3’- end of the corresponding PCR products 
(Table 1). Oligonucleotides were from Life Technologies (Breda, The Netherlands). Purified 
plasmids from the previously described clones Cs1, Cs2 and Cs4 were used as template DNA 
(GenBank AF016903) [28]. The PCR products were double-digested with BamHI and EcoRI 
(Life Technologies), and ligated into the corresponding sites of the appropriate vector (pGEX- 
4T1, -4T2 or -4T3, each vector contains the multiple cloning site in a different reading frame). 
An alternative procedure was applied for the constructs AGR10 and AGR17. For AGR10, the 
internal 1.7 kb SrfI fragment of clone Cs1 was subcloned into the SmaI-digested, alkaline 
phosphatase-treated vector pGEX4T3. AGR17 was prepared by inserting the 2.1 kb NotI 
fragment of Cs1 into the alkaline phosphatase-treated NotI sites of the vector pGEX4T1. The 
resulting clones were screened for a correct orientation of the insert by restriction enzyme 
digestion analysis. To prepare AGR18, the 179 bp EcoRI-NotI restriction fragment of Cs1 
was introduced into the corresponding sites of AGR10. For AGR19, the 2.1 kb NotI fragment 
from AGR17 was introduced into the NotI site of AGR18.
Biosynthesis of the recombinant agrin fragments was performed in batch cultures of 
Escherichia coli strains JM109 and BL21 following established procedures [29], except that 
the incubation temperature was 30°C which increased the solubility for many fusion proteins 
[30]. Cells were lysed in PBS containing 2% Triton-X100 and fusion proteins were purified 
by affinity chromatography to glutathione-conjugated Sepharose beads (Pharmacia). No 
protease inhibitors were used to avoid interference with functional assays. The cellular 
localization was analyzed by western blot detection of GST-like immunoreactivity in 
supernatants, cell lysates and insoluble fractions using an anti-GST mAb [29]. The yield of 
purified fusion proteins was determined by the Bradford method with bovine serum albumin 
(BSA) as standard. For molecular mass analysis, samples were analyzed by SDS-PAGE 
(T=12.5%, C=1%) under denaturing conditions. Molecular mass markers were from New 
England Biolabs. Predictions for molecular mass were calculated with the “Compute pI/MW” 
algorithm provided by the Swiss Institute of Bioinformatics (Geneva, Switzerland) [31].
Monoclonal antibodies and epitope mapping
A mAb against S. japonicum  GST [29] was a kind gift from Dr. L. Uitto, Oulu, Finland. Anti- 
agrin mAbs were raised in mice against purified HSPG extracted from human GBM and TBM 
[21, 22]. We selected 25 mAbs that produced a linear staining of the glomerular capillaries in 
immunofluorescence, and recognized purified agrin in ELISA [22, 23]. These were named 
HAM1-25. To localize their epitopes, we assayed the immunoreactivity of each mAb towards 
all recombinant fusion proteins. Fusion proteins, along with BSA and GST as two negative
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Table 1: Names and exact borders of the produced fusion proteins. Nucleotide sequences of 
the expression vectors are aligned above the encoded amino acids. Underlined residues indicate 
the restriction sites used for subcloning. Unrecovered restriction sites are dotted-underlined. The 
N-terminus of the fusion proteins are formed by glutathione-S-transferase (amino acids in normal 
face), fused to fragments of human agrin at the C-terminus (amino acids in bold). In-frame stop 
codons are located within 11 amino acids from the displayed C-terminal borders.
Name GST/agrin fusion site_____________C- terminal border______________
AGR1
AGR2
AGR3
AGR4
AGR5
AGR6
AGR7
AGR8
AGR9
A G R 1 0
A G R 1 1
A G R 12
A G R 1 3
A G R 1 4
A G R 1 5
A G R 1 6
A G R 17
A G R 18
A G R 1 9
GTGGATCCACATGCCCGGAGC  
R G S T C P E ... 
GTGGATCCACATGCCCGGAGC  
R G S T C P E ... 
GTGGATCCTGTCAGGGCGCCC  
R G S C Q G A  ... 
GTGGATCCTGCCCGGAGCCCT  
R G S C P E P ... 
GTGGATCCCAGGCCCCGTCCC  
R G S Q A  P S ... 
GTGGATCCTGTGACCGCTGCG  
R G S C D R C ... 
GTGGATCCTGTGGAGATGCCG  
R G S C G D A  ... 
GTGGATCCGGAGGCTCTGGCT
R G S G G S G ...
GTGGATCCGCTTCTGCGCCTG  
R G S A  S A  P ... 
ATTCCCGGGCAGGGCCGTGCG
N S......R ..... A  G P C ...
GTGGATCCCATGGCTCTTACG  
R G S H G S Y ... 
GTGGATCCTCGTGTAAGCCCG  
R G S S  C K P ... 
GTGGATCCTGTCCAGAGGCCA  
R G S C P E A  ... 
GTGGATCCGTGACTGTGACCA  
R G S V  T V  T ... 
GTGGATCCCCTGCACCCAGCC  
R G S P A  P S ... 
GTGGATCCTTCAGGGCACCCG  
R G S F  R A  P ... 
AGCGGCCGC TGCAGGAGCACG
E R P L Q E H ...
ATTCCCGGGCAGGGCCGTGCG
N S......R ..... A  G P C ...
ATTCCCGGGCAGGGCCGTGCG  
N S......R ..... A  G P C ...
CGCCTGCTCAGCCGCATCGTG
. R  L L S .....R "  I  V
GGCCCGTGTGACCAGAATTCC 
. G  P C D Q N S 
AGTGCCAGGGTCGAGAATTCC  
Q C Q G R E F 
TGTGACCAGGCCCCGAATTCC  
. C  D Q A  P N S 
GCAAAGGACCCTGTGAATTCC 
R K G P C E  F 
GCTGGACCCTGCGAGAATTCC  
. A  G P C E N S 
GCTCTGGCTCTGGGGAATTCC  
G S G S G E F 
TTACACTGTGCCCAGAATTCC 
. L  H C A  Q N S 
CCCAGCACTCACCCGAATTCC
. P S T H P N S
GCACCCGACGTGGCCCGGGTC
. A  P D V  " A .....R ..... V
GACTGTGAGCAGATGAATTCC 
. D  C E Q M N S 
TGCTCACCTGTCCAGAATTCC  
M L T C P E F 
GCCTCCGTGACTGTGAATTCC  
. A  S V  T V  N S 
C GTCCGCCTTTGGTGAATTCC 
A  S A  F  G E F 
CCCGCCACCAAGGTGAATTCC  
. P  A  T K V  N S 
GGGAGCCACGGCCAGAATTCC  
... G A  T A  R N S 
CCGTCAACACCAACGGGCTAG
P V  N T N "'G.....L
GGGGTGAGGCGGCCGCATCGT 
. G  V  R R P H R 
CCGTCAACACCAACGGGCTAG  
P V  N T N "G.....L
controls and purified human agrin as positive control, were coated during 16 h at 4°C in 
ELISA wells. Subsequently the wells were blocked with BSA for 1 h at 22°C, incubated with 
hybridoma supernatants (diluted 1:5 in PBS containing 0.2% Tween-20) for 1 h at 22°C. After 
washing 5 times with the same buffer, bound antibody was detected following standard 
methods using peroxidase conjugates [32].
Protease inhibition assays
The capability of human kidney agrin and recombinant agrin fragments to inhibit the activity 
of various proteases was investigated as follows. Reaction mixtures containing fluorigenic 
protease substrates were incubated with the corresponding protease and the potential inhibitor. 
Unless otherwise indicated, reactions were performed at 37°C in PBS containing 0.01% BSA
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and liberated fluorescent product was measured at 1 ex=340 nm and 1 em=440 nm. The 
proteases and their substrates used were: trypsin from porcine pancreas (ICN) was incubated 
at a final concentration of 10 USP/ml with Na-benzoyl-L-Arg-7-AMC; elastase from porcine 
pancreas (Sigma) at 2.3 |ig/ml with N-succinyl-Ala-Pro-Ala-7-AMC at 25°C; collagenase 
type 2 (Worthington Biochemical Corp., Freehold, New Yersey, USA) with 7-MCA-Pro-Leu- 
Gly-Leu-b-(2,4-dinitrophenylamino)-Ala-Ala-Arg-amide in PBS containing 0.01% BSA and
1 mM CaCl2 at 1 ex =328 and 1em=393 nm, plasmin from porcine blood (Sigma) at 0.8 |ig/ml 
with Ala-Phe-Lys-7-AMC at 25°C, urokinase from human kidney cells (Sigma) with the same 
substrate as plasmin, and angiotensin converting enzyme (Sigma) at 3.7 mU/ml with o- 
aminobenzoyl-Gly-p-nitro-Phe-Pro in 100 mM Tris pH 8.3, 300 mM NaCl and 10 |iM ZnSO4 
at 1 ex =360 and 1 em=410 nm. The aminopeptidase M substrate L-Leu-7-AMC (Sigma; at 
25°C) and the renin substrate N-succinyl-Arg-Pro-Phe-His-Leu-Leu-7-AMC were incubated 
with crude kidney cortex extract, depleted of endogenous HSPG by anion exchange 
chromatography on a DEAE column in 50 mM Tris pH 6.8 containing 140 mM NaCl (the 
flow-through is devoid of HSPG). Reactions were allowed to proceed for 1 to 3 h (depending 
on the protease) in presence or absence of potential inhibitors. Full activity was defined as the 
amount of fluorescence units generated in absence of inhibitors. Zero activity was defined as 
the fluorescence after incubation in absence of protease. As potential inhibitors we added the 
peptides AGR3-AGR9 and purified agrin, and as a control GST. To allow mutual comparison 
the reaction volume was kept constant, all reactions were kept on ice during pipetting and 
mixing, and protease/substrate reaction mix was added from a single “master mix” to equal 
volumes of the potential inhibitors.
Localization of laminin-associated binding sites for agrin
The recombinant fusion protein AGR1 that contains the laminin-binding domain was used to 
visualize the distribution of laminin isoforms that may function as agrin binding sites. 
Cryosections from human kidney cortex tissue and coverslips with confluent glomerular cell 
monolayers were incubated with affinity-purified AGR1 (diluted to 200 |ig/ml in PBS) for 2 h 
at 22°C. No fixatives were used. After washing 3 times for 5 min with PBS, the sections and 
monolayers were incubated with the anti-GST mAb (hybridoma supernatant diluted 5-fold in 
PBS). This mAb does not produce endogenous staining of the sections or cells. After 1 h at 
22°C and washing as above, the sections and monolayers were incubated for 1 h with a FITC- 
conjugated goat-anti-mouse antiserum (Dakopatts, Copenhagen, Denmark), washed again, 
mounted in Vectashield mounting medium (Brunschwig, Amsterdam, The Netherlands), and 
analyzed on a Leitz fluorescence microscope. To ensure the specificity of the observed 
binding we replaced the fusion protein by GST purified from the identical host strain carrying 
the parental plasmid. In another parallel control experiment, we omitted the primary antibody 
in the procedure. Furthermore we checked that binding could be inhibited by competition with 
soluble laminin (isolated from human placenta, Sigma, St. Louis, USA), which was mixed 
with the fusion protein at a final concentration of 200 |ig/ml.
Primary culture of glomerular cells
Human glomerular endothelial cells (HGEC) were taken into primary culture as described in 
detail elsewhere [33]. In short, glomeruli were obtained from human cortex tissue by gradual 
sieving under sterile conditions. Endothelial cells were isolated from collagenase-digested 
glomeruli and cultured on gelatin-coated wells in M199 medium (Biowithaker, MD, USA) 
supplemented with 10% newborn calf serum (Gibco, Grand Island, NY, USA), 10% human 
serum (local bloodbank), 2 mM glutamine (ICN Biomedicals, Zoetermeer, The Netherlands), 
100 U/ml penicillin, 100 mg/l streptomycin, 5 U/ml heparin (Leo Pharmaceuticals, Weesp, 
The Netherlands) and 150 mg/l crude endothelial cell growth factor from bovine brain [34]. 
Endothelial origin and purity of the cells was ascertained by a fenestrated morphology, the
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presence of PECAM-1, C3b receptor, EN-4 antigen, V,E-cadherin, and Von Willebrand factor 
and the absence of a-sm ooth  muscle actin and cytokeratin-8 [33].
Human podocytes were cultured from isolated glomeruli according to described procedures 
[35-37]. The culture medium was DMEM (Seromed Biochrom K.G., Berlin, Germany) with 
15 mM HEPES (Sigma), 20% fetal calf serum (Hyclone Laboratories, Logan, UT, USA), and 
100 U/ml penicillin and 100 mg/l streptomycin (Gibco). Identity and purity of the cells were 
confirmed by the presence of cytokeratin, CD10, TN10, BA-1, BA-2, J5 and the extracellular 
matrix components collagen type IV, fibronectin, laminin and HSPG. The Von Willebrand 
factor, TN9, C3b receptor, desmin, and collagen types I and III were absent as expected for 
podocytes. The cells also developed interdigitating microvilli, reminiscent of foot process 
structures [35, 36]. Both HGEC and podocytes were seeded onto gelatin-coated glass 
coverslips in 12-wells plates (Costar, Cambridge, MA, USA) and cultured for 8 days to allow 
the production of an extracellular matrix. The confluent monolayers were subjected to 
conventional immunofluorescence microscopy [32] and agrin-binding assays without the use 
of fixatives.
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Figure 1: Schematic alignment of the fragments of human agrin produced as recombinant fusion 
proteins with full-length human agrin cDNA. SS: signal sequence; NtA: N-terminal agrin (laminin-binding) 
domain; FS: follistatin-like module; LE: laminin-III-like EGF repeat; S/T: serine/threonine-rich module; SEA: 
module first found in sperm protein, enterokinase and agrin; EG: EGF-like repeat; lamG: laminin-G-like module 
The exact borders of each fragment are defined in Table 1.
R e s u l t s
Production of recombinant fragments of human agrin
An array of hybrid recombinant proteins was designed that consisted of GST from S. 
japonicum  on the N-terminus and different fragments of human agrin on the C-terminal side. 
An overview of the produced fusion proteins is shown in Figure 1, and the exact borders of 
each clone are defined in Table 1. The fused GST polypeptide provides a tag for affinity 
purification. To characterize the recombinant fusion proteins, we first checked their cellular 
localization in small-scale pilot cultures. Fourteen fragments (the smaller ones) were 
synthesized in abundant amounts in the cytoplasm. Especially the larger fragments (AGR2, -
10, -17, -18 and -19) accumulated in inclusion bodies, indicating that they were insoluble 
under the used conditions. Consistent with previous reports [30] their solubility was much
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higher after biosynthesis at 30°C, allowing purification of the fusion proteins from the cell 
lysates.
The affinity-purified fusion proteins were analyzed by SDS-PAGE and their apparent 
molecular mass was compared with predicted values. Most fusion proteins migrated with the 
expected mobility compared to GST and to each other (Figure 2). In general, short fragments 
were more stable and displayed a major band at the expected height (e.g. AGR1, -4, -5, -6, -8, 
-9, -11, -13 and -15). Few relatively short fusion protein produced multiple bands, including 
AGR3, -6, -14 and -16. Larger fusion proteins were generally less stable and produced 
multiple additional bands (e.g. AGR2, -10, -17, -18 and -19). The additional bands were 
recognized by an anti-GST mAb in Western blot experiments, indicating that they represent 
degradation products of the full-length fusion proteins (data not shown). The functional and 
immunological analyses described in this study were performed with these preparations of 
affinity-purified fusion proteins.
Epitope localization of anti-agrin monoclonal antibodies
In a previous investigation, our laboratories generated a large panel of mAbs against HSPG 
isolated from the human GBM and TBM [21, 22]. Since agrin was recently identified as a 
predominant HSPG of the GBM [28], we analyzed if these antibodies recognized human 
agrin. Each mAb was screened for immunoreactivity towards the different recombinant fusion 
proteins in ELISA (Table 2). In this way, epitopes were mapped on regions of the core protein 
of human agrin. The central region of the molecule (AGR 9, -12 and -13) appeared to be 
especially immunogenic in mice. Also the N-terminal region contained epitopes recognized 
by this panel of antibodies, including the fragment AGR1 that was recognized by HAM-1. In 
contrast to this, no epitopes could be mapped in the C-terminal region included in AGR17. 
The reactivity of the mAbs raised against HSPG from the GBM and TBM with the
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Figure 2: SDS-PAGE of recombinant fusion proteins and staining by Coommassie Brilliant Blue. Molecular 
mass markers are specified on the left (the 6.5 kDa marker is not present in the gel fragment shown on the rigth). 
The predicted molecular mass (in kDa) and obtained yield (in mg fusion protein per L of culture) are given for 
each fusion protein on the bottom.
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recombinant fusion proteins confirms unequivocally that they are directed to the core protein 
of agrin.
Table 2: Immunoreactivity of monoclonal antibodies with recombinant fragments of human agrin 
in ELISA. To check the specificity of the mAbs, bovine serum albumin (BSA) and GST were included as 
negative controls. Purified agrin from human glomerular basement membranes was included as a 
positive control. 1) In case multiple overlapping fusion proteins were recognized, the smallest and 
therefore most informative fragment is given. 2) Background signal was calculated as the mean optical 
density of all fragments that do not overlap the recognized fusion protein. 3) Besides AGR9 this antibody 
also recognized AGR13, indicating that the epitope is located within the overlap of these fragments. 4) 
Besides AGR9 this antibody also recognized AGR12, indicating that the epitope is located within the 
overlap of these fragments.
Recognized Background
BSA GST Agrin fusion protein 1) (mean ± SD) 2)
OD492 OD492 OD492 OD492 name OD492
HAM1 0.04 0.08 1.43 0.49 AGR1 0.08 ± 0.01
HAM2 0.04 0.05 0.85 2.67 AGR9 3) 0.05 ± 0.01
HAM3 0.05 0.04 0.50 1.38 AGR10 0.06 ± 0.01
HAM4 0.04 0.04 1.76 3.20 AGR9 3) 0.09 ± 0.15
HAM5 0.08 0.28 1.69 2.91 AGR9 4) 0.21 ± 0.12
HAM6 0.05 0.06 1.75 3.52 AGR12 0.09 ± 0.06
HAM7 0.05 0.04 0.73 0.88 AGR15 0.05 ± 0.01
HAM8 0.04 0.04 0.97 0.27 AGR3 0.04 ± 0.01
HAM9 0.05 0.05 1.31 2.25 AGR12 0.05 ± 0.01
HAM10 0.06 0.06 0.66 1.20 AGR15 0.07 ± 0.03
HAM11 0.04 0.05 0.79 2.76 AGR9 3) 0.05 ± 0.00
HAM12 0.12 0.06 0.86 2.58 AGR6 0.18 ± 0.34
HAM13 0.05 0.05 1.62 2.50 AGR9 3) 0.13 ± 0.28
HAM14 0.04 0.05 1.98 1.25 AGR9 3) 0.07 ± 0.02
HAM15 0.05 0.11 1.34 3.49 AGR10 0.15 ± 0.04
HAM16 0.04 0.05 1.17 0.80 AGR3 0.05 ± 0.01
HAM17 0.04 0.05 1.16 2.61 AGR9 3) 0.05 ± 0.01
HAM18 0.04 0.05 1.08 3.04 AGR9 3) 0.05 ± 0.01
HAM19 0.04 0.04 1.47 0.70 AGR3 0.07 ± 0.07
HAM20 0.04 0.04 0.91 2.87 AGR19 0.05 ± 0.02
HAM21 0.05 0.11 1.55 3.01 AGR10 0.12 ± 0.04
HAM22 0.04 0.05 1.62 0.18 AGR9 3) 0.05 ± 0.01
HAM23 0.05 0.05 0.42 0.20 AGR10 0.07 ± 0.02
HAM24 0.07 0.08 1.11 2.58 AGR10 0.09 ± 0.04
HAM25 0.05 0.05 1.07 2.68 AGR9 3) 0.04 ± 0.01
anti-GST 0.05 2.88 0.05
Protease inhibition by individual follistatin-like domains
Based on primary structure predictions, the nine follistatin-like domains of the agrin molecule 
may function as protease inhibitors. Different concentrations of agrin purified from human 
kidney were tested for their ability to inhibit various proteolytic enzymes. We observed a 
dose-dependent inhibition of trypsin, plasmin and elastase activity (Figure 3). Collagenase, 
urokinase, renin, aminopeptidase M  and the angiotensin converting enzyme were not inhibited 
(data not shown). To investigate protease-inhibiting functions in a domain-specific manner,
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Figure 3: Protease inhibitory activity of agrin purified from human 
kidney. The decrease of protease activity is given as a percentage of the 
activity in absence of agrin. A dose-dependent inhibition of trypsin 
(circles), plasmin (squares) and elastase activity (triangles) was 
observed.
we next used the fusion proteins AGR3-AGR9 as potential inhibitors. For plasmin, the fusion 
protein AGR5 that contains the fifth follistatin-like domain displayed the highest inhibitory 
activity (data not shown). Other fragments did not cause inhibition. To achieve a plasmin 
inhibition of 5% the required concentration of AGR5 was 3.8 |iM, whereas agrin was required 
at 0.08 |iM. This difference could suggest an involvement of additional domains in plasmin 
inhibition, or a different tertiary structure of the recombinant fragment. For trypsin and 
elastase, the inhibitory effect could not be assigned to a distinct domain by this procedure.
Agrin expression by glomerular cells in primary culture
Since agrin is expressed in the GBM along the full length of the capillary loops (Figure 4a), it 
is likely synthesized by either glomerular endothelial cells, podocytes, or both. To investigate 
the precise cellular origin of agrin, we used primary cultures of both cell types from human 
kidneys. A high purity and well-differentiated state of the two cell types was ascertained [33,
35, 36]. Cells grown to confluence produce an extracellular matrix, and we investigated the 
presence of agrin-like antigenicity herein by indirect immunofluoresence staining with the 
anti-agrin mAb HAM-6. This antibody recognizes fragment AGR12, located in the central 
region of the agrin core protein (Table 2). Podocytes produced readily detectable amounts of 
agrin (Figure 4b and c). In areas of relatively high cell density, large fibrillar structures were 
observed that stained strongly with mAb HAM-6. Antibodies directed towards other regions 
of the molecule (HAM-1, -5, -13 and -20) produced similar staining patterns (data not shown). 
Endothelial cells did not produce detectable amounts of agrin (data not shown). Despite this, 
they produced an extracellular matrix with binding sites for agrin as described below. The 
data suggest that podocytes are the main source of agrin in the GBM.
The GBM contains functional binding sites for fragment AGR1
Agrin was demonstrated to bind laminin, and this interaction may be important for the 
immobilization of the proteoglycan within basement membranes [13]. We investigated if 
agrin-laminin binding also occurs in the GBM. To visualize the distribution of functional 
agrin-binding sites in the glomerulus we used the recombinant fusion protein AGR1. This 
fragment contains the laminin-binding domain, and showed affinity to laminin in ELISA (data
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Figure 4: Immunofluorescence staining of agrin 
using the mAb HAM-6. a: On cryosections of 
human kidney cortex. b and c: On monolayers of 
human podocytes in primary culture (two typical 
areas are shown). Bar, 50 pm.
not shown). The GST tag was used to detect 
binding. In this way we localized the binding 
sites for AGR1 in cryosections from human 
kidney cortex tissue, monolayers of human 
podocytes, and monolayers of human 
glomerular endothelial cells. In kidney 
cortex, AGR1 binding was detected in the 
GBM and the peritubular capillary walls 
(Figure 5a). Tubular basement membranes 
were also weakly stained. When soluble 
laminin from human placenta was added as 
a competitor, binding of the fusion protein 
was markedly reduced (Figure 5b). As a 
control, GST alone did not bind to renal 
cortex tissue (Figure 5c). The extracellular 
matrix produced by cultured human 
podocytes also contained binding sites for 
AGR1 (Figure 5d-f). The observed staining 
was more irregular than that of endothelial 
cells. In addition to a fibrillar staining of the 
extracellular matrix juxtaposing most cells 
(Figure 5d), some regions of the monolayers 
were covered with strongly stained sheet­
like or fibrillar structures (arrowhead in 
Figure 5d, and Figure 5e-f). On cultured 
human endothelial cells, the AGR1-binding 
assay yielded an intense fluorescence in the 
extracellular matrix, following a granular 
and homogeneous pattern (Figure 5g-h). 
The cell membrane and cytoplasm were not 
stained. Again, incubation with GST as a 
control did not produce any staining (Figure 
5i). In conclusion, the results demonstrate 
that the GBM contains laminin isoforms that 
bind agrin. These laminins are presumably 
produced by both the endothelial and 
visceral epithelial cell layer.
D is c u s s io n
In this study we described the epitope lo­
calization of the first available mAbs known 
to recognize human agrin. The antibodies 
recognize both native (on tissue) and 
denatured (isolated) agrin, indicating that 
they bind linear epitopes rather than tertiary 
structures. The scattered epitope distribution 
enables to detect differences in the domain 
organization of agrin in different tissues.
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Figure 5: Detection of binding sites for the fusion protein AGR1 that contains the laminin- 
binding domain of human agrin. a c: in human kidney cortex cryosections; d f  on monolayers of 
human podocytes in primary culture; g i: on monolayers of human glomerular endothelial cells in 
primary culture. a: In cryosections of human kidney cortex, AGR1 binds to the glomerular capillary 
wall and the basement membrane of renal venules. b: Same as a, but by addition of purified laminin 
as a competitor the staining was considerably reduced ( G indicates a glomerulus). c: Same as a, 
but AGR1 was replaced by GST as a control. d: AGR1 binds to the extracellular matrix of 
podocytes in culture in a fibrillar pattern. In some regions this pattern assumes a sheet-like 
appearance (arrowhead). e, f: Same as d, illustrating two typical sheet-like structures in the 
podocytes extracellular matrix with binding sites for AGR1. g, h: In the extracellular matrix 
produced by glomerular endothelial cells in culture, AGR1 binds in a homogeneous granular pattern 
surrounding the cells. Two typical examples are shown. i: Same procedure and exposure as g, but 
with GST as a control. Bar = 50 pm.
For example, truncated agrin isoforms that lack a C-terminal region of the molecule were 
described to occur i the TBM [38]. Consistent with this, the mAbs used in this study reacted 
mostly with N-terminal and central regions of agrin.
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Some of the mapped antibodies were applied in previous investigations in ignorance of the 
identity of the antigen. First, HAM-21 that recognizes AGR10 was shown to intensely stain 
the GBM in a linear homogeneous way by immunofluorescence microscopy [23]. The 
assumption that the involved antigen was agrin, is convincingly affirmed by the present 
results. Second, HAM-15 that also recognizes AGR10 was previously shown to stain the 
amyloid deposits in AL and AA amyloidosis with increased intensity [39]. Also the expanded 
mesangial matrix in focal segmental glomerulosclerosis, lupus nephritis, IgA nephropathy and 
membranoproliferative nephritis appears to produce increased amounts of agrin [39]. 
Moreover, the staining of glomerular capillaries by HAM-15 was previously reported to 
decrease under diabetic conditions [40]. The localization of the corresponding epitope on the 
central region of the agrin core protein places these results in a new perspective. Agrin may 
contribute to the decrease of GBM-HSPG known to occur in diabetic nephropathy [41-43]. In 
the future we will investigate agrin’s role in the pathogenic mechanism of this diabetic 
complication in more detail.
Although purified agrin markedly inhibits trypsin activity in accordance with previous results 
[19], we could not allocate this action to distinct folli statin-like domains. The trypsin- and 
elastase- inhibiting activity could be associated with other or multiple regions of the agrin 
molecule. Alternatively, the inhibitory activities of individual domains may be underestimated 
or missed in this study due to limitations of the prokaryotic expression system. This may also 
explain the relatively low plasmin-inhibitory activity of the recombinant fusion protein AGR5 
compared with agrin purified ex vivo. The specificity of the observed inhibition was 
confirmed by parallel controls, including GST purified by the same procedure and from the 
same host strain. We avoided the use of protease inhibitors during purification of the fusion 
proteins. Thus, we ascertained that the observed inhibition of plasmin by AGR5 is specific.
The distribution of agrin in the matrix of cultured podocytes resembles that of laminin [35]. 
The finding that agrin is produced by podocytes, but not endothelial cells is analogous to the 
expression pattern of perlecan. This HSPG, expressed in the GBM at a lower level than agrin 
was also shown to originate exclusively from podocytes [44]. This is in line with the general 
idea that podocytes contribute for a large part to GBM synthesis. Only a few exceptions were 
reported, e.g. nidogen is synthesized by all glomerular cell types [44]. The epithelial origin of 
agrin in the GBM further strengthens the established opinion that podocytes play a major role 
in the maintenance of the glomerular charge-selective ultrafiltration barrier. The majority of 
heparitinase-degradable polyanionic sites resides in the lamina rara externa of the GBM [42], 
and detachment of the podocyte foot processes from the GBM augments permeability for 
macromolecules [45, 46]. Our data suggest that podocytes are also primarily responsible for 
the production of HSPGs of the GBM.
Whereas agrin was previously shown to bind laminin-1 ( a ip iy l) ,  -2 (a2piy1) and -4 
(a2p2y1), the GBM is particularly rich in laminin-11 (a502y1) [3, 13, 47]. The interaction of 
the fusion protein AGR1 with the matrix produced by glomerular cells and the GBM in vivo 
demonstrates, that binding to laminin also occurs in the kidney. In addition to its affinity for 
laminin, renal agrin also interacts with a-dystroglycan, a peripheral cell surface glycoprotein 
that is associated with the dystrophin-associated glycoprotein complex [48, 49]. The splice 
composition of human kidney agrin supports a-dystroglycan binding in a heparin­
independent way [28, 50, 51]. a-Dystroglycan was shown to be present in the epithelium of 
the developing nephron and remains present in the mature glomerular basement membrane 
[52]. Co-purification and co-immunoprecipitation of a-dystroglycan with kidney agrin 
showed that both components interact with high affinity [17]. Together there is now 
substantial experimental evidence that renal agrin forms a link between the cytoskeleton (via 
a-dystroglycan) and the GBM (via laminin).
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In summary, the functions of agrin in the GBM appear to be manifold. Agrin contributes to 
the polyanionic charge of the glomerular ultrafiltration barrier, and we have identified 
podocytes as its primary cellular source. The anchorage of agrin within the GBM via its N- 
terminus suggests a potential role in cell-matrix interaction. The functional properties of agrin 
in the GBM should be analyzed in more detail. Of special interest is the interaction between 
agrin and a-dystroglycan, which may trigger intracellular signals in the podocyte. The 
availability of the cDNA clones, fusion proteins and region-specific mAbs presented in this 
study facilitate new approaches for this purpose. Furthermore, the possible involvement of 
agrin in various nephropathies associated with a decreased anionic charge of the GBM may be 
investigated.
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Urinary excretion of basic fibroblast growth factor by nephrotic 
children with focal segmental glomerulosclerosis
chapter eight S u m m a r y  The pathogenesis of focal segm ental 
glom erulosclerosis (FSGS) is accom panied by hypertrophy of 
glom erular epithelial cells. Basic fibroblast growth factor (bFGF) w as 
previously shown to induce podocyte m itogenesis and 
dedifferentiation in rats, resulting in a  FSGS-like nephropathy (Kriz et 
al., Kidney Int. 48:1435, 1995). This study w as designed  to evaluate 
the relevance of this m echanism  in the clinical pathogenesis of 
FSGS. Thirty-four subjects w ere categorized in four groups 
according to their diagnosis: FSG S (n=13), minimal change d isease  
(MCD; n=10), other nephropathies (n=4) and healthy controls (n=7). 
Four patients with FSG S produced strongly increased urinary bFGF 
concentrations up to 11.6 ng/mmol creatinine, w hereas other 
patients of this group had normal excretion levels. Marked increases 
w ere exclusively found in urine sam ples with >5 g/l protein. 
Interestingly, the urinary bFGF concentrations detected  in FSGS 
correlated in a  linear way with proteinuria (correlation coefficient 
0.98). In MCD, less pronounced increases (up to 2.2 ng/mmol) w ere 
found in three cases. Subjects from other groups show ed no 
significant increase in urinary bFGF levels. Serum  bFGF levels w ere 
within normal range in all subjects. Tubular dysfunction, a s  indicated 
by increased urinary concentrations of retinol-binding protein, w as 
encountered  in a  few subjects but did not correlate with bFGF 
excretion. In biopsies from patients with FSG S and MCD, increased 
bFGF immunoreactivity w as p resen t in the glomerulus, w here it w as 
primarily assoc ia ted  with the capillary loops and Bowman’s capsule. 
T ogether the results su g g est that increased bFGF concentrations in 
the glomerulus may contribute to the pathogenesis of FSG S in the 
human.
In t r o d u c t io n
Focal segmental glomerulosclerosis (FSGS) is a histological appearance occurring in patients 
with nephrotic syndrome, characterized by partial sclerotic lesions in some but not all 
glomeruli [1,2]. Glomeruli in the juxtamedullary zone are more frequently affected. The 
sclerotic lesions often display hyalinosis (acellular accumulations of lipid and glycoprotein 
material) and contain IgM, C3 and C4 deposits. When the affected segments are analyzed by 
electron microscopy, the glomerular basement membrane shows a thickened and laminated 
morphology. Podocytes become detached and show effacement of the foot processes. The 
mesangial matrix is expanded, containing accumulated laminin and collagen IV deposits. 
Foam cells may also be present in the capillary lumen. The pathological mechanism that 
causes these changes is not understood. Recurrence of the disease in approximately 20-25% 
of renal allografts suggests the involvement of a circulating factor [1, 3]. A polymorphism in 
the gene encoding angiotensin-converting enzyme was suggested as a hereditary risk factor 
for FSGS [4].
Several experimental animal models for FSGS have been generated by procedures which 
include nephrectomy, administration of adriamycin and puromycin aminonucleoside (PAN)
T o Index
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[5-8]. A common hallmark in the progression of these experimental animals to FSGS is the 
observed hypertrophy of glomerular epithelial cells [9]. This hypertrophy might be an attempt 
to restore the glomerular structure after mechanical or inflammatory injury. Interestingly, 
long-term subcutaneous administration of basic fibroblast-growth factor (bFGF) also 
provokes the development of FSGS in rats [10]. In an attempt to proliferate, the podocytes 
undergo mitosis but fail to complete cell division. As a result, an increased number of bi- and 
multinucleated podocytes appears. Many dysmorphic features occur, including pseudocyst 
formation, cell body attenuation, effacement and detachment of the foot processes. Denuded 
regions of the glomerular basement membrane adhere to the parietal epithelium of Bowman’s 
capsule. Thus, this bFGF-induced experimental nephropathy shows characteristic features of 
FSGS [10].
Basic FGF is mostly expressed as an 18 kDa peptide, but 16, 20, 22 and 24 kDa variants also 
occur [11-15]. Although bFGF does not contain a classical signal peptide for extracellular 
targeting, an unknown export mechanism may exist [16-19]. Cell injury also induces the 
release of biologically functional bFGF [20-22] Extracellular bFGF is activated by heparan 
sulfate proteoglycans that are immobilized in the glomerular basement membrane, mesangial 
matrix and on the cell surface [13, 23-27]. After binding a dimer complex recognizes the 
high-affinity receptor and triggers signal transduction [14, 28]. The cellular response of bFGF 
greatly differs between cell types. Endothelial cells are stimulated to migrate and proliferate 
[17, 29, 30]. Podocytes were demonstrated to show a mitogenic response, associated with 
morphological changes that suggest dedifferentiation (pseudocyst formation, multinucleation, 
foot process retraction and focal detachment from the GBM) [31, 32]. This may relate to the 
fact that differentiated podocytes are not mitotic. Mesangial cells normally do not show a 
mitogenic response, but after injury bFGF induces an increased proliferation [12, 21, 33]. In 
the present study we detected elevated concentrations of bFGF in the urine of patients with 
FSGS associated with massive proteinuria. The data suggest a possible role for bFGF in the 
pathogenesis of FSGS in the human.
S u b je c ts  a n d  m e th o d s  
Subjects and sample collection
Patients were asked to participate in this study and parental consent was ascertained. In total 
34 subjects were categorized in four groups according to their diagnosis. FSGS patients 
(n=13) had a mean age of 10.8 years in the range 1-20 at sample collection (Table 1). Of two 
FSGS patients a biopsy but no urine sample was available; these patients are listed in Table 2. 
Subjects with minimal change disease (MCD; n=10) had a mean age of 7.9 years, range 2-14 
years. Two of these patients were in remission (12, 13), three had a relapse (14-16) and two 
had their first period of nephrotic syndrome (17, 18). Of three patients (32-34), a kidney 
biopsy but no urine sample was available (Table 2). Subjects with other nephropathies than 
FSGS or MCD (n=4) had a mean age of 8.8 years, range 0-13 years. This group included 
patients with IgA nephropathy, systemic lupus erythematosus and mesangiocapillary 
glomerulonephritis type II. Healthy control subjects (n=7) had a mean age of 8.9 years in the 
range of 5-20 years, they received no medication and displayed no signs of renal 
abnormalities. Further information is given in Tables 1 and 2.
Fresh mid-stream urine samples were collected in sterile containers and immediately 
centrifuged for 10 min at 2000 x g. Creatinine and total urinary protein were quantitated in the 
supernatant by standard procedures. For quantitation of bFGF and retinol-binding protein 
(RBP), the supernatant was aliquotted and stored at -80°C freezer within 30 min after 
collection.
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Table 1: Characteristics of patients and control subjects participating in this study. 1)FSGS: focal 
segmental glomerulosclerosis, MCD: minimal change disease, IgA: IgA nephropathy, SLE: systemic lupus 
erythematosus, MCGN2: mesangiocapillar glomerulonephritis type II. ^Abbreviations used are P (prednisone), 
C (cyclosporine). na , not analysed. Data of healthy control subjects (nr. 23 29) are not included in the table.
Subjects Urine sam ples Serum  sam ples
Patient Diagnosis Age 
nr. 1) (y)
Sex Medication 
(M/F) 2)
Total
protein
(g/i)
Creatinine
(mM)
RBP
(mg/l)
bFGF
(ng/i)
Creatinine bFGF 
(MM) (ng/l)
1a FSGS 15 F P+C 0.1 17.2 <0.30 0.9 68 0.4
1b FSGS 15 F P+C 0.5 19 <0.30 1.1 61 6.1
2 FSGS 12 F P+C 6.8 20 <0.15 5.5 56 0
3 FSGS 10 M P+C 10.1 7.2 11 6 141 na
4 FSGS 20 M - 4.4 8.9 3.4 5 169 na
5a FSGS 4 F - 3.1 6.2 <0.15 2.3 45 na
5b FSGS 4 F C 1.5 5.4 <0.15 1.7 61 0.4
6 FSGS 12 M C 1.1 12.3 <0.15 1.1 89 na
7 FSGS 10 F - 7.4 3.9 14 15 na 0.3
8 FSGS 15 F C 4.9 8.1 5.5 0.5 225 1.6
9 FSGS 11 F - 15.3 8.1 <0.15 31.6 53 0
10 FSGS 11 M - 1.7 1.2 0.9 3.4 64 1.8
11 FSGS 1 M P+C 18.8 2.7 1.7 31.3 27 4.7
12 MCD 12 M P+C 0 12 <0.15 4.5 66 0
13 MCD 10 M P 0 8.1 <0.15 0.6 60 0.9
14 MCD 14 F P 19.4 14.6 0.5 31.6 56 4.1
15 MCD 13 F - 11.5 11.4 <0.15 0.6 na na
16 MCD 5 F P+C 5.5 5 0.3 8.5 52 na
17 MCD 2 F - 14.8 1.8 <0.15 3.8 na na
18 MCD 3 F - 0.6 3.5 <0.15 2.2 na na
19 IgA 13 M - 0.3 20.6 <0.15 2.8 69 1.6
20 IgA 10 F - na 7.8 <0.15 0.6 na na
21 SLE 12 M P 1.7 7.4 <0.15 5.7 68 0.9
22 MCGN2 0 M P 3.4 3.5 9 3.4 125 na
Serum samples were collected only when blood sampling was required for the patient. Five to
10 ml of blood sample was collected in absence of anticoagulants and allowed to clot for 30 
min. After centrifugation for 10 min at 1500 x g, the supernatant was transferred to sterile 
polypropylene ampules. Creatinine and ureum were measured by standard methods. For bFGF 
assays, sera aliquots were stored at -20°C until analysis within 60 min after collection.
Quantification of bFGF concentrations in urine and serum
Quantitative determination of bFGF concentrations in urine samples and sera was performed 
with the “Quantikine” high-sensitivity kit (R&D systems, Minneapolis, MN, USA). Urine 
samples (200 |il) and serum samples (100 |il) were added to ELISA wells pre-coated with a 
monoclonal anti-human-bFGF antibody. After incubation for 3 h at 22°C, the wells were 
washed 6 times and incubated for 2 h at 22°C with an alkaline phosphatase-conjugated 
polyclonal antibody against human bFGF. After washing 6 times again NADPH was added as 
a substrate, converted into NADH and Pi by bound conjugate (60 min at 22°C). Subsequently, 
an amplification reaction was performed (30 min at 22°C) with INT-violet as a chromogenic 
substrate. The colored end product formazan was measured by optical density at 490 nm. All 
samples were assayed in duplicate, and the produced absorbances were compared with that of 
serial dilutions of recombinant human bFGF included on the same 96-wells plate (also in
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duplicate). To determine the stability of bFGF during storage in urine, a 16 ng/l standard 
dilution of bFGF was incubated for 0, 2, 4, 8, 12, 24, 30 and 48 h at 4°C and 25°C 
respectively. Immediately thereafter, samples were placed in a -80°C freezer until analysis.
Measurement of retinol-binding protein in urine samples
RBP was quantitated by laser immunonephelometry using a Hyland Disc 120 nephelometer 
(Hyland, Nivelles, Belgium). 250 |il of the urine samples was mixed with 850 ul anti-RBP 
antiserum (Dakopatts, Copenhagen, Denmark) diluted 100-fold in 120 mM NaCl, 130 mM 
phosphate, 2.3% (w/v) polyethyleneglycol-2000, 2.3% (w/v) 
polyethyleneglycol-4000 and 0.025% sodium azide at pH 7.4. After overnight incubation at 
22°C, light scatter of the samples was measured at a wavelength of 633 nm and an angle of 
31°.
Immunostaining of bFGF in kidney biopsies
Biopsy specimens taken for pathohistological examination were available from storage in 
liquid nitrogen. For immunofluorescence, cryostat sections were fixed for 5 min in 
ethanol/acetic acid (19:1) at 4°C, washed twice with PBS during 5 min, and incubated for 60 
min at room temperature with a mouse monoclonal anti-bFGF IgG (Upstate Biotechnology, 
Waltham, MA, USA) diluted 1:50 in PBS + 1% bovine serum albumin. The slides were then 
washed as above, incubated with a FITC-conjugated secondary antibody (sheep-anti-mouse, 
Cappel, Oss, The Netherlands) and washed again. After mounting in Vectashield medium 
(Brunschwig, Amsterdam, The Netherlands), the sections were examined using a Leitz 
fluorescence microscope.
Statistics
Based on their diagnosis, the subjects were regarded as four individual sample populations 
(FSGS, MCD, other nephropathies, and healthy controls). Mean values and standard 
deviations were calculated for each group. Student’s t test was used to evaluate the 
significance of differences in bFGF excretion between groups. To evaluate a possible 
correlation of bFGF excretion levels with proteinuria, we performed linear regression and 
calculated Pearson’s correlation coefficient for each subject group.
R e s u l t s
Assessment of urinary bFGF excretion
To determine the concentrations of bFGF in urine, we used a high-sensitivity immunoassay 
with a lower detection limit of 0.1 ng/l. A calibration line in the range of 0 - 32 ng/l bFGF 
showed a strict linear dependence on the concentration of bFGF (correlation coefficient was 
0.9998). To ensure that the measurements were not biased by degradation effects, we checked 
the stability of bFGF in urine samples. We compared storage at 4°C and 25°C for up to 48 h. 
When urine samples are processed at 25°C, freezing within 3 h after collection is necessary to 
minimize degradation. After storage during 48 at 25°C an approximately threefold decrease in 
the detected bFGF concentration was observed. In contrast, the detected concentration was 
undiminished after storage for 48 h at 4°C (data not shown).
The concentrations of bFGF detected in urine samples from all subjects ranged from 0.0 to 
31.6 ng/l (Table 1). The bFGF/creatinine ratio was calculated (Figure 1). A previously 
published normal mean value for bFGF excretion by children is 0.34 ng/mmol creatinine 
(dotted line in Figure 1) [34]. As an upper limit for normal range we used 1.29 ng/mmol 
(normal mean value plus two standard deviations; dashed line in Figure 1). The urinary bFGF 
concentrations produced by patients with FSGS had a mean value of 1.91 ± 3.24 ng/mmol.
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Figure 1: Comparison of urinary bFGF excretion by patients with FSGS (subjects 1 11), MCD (12 
18) and control subjects (19 29). Values are given as ng of bFGF per mmol of creatinine to correct for 
urine concentration. Dotted line indicates normal mean, dashed line the upper limit for normal range in 
children [34].
This increase was significant (P=0.05). Excretion levels in the group of subjects with MCD 
were above-normal in three cases, and the mean value was 1.02 ± 0.95 ng/mmol. Mean bFGF 
excretion by healthy subjects and patients with other nephropathies than FSGS or MCD was
0.32 ± 0.36 ng/mmol, which corresponds well with previously reported normal mean values 
[34-36].
Interestingly, markedly increased urinary bFGF values were exclusively detected in 
association with high (>5 g/l) proteinuria. As shown in Figure 2, the dispersion of the paired 
values suggests a linear correlation between bFGF excretion and the extent of proteinuria. 
This was confirmed by linear regression on the paired values in the FSGS group, resulting in a 
correlation coefficient of 0.98 (the slope was 1.7 ng bFGF / g protein). The correlation 
between bFGF excretion and proteinuria suggests a role for bFGF in the pathogenesis of 
proteinuria.
Assays to determine the mechanism of increased bFGF excretion
Various mechanisms are conceivable to explain the increased bFGF excretion. Glomerular 
permeability may not influence bFGF excretion, because this small molecule can pass the 
filtration barrier freely. Does the bFGF excretion arise from its increased concentration in the 
circulating plasma? To address this question, we first analyzed the concentrations of bFGF in 
the sera of subjects (Table 1). No significant increase was found in any of the subject groups. 
The mean concentration of bFGF in serum from FSGS patients was 1.7 ± 2.2 ng/l (n=9), 
which is comparable with the normal mean value described in the test kit, 2.45 ng/l (n=52).
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Figure 2: Relation between urinary bFGF concentrations and proteinuria in patients with FSGS, 
MCD, other nephropathies and subjects from the control group. In patients with FSGS, above­
normal bFGF concentrations displayed a linear correlation with the degree of proteinuria (correlation 
coefficient 0.98).
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Alternatively, the urinary bFGF values could reflect a deficiency in tubular reabsorbtion. To 
investigate this possibility we screened all subjects for tubular dysfunction. Retinol-binding 
protein (RBP) provides a good marker for tubular dysfunction, because this 22 kDa protein 
has a fractional tubular reabsorbtion near 100% in healthy individuals [37] Retinol-binding 
protein is stable in urines with pH>5 [38, 39]. Normal ranges of RBP excretion are age- 
dependent [40, 41]. The RBP concentrations in urines from our subjects (Table 1) were 
compared with the proposed upper limits for normal subjects [41]. Four subjects with FSGS 
(nr. 3, 4, 7 and 8) produced increased urinary RBP levels. Of these, patient 7 also had 
increased bFGF excretion. The measured bFGF concentration in the urine from this patient 
may therefore be influenced by reduced tubular uptake. Patients 3, 4 and 8 had normal urinary 
bFGF concentrations. Patients 9, 10, 11, 14, 16 and 17, who produced high urinary bFGF 
concentrations, clearly displayed normal tubular function. Thus, no correlation between bFGF 
release and RBP excretion was present. Although we cannot exclude a bias in bFGF detection 
for patient 7, the above results indicate that the observed bFGF excretion is not the 
consequence of tubular dysfunction. The low levels of bFGF in the serum of all subjects, and 
the exclusion of tubular dysfunction as a cause for bFGF excretion, suggest that bFGF is most 
likely released in the urogenital system of patients with FSGS.
Immunological detection of bFGF in focal segmental glomerulosclerosis
To localize the sites of bFGF release in FSGS, we stained kidney biopsy specimens using a 
monoclonal antibody against bFGF. The same procedure was performed for sections of 
minimal change nephrotic syndrome and normal kidney. The staining of individual biopsies 
was interpreted by visual scoring as listed in Table 2.
In the normal kidney, anti-bFGF staining in the glomeruli was very weak (Figure 3A) which 
corresponds well with previous observations [42]. The tubules of normal kidney showed a 
marked staining with anti-bFGF antibodies. In glomeruli from patients with MCD and FSGS
1 3 7
Figure 3: Indirect immunofluorescence staining of bFGF in kidney cortex tissue. (A)
Patient with normal kidney, (B) patient nr. 31 with FSGS, (C) patient nr. 34 with minimal 
change nephrosis, and (D) patient nr. 9 with FSGS. Magnification 400x.
(Figures 3B and 3C) an increased staining was evident, with a degree that varied between 
individual subjects. Figure 3D represents a typical staining of a biopsy from a patient with 
FSGS. The staining pattern followed an irregular pattern along the capillaries. Tubular anti- 
bFGF staining showed a slight increase in biopsies from patients with MCD and FSGS 
compared to normal controls. We found that tubular anti-bFGF staining was dependent on the 
fixation temperature used. Compared with the sections that were fixed at 4°C (Figure 3), 
sections fixed at -20°C showed a less intense staining of bFGF in the tubuli (not shown). The 
glomerular staining was independent of the fixation temperature (data not shown). In some 
cases the Bowman’s capsule also expressed substantial amounts of bFGF (e.g. Figure 3D). 
Interestingly, this latter biopsy originates from a FSGS patient who also produced high 
concentrations of urinary bFGF (Table 1). Urine samples of patients relating to the other 
shown sections were unavailable. The immunological detection of bFGF in glomeruli of 
patients with FSGS and MCD is in line with the increased urinary bFGF concentrations found 
in these nephropathies.
D is c u s s io n
The increased urinary excretion of bFGF in 3 out of 4 patients with FSGS was not caused by 
defective tubular reabsorption. Besides these cases, a large subset of the FSGS patients
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Table 2: Typical anti-bFGF staining intensity in glomeruli and tubules from six 
subjects with FSGS and three with MCD. From patient 3, a second biopsy was taken 
after recurrence of the disease in a renal allograft ( FSGS-R ). Visual scoring indicates 
changes in bFGF expression as follows: = normal intensity; + slight increase; ++ 
moderate increase; +++ strong increase compared to normal kidney. 1)Abbreviations 
are listed in Table 1.
Patient Diagnosis Age Sex Medication Anti-bFGF staining intensity
nr. 1) (y) 2) Glomeruli Tubules0 normal - = =
3a FSGS 9 M - + +
3b FSGS-R 1 M P+C + +
4 FSGS 1 M - ++ +
9 FSGS 8 F P ++ +
30 FSGS 15 F P ++ +
31 FSGS 12 M C +++ =
32 MCD 4 M P ++ +
33 MCD 7 M P + +
34 MCD 9 M P +++ +
displayed urinay bFGF values in the normal range. It is possible that a bFGF-independent 
mechanism of pathogenesis induces FSGS in these patients. Alternatively, a small increase in 
filtered bFGF may remain undetected through effective reabsorbtion.
Above-normal bFGF excretion was not detected only in FSGS, but also in three patients with 
MCD. Nevertheless a key role of bFGF in the pathogenesis of MCD is unlikely. Patients with 
MCD respond well to corticosteroid therapy and episodes of high proteinuria are relatively 
short. Since bFGF excretion correlated with proteinuria, we speculate that in MCD the 
influence of bFGF is only temporarily present and disappears when the patient is in remission. 
In contrast, proteinuria of FSGS patients is persistent and a long-term influence of bFGF is 
conceivable.
The presence of bFGF immunoreactivity in glomeruli of patients with FSGS is in agreement 
with the increased bFGF transcription in glomeruli from rats with progressive PAN-induced 
glomerulosclerosis [43]. The immunoreactivity seems to be mainly associated with the 
glomerular capillaries, suggesting that podocytes could be influenced by bFGF. The 
immunoreactivity was also associated with Bowman’s capsule in some patients. This structure 
is particularly rich in perlecan, a receptor of bFGF [14, 44]. The finding that tubular anti- 
bFGF staining was dependent on the fixation procedure, was also reported by others [45]. In 
contrast to previous findings in Thy 1.1-induced glomerulopathy in rats [33], we did not 
observe prominent staining in mesangial areas.
The glomerulus contains both the low- and high affinity receptors necessary for a bFGF- 
induced mitogenic response. The low-affinity receptors, heparan sulfate proteoglycans, are 
abundantly present in the glomerular basement membrane and mesangial matrix [44, 46, 47]. 
High-affinity receptors expressed in glomeruli were studied for the composition of their 
ligand-specificity-determining region, the second half of their third immunoglobulin-like 
domain [48-50]. This region is encoded by either exon Illb or IIIc, determined by alternative 
splicing. For fibroblast growth factor receptor 2 it was shown, that the IIIc splice variant binds 
both aFGF and bFGF, whereas the IIIb variant recognizes only aFGF and FGF-7. The 
glomerulus contains exclusively mRNA that encodes type IIIc receptors [50]. This suggests 
that the high affinity receptors expressed in glomeruli recognize bFGF very well. Thus bFGF 
may influence the function of the podocyte, the cell type considered to be responsible for the
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development of FSGS. The modulation of bFGF-induced glomerular hypertrophy could 
theoretically provide novel therapeutic tools for the clinical management of FSGS. Of special 
interest in this regard are low-molecular-weight heparin species or sulfated malto- 
oligosaccharides [51], and neutralizing antibodies or peptide antagonists [52] which can block 
the activity of bFGF.
In conclusion, this study suggests that increased glomerular bFGF may be involved in at least 
some forms of FSGS. The relation between urinary bFGF excretion and urinary protein 
content suggests that this growth factor could contribute to the pathogenesis of proteinuria.
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Ba c k g r o u n d  a n d  a im s  o f  t h e  s t u d y
Heparan sulfate proteoglycans (HSPGs) are important components of the glomerular base­
ment membrane (GBM) as they contribute to the selectivity of renal clearance of proteins. 
This activity is based on the anionic charge of their heparan sulfate (HS) side chains, that 
diminishes the permeability of the GBM for negatively charged molecules in the blood 
plasma (e.g. most proteins). There is convincing evidence that absence of HS in the GBM 
results in a nephrotic syndrome (albuminuria, hypoproteinemia and edema). In line with this, 
many researchers have investigated the role of HSPGs in the development of various ne­
phropathies associated with a nephrotic syndrome. The first identified HSPG that occurs in 
basement membranes, perlecan, was the subject of most of these studies. The objective of the 
study described here was to analyze the functional role of perlecan, to investigate whether 
additional HSPG molecules other than perlecan could be present in the GBM, and to investi­
gate how HSPGs may be involved in various nephropathies.
A MODEST ROLE FOR PERLECAN IN THE GBM
To investigate the functional properties of perlecan, recombinant fragments (containing 
domains I and different parts of domain II) were produced in Escherichia coli (bacteria), 
Pichia pastoris (yeast) and Spodoptera frugiperda  (insect cells). Based on primary structure 
predictions, domain I was proposed to be responsible for heparan sulfate attachment. Domain
II does not contain sites for attachment. In insect cells, the perlecan fragment was produced as 
a chondroitin sulfate proteoglycan ¡(chapter 2 ) . This demonstrates the functionality of the 
glycosaminoglycan attachment sites in the SEA module. Furthermore this indicates that this 
domain can be alternatively glycosylated dependent on the cell type in which it is synthesized. 
Interestingly, chondroitin sulfate carrying perlecan isoforms also occur in cartilage matrix. 
Domain II is similar in structure to the low-density lipoprotein receptor. We therefore 
investigated if the recombinant perlecan fragments showed affinity to lipoprotein fractions of 
human serum (chapter 3). The affinity of the various fragments differed: the glycosaminogly- 
can-free peptides produced in E. coli and P. pastoris  bound to apolipoprotein-B-containing 
lipoproteins, while the chondroitin sulfate-containing peptide from S. frugiperda  showed no 
detectable binding. This provides the first in vitro  evidence that domains I and II of the core 
protein may act as a lipoprotein receptor. The data further suggest that the glycosylation 
characteristics of perlecan modulate its lipoprotein-binding activity. If this mechanism is of 
physiological importance, it may contribute to the adhesion of lipoproteins to the subendothe­
lial matrix in blood vessels.
The recombinant proteins were also used to generate a well-defined monoclonal antibody 
against human perlecan, named 95J10. This antibody was used to investigate the distribution 
of perlecan immunoreactivity by immunofluorescence and immuno-electron microscopy. 
Although abundantly present in Bowman’s capsule and the tubular basement membranes, 
perlecan was absent in many regions of the GBM. This suggests a more modest role for 
perlecan in renal ultrafiltration than was initially assumed. Different results obtained with 
previously prepared monoclonal antibodies demonstrated that additional HSPG species are 
present in the GBM (chapter 4)
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A g r in  a s  a  m a j o r  HSPG o f  t h e  GBM.
A major HSPG component of the GBM was identified as agrin, known as a mediator during 
development of the neuromuscular junction (chapter 5). In immuno-electron microscopy, anti- 
agrin antibodies produced an intense linear homogenous staining of the GBM. Anti-agrin 
antisera recognized HSPG purified from the GBM. By northern hybridization, agrin tran­
scription levels were compared between multiple human tissues. Of all tissues the highest 
agrin mRNA levels were detected in adult kidney and lung. Given its potential relevance for 
GBM permselectivity, we cloned and sequenced the cDNA that encodes human renal agrin 
. The sequence comprises 7032 base pairs and encodes a mature protein of 212 
kDa with several potential HS attachment sites and a laminin-binding domain. As far as can 
be predicted, two sites are particularly favorable for substitution with HS. Sites of alternative 
splicing (designated c , x , y  and z) were devoid of inserts except the x  site where a 9-amino 
acid insert was present.
Nineteen recombinant fragments of human agrin, distributed along the core protein, were 
engineered and expressed as fusion proteins in E. coli. Previously raised MAbs against human 
GBM HSPG were tested for immunoreactivity towards these constructs. In this way, the 
epitopes of 25 antibodies were mapped to regions of the agrin core protein (chapter 7 ). Then 
the anti-agrin MAbs were used to stain the extracellular matrix produced by human podocytes 
and human glomerular endothelial cells in primary culture. The results suggest that agrin is 
exclusively synthesized by podocytes.
Since agrin was shown to bind to laminin in the neuromuscular junction, we asked whether 
these molecules could also interact in the GBM. The fusion protein AGR1, that contained the 
laminin-binding domain, displayed laminin-binding activity in vitro. AGR1 also bound to the 
extracellular matrix of kidney cortex tissue and of cultured glomerular cells. This indicates 
that laminin-binding is likely a mechanism by which agrin is anchored within the GBM
(chapter 7)
T h e  p o t e n t ia l  r o l e s  o f  H S P G s  in  r e n a l  d is e a s e
Regarding the limited expression of perlecan in the GBM, it is not surprising that we found no 
indications for a causal role of perlecan in the development of nephropathies. In contrast, 
agrin may be involved in such processes. Previous studies reported a relative decrease of 
GBM HSPG in diabetic nephropathy. By localizing the epitope of the antibody used in these 
studies, it has now become clear that agrin is involved in these changes.
In other nephropathies (e.g. in minimal lesions and renal manifestations of Denys-Drash 
Syndrome) a reduced HS content was previously shown to be associated with a normal 
expression of the core protein. These alterations may therefore be related to disturbances in 
the synthesis, modification or degradation of HS.
Not only do HSPGs contribute to GBM anionic charge, they also function as storage sites and 
activators of various growth factors. Among these is basic fibroblast growth factor (bFGF). 
Glomerular cells respond to bFGF by cell proliferation. Long-term exposure of glomerular 
podocytes to bFGF was previously shown to induce their dedifferentiation and damage, 
resulting in a nephropathy that resembled focal segmental glomerulosclerosis (FSGS). To 
investigate if a similar mechanism could occur during the clinical pathogenesis of FSGS, 
bFGF concentrations were measured in urine and serum from patients with various ne­
phropathies (chapter 8). In four patients with FSGS and severe proteinuria, a marked increase 
in urinary bFGF excretion was found. Other patients with FSGS had normal urinary bFGF 
concentrations. The results suggest that increased glomerular bFGF concentrations may 
contribute to the pathogenesis of FSGS in the human.
(chapter 6)
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C o n c l u s io n s
The results presented in this thesis together support the following conclusions:
- Domain I of human perlecan can also be glycosylated with chondroitin sulfate (chapter 2)
- Domains I and/or II of the core protein of human perlecan can bind apoB-containing 
lipoproteins and this activity is influenced by its glycosylation (chapter 3)
- The GBM contains at least two different HSPG molecules: agrin and perlecan (chapter 4 
and 5)
- Perlecan is absent from the GBM in many regions of the capillary loop (chapter 4)
- Agrin is a major HSPG of the GBM (chapter 5)
- Human agrin consists of a 212 kDa core protein and supports glycosylation by the 
presence of a SEA module and two especially favorable sites for HS attachment (chapter 
6).
- Human renal agrin is expressed by podocytes and binds to the GBM via its laminin- 
binding domain (chapter 7).
- Human renal agrin inhibits the proteases trypsin, plasmin and elastase (chapter 7)
- The influence of basic fibroblast growth factor on podocytes may be involved in the 
development of proteinuria in FSGS (chapter 8)
INDICATIONS FOR FUTURE RESEARCH
The results from this study offer new perspectives for investigating the functions of HSPGs 
and the structure of the GBM. Here, possible future approaches are discussed in relation to the 
current status of knowledge in this field.
Our data suggested a low expression of perlecan in the GBM, and therefore a limited role in 
determining permselectivity. The affinity of its core protein for lipoproteins could be of 
importance especially in the subendothelial matrix of the vascular system, and this possible 
function deserves further attention. First, the physiological relevance of the described 
interactions should be assessed by in vivo experiments. Subsequently it is important to 
understand how heparan sulfate residues attached to domain I influence the affinity of 
lipoproteins for perlecan. Investigation of these issues may contribute to an increased 
understanding of the mechanisms involved in the retention of atherogenic lipoproteins in the 
subendothelial matrix.
The high expression of agrin in the GBM suggests that it is contributes importantly to the 
maintenance of the charge-selective permeability in ultrafiltration. This hypothesis may be 
investigated by a targeted elimination of the HS attachment sites of agrin in mutant mice. In 
relation to this, the number of HS residues on the human agrin core protein and the location of 
their attachment sites should be confirmed experimentally. The attachment of two to three HS 
chains was already demonstrated for recombinant chick agrin by rotary shadowing electron 
microscopy. It is however uncertain if  human agrin is glycosylated in the same way. Another 
topic for future investigation is the temporal regulation of agrin transcription and expression 
during nephrogenesis. Regulatory mechanisms that influence agrin expression in the kidney 
are largely unknown. The promoter area of the agrin gene should be characterized to identify 
the potentially involved transcription factors. Completion of the Human Genome Project will 
provide novel clues in this respect. Furthermore, it would be interesting to know if the cloned 
agrin isoform (with the splice composition CoX9Y0Zo) is the only isoform expressed in the 
glomerulus. And how does alternative splicing at site x influence the functions of agrin?
The functional properties of renal agrin should be analyzed in more detail. The cDNA clones, 
recombinant fusion proteins and region-specific monoclonal antibodies described in this study 
facilitate new approaches for this purpose. Of special interest are the interactions of agrin with 
a-dystroglycan and integrin. These cell-matrix interactions, besides providing a link between
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the cytoskeleton and the basement membrane, have the potential to trigger signal transduction 
processes.
A subject of great interest is the possible involvement of agrin in various nephropathies where 
a decrease in polyanionic sites of the GBM occurs. These include the minimal change 
nephrotic syndrome and diabetic nephropathy. It would be interesting to know how HSPG 
expression and glycosylation are influenced by the circulating factors that induce minimal 
change lesions and focal segmental glomerulosclerosis.
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Samenvatting in het Nederlands
A c h t e r g r o n d  en  d o e l s t e l l in g  v a n  h e t  o n d e r z o e k
De nieren hebben een onmisbare functie in het menselijk lichaam: ze zijn onder andere 
verantwoordelijk voor het zuiveren van het bloed en het produceren van de urine. Het is 
hierbij belangrijk dat nuttige bestanddelen van het bloed zo goed mogelijk worden behouden, 
terwijl schadelijke zoveel mogelijk worden uitgescheiden. De eerste stap in dit 
scheidingsproces vindt plaats in de glomerulaire basaalmembraan (GBM). De GBM fungeert 
als een filter tussen het bloed aan de ene, en de voorurine aan de andere kant. Doordat de 
bloeddruk in de nieren hoog is, komen alle stoffen die het filter kunnen passeren in de 
voorurine terecht. Andere delen van de nier verfijnen deze grove scheiding nog. Zo ontstaat 
uiteindelijk de urine.
De selectieve doorlaatbaarheid van de GBM is van groot belang voor een goede werking van 
de nieren. Bij afwijkingen hierin kunnen verschillende nierziekten ontstaan. Wanneer 
bijvoorbeeld eiwitten uit het bloed weglekken, ontstaat oedeem (zwelling van lichaamsdelen). 
Om zulke nierziekten te kunnen begrijpen en behandelen, wordt sinds lange tijd onderzocht 
hoe de doorlaatbaarheid precies wordt geregeld. Al in 1980 heeft men ontdekt dat de GBM 
moleculen bevat die de doortocht van eiwitten bemoeilijken. Deze moleculen heten 
heparansulfaatproteoglycanen (HSPG’s). HSPG’s bestaan deels uit eiwit en deels uit 
suikerketens (heparansulfaat) die sterk negatief geladen zijn. De aanwezigheid van HSPG’s in 
de GBM zorgt ervoor dat de meeste eiwitten in het bloed -die eveneens negatief geladen zijn- 
worden afgestoten en dus in het bloed blijven. Wanneer de heparansulfaatketens afwezig zijn 
ontstaat dan ook een eiwitlek.
Onze groep slaagde er in het verleden in om het HSPG uit de GBM van menselijke nieren te 
zuiveren. Dit preparaat werd gebruikt om antistoffen tegen het HSPG te maken (in het 
laboratorium een belangrijk hulpmiddel om het HSPG zichtbaar te kunnen maken). Ondanks 
deze vorderingen bleef de precieze identiteit van het HSPG-molecuul lange tijd onbekend. In 
1988 ontdekte men een HSPG genaamd perlecan, dat drie heparansulfaatketens draagt en 
inderdaad voorkomt in basaalmembranen. Toch werd tot op heden niet aangetoond dat 
perlecan de doorlaatbaarheid van de GBM bepaalt.
Het hier beschreven onderzoek richt zich op de HSPG-samenstelling van de GBM. De 
vraagstelling was drieledig. Welke functies heeft perlecan? Komen er nog andere HSPG’s 
voor in de GBM en zo ja, welke? En tenslotte: zijn HSPG’s betrokken bij het ontstaan van 
nierziekten?
E e n  b e s c h e id e n  r o l  v a n  p e r l e c a n  in  d e  GBM
Om de functies van perlecan te kunnen onderzoeken is natuurlijk perlecan nodig. Om dit in 
handen te krijgen werd gebruik gemaakt van de recombinant-DNA-technologie. Delen van 
het erfelijke materiaal (het DNA) dat voor de productie van menselijk perlecan zorgt, werden 
hierbij in bacterie-, gist- en insectencellen geplaatst. Normaal gesproken bestaat perlecan uit 
vijf verschillende delen, domeinen genoemd. Bij dit onderzoek werd alleen het DNA dat 
codeert voor domein I en II naar de gastheercellen overgebracht. Op grond van de structuur 
van het perlecan bestonden al vermoedens voor een mogelijke functie van deze twee 
domeinen: domein I was waarschijnlijk betrokken bij de aanhechting van de suikerketens van 
het HSPG, domein II leek veel op een eiwit dat belangrijk is in het lipoproteïnenmetabolisme 
(de omzetting van vet-eiwitcomplexen die in het bloed voorkomen). De door recombinant- 
DNA-technologie verkregen perlecan-fragmenten werden gebruikt om te onderzoeken of deze 
vermoedens terecht waren.
Het perlecanfragment dat door insectencellen werd geproduceerd, bleek in het bezit te zijn 
van suikerketensl (hoofdstuk 2 ) . De structuur van de gevormde suikerketens verschilde echter
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van heparansulfaat. Het bleek een variant te zijn: chondroïtinesulfaat. Ook in het menselijk 
lichaam zijn perlecanvarianten aangetroffen die in het bezit waren van chondroïtinesulfaat, 
bijvoorbeeld in kraakbeen. Het celtype dat perlecan maakt, beïnvloedt waarschijnlijk de 
structuur van de suikerketens. Door verschillen in suikeraanhechting zou perlecan in het ene 
weefsel andere functies uit kunnen oefenen dan in het andere.
Vervolgens werd de mogelijke functie van domein II van perlecan onderzocht. Hieruit bleek 
dat perlecan mogelijk een rol speelt bij de binding van lipoproteïnen I(hoofdstuk 3 ) . De 
perlecanfragmenten gemaakt door bacterie- en gistcellen, die niet voorzien waren van 
suikerketens, bleken in staat te zijn om lipoproteïnen te binden. Het door insectencellen 
gemaakte perlecanfragment vertoonde deze activiteit niet. De binding van lipoproteïnen aan 
perlecan is dus mogelijk, en deze functie wordt beïnvloed door de aanwezigheid van de 
suikerketens. Indien deze wisselwerking ook in het lichaam plaatsvindt, is dit vooral van 
betekenis voor de binding van lipoproteïnen in de bloedvaten.
Behalve voor bovenstaande studies werd een perlecanfragment ook gebruikt om een nieuwe 
antistof, genaamd 95J10, te maken dat het menselijke perlecan herkent. Door de manier 
waarop 95J10 opgewekt is, staat onomstotelijk vast dat deze antistof perlecan herkent. Dit 
maakte het mogelijk om te achterhalen op welke plaatsen van de nier perlecan precies 
aanwezig is. Verassend genoeg bleek de GBM slechts zeer weinig perlecan te bevatten, en in 
grote delen ervan is het zelfs geheel afwezig. Dit betekent dat perlecan niet verantwoordelijk 
kan zijn voor het regelen van de doorlaatbaarheid van de GBM; het kan hoogstens een kleine 
bijdrage leveren. Gezien de grote hoeveelheid HSPG’s moet er dus nog een tweede HSPG in 
de GBM bestaan (hoofdstuk 4)
A g r in e : e e n  b e l a n g r ij k  HSPG in  d e  GBM
Op grond van bovenstaande resultaten werd een zoektocht gestart naar de identiteit van een 
tweede HSPG in de GBM. Hierbij dienden het opgezuiverde HSPG uit de GBM en de ertegen 
opgewekte antilichamen als een belangrijk hulpmiddel. De zoektocht eindigde bij agrine. 
Agrine stond al geruime tijd bekend als een onderdeel van basaalmembranen, in het bijzonder 
op de plaats waar zenuwuiteinden in contact staan met de skeletspiercellen (de 
neuromusculaire overgang). Onlangs werd ontdekt dat agrine heparansulfaatketens draagt en 
dus een HSPG is. Naar aanleiding hiervan werd onderzocht of agrine toevallig ook voorkomt 
in de basaalmembranen van de nier. Het bleek sterk vertegenwoordigd in de GBM, 
gelijkmatig verdeeld over de volle breedte en lengte. Het totaal aantal agrinemoleculen was 
vele malen groter dan het aantal perlecanmoleculen. Deze bevindingen wijzen op een 
mogelijk zeer belangrijke rol van agrine in de selectieve doorlaatbaarheid van de GBM
(hoofdstuk 5)
Daarom werd de structuur van het erfelijke materiaal (het cDNA), dat de code van het 
menselijke agrine draagt, vervolgens ontrafeld (hoofdstuk 6 ) . Dit levert meer inzicht op in de 
structuur van menselijk agrine. Zo bleek dat menselijk agrine een eiwit met een massa van 
212 kilodalton bevat, waaraan tenminste twee heparansulfaatketens kunnen worden gehecht. 
De beschikbaarheid van het cDNA biedt nieuwe mogelijkheden voor onderzoek. Een van 
deze mogelijkheden is het meten van de activiteit van het agrinegen, transcriptie genaamd. 
Van de 44 geteste weefsels werd duidelijk de hoogste transcriptie gemeten in de nieren en de 
longen. De hoge transcriptieniveaus kwamen inderdaad overeen met de ophoping van agrine 
in deze weefsels.
Om onomstotelijk te bewijzen dat het HSPG uit de GBM echt identiek is aan agrine, werd 
getoetst of de tegen GBM HSPG opgewekte antilichamen het zuivere agrinemolecuul 
herkennen. Dit gebeurde door recombinant-DNA-technologie. Fragmenten van het DNA dat 
codeert voor agrine werden overgebracht naar bacteriën, zodat stukken van het 
agrinemolecuul konden worden geproduceerd, geoogst en gezuiverd. De antilichamen 
vertoonden een sterke reactie met delen van het agrinemolecuul. Het ene antilichaam
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herkende een andere plek op het molecuul dan het andere antilichaam. Zo’n herkenningsplaats 
heet een epitoop. Van 25 antilichamen werd zo het epitoop gelocaliseerd 
Agrine is dus aanwezig in de GBM. Maar hoe komt het er terecht en hoe blijft het er? De 
GBM wordt op de meeste plaatsen geflankeerd door twee soorten cellen: endotheelcellen en 
podocyten. Beide celtypen werden afzonderlijk van elkaar gekweekt en getest op agrine- 
productie. Agrine bleek uitsluitend door de podocyten te worden gemaakt. Waarschijnlijk is 
dat in de nier ook het geval. Vervolgens wordt agrine in de GBM verankerd via laminine, een 
integraal onderdeel van de basaalmembraan. Dit lijkt veel op wat er gebeurt bij de 
neuromusculaire overgang: ook daar hecht agrine zich aan laminine.
N ie u w e  in z ic h t e n  in  h e t  o n t s t a a n  v a n  n ie r z ie k t e n
De nieuwe inzichten in de HSPG-samenstelling van de GBM suggereren dat perlecan 
waarschijnlijk geen belangrijke rol speelt bij het ontstaan van een eiwitlek. Een betere 
kandidaat is agrine. Bij nierafwijkingen die bij sommige diabetici ontstaan, is eerder 
aangetoond dat de hoeveelheid HSPG in de GBM afneemt. De bij dat onderzoek gebruikte 
antistoffen blijken nu het agrinemolecuul te herkennen. Agrine is dus waarschijnlijk 
betrokken bij veranderingen in de GBM die plaatsvinden tijdens het ontstaan van diabetische 
nierziekte.
In andere nierziekten (bijvoorbeeld “minimale lesies”) blijft het agrine-eiwit onveranderd 
aanwezig in de GBM, terwijl de hoeveelheid heparansulfaat wél afneemt. In deze gevallen 
spelen mogelijk enzymen die betrokken zijn bij de opbouw, modificatie en afbraak van 
heparansulfaat een rol.
Naast het regelen van de doorlaatbaarheid van de GBM vervullen HSPG’s nog meer 
belangrijke functies. Zo binden ze aan het celoppervlak en activeren ze groeifactoren als 
basische fibroblast-groeifactor (bFGF). Podocyten reageren op bFGF door te gaan groeien en 
delen. Bij langdurige blootstelling aan bFGF raken ze beschadigd, wat een nierziekte oplevert. 
Het ziektebeeld lijkt veel op een ziekte met de naam “focale segmentale glomerulosclerose” 
(FSGS), waarvan de precieze oorzaak onbekend is. Om te kijken of deze ziekte door hetzelfde 
mechanisme ontstaat, werden de concentraties van bFGF in urine en bloed van patiënten met 
FSGS gemeten. Patiënten met een ernstige vorm van FSGS produceerden urine met 
verhoogde concentraties bFGF. Controlepersonen en patiënten met een milde vorm van FSGS 
hadden normale waardes. Deze bevindingen suggereren een mogelijke rol van bFGF bij de 
ontwikkeling van deze ziekte
C o n c l u s ie s  u it  d it  o n d e r z o e k
De resultaten van dit onderzoek leiden tot onder andere de volgende conclusies:
- Domein I van het menselijke perlecan kan naast heparansulfaat ook chondroïtinesulfaat 
dragen (hoofdstuk 2).
- Het eiwitdeel van perlecan kan lipoproteïnen binden (hoofdstuk 3). Dit gebeurt via het 
gedeelte dat domein I en II bevat. Deze activiteit wordt beïnvloedt door de aanwezigheid 
en samenstelling van de suikerketens (hoofdstuk 3).
- Er komen ten minste twee verschillende HSPG’s voor in de GBM: agrine en perlecan 
(hoofdstuk 4 en 5).
- De hoeveelheid perlecan in de GBM is slechts zeer beperkt (hoofdstuk 4).
- Agrine is een belangrijk HSPG van de GBM (hoofdstuk 5). Van alle geteste weefsels 
komt het meeste agrine-mRNA voor in de volwassen nier en long (hoofdstuk 6).
(hoofdstuk 8)
(hoofdstuk 7)
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- Het menselijke agrine-eiwit heeft een massa van 212 kilodalton en ondersteunt de 
aanhechting van heparansulfaat door de aanwezigheid van een zgn. SEA-module en 
geschikte aanhechtingsplaatsen voor suikerketens (hoofdstuk 6).
- Het menselijke agrine wordt gemaakt door podocyten en kan zich via laminine aan de 
GBM vasthechten (hoofdstuk 7).
- Agrine remt de activiteit van trypsine, plasmine en elastase (hoofdstuk 7).
- De afgenomen HSPG-concentratie in de GBM, die eerder werd waargenomen bij 
diabetische nierziekte, is (deels of geheel) te verklaren door een afname van agrine- 
concentratie (hoofdstuk 7).
- De invloed van bFGF op podocyten zou in de mens betrokken kunnen zijn bij de 
ontwikkeling van FSGS (hoofdstuk 8).
B e k n o p t e  a a n w ij z in g e n  v o o r  t o e k o m s t ig  o n d e r z o e k
De resultaten van dit onderzoek bieden meer inzicht in de functies van HSPGs en de 
samenstelling van de GBM. Agrine speelt waarschijnlijk een grotere rol in het bepalen van de 
ladingsafhankelijke doorlaatbaarheid van de GBM dan perlecan. Het is daarom belangrijk om 
te onderzoeken of er een verband is tussen veranderingen in de agrineproductie en de 
ontwikkeling van verschillende nierziekten waarbij een eiwitlek optreedt, zoals de diabetische 
nierziekte. Zulke veranderingen zouden zowel in de suikerketens als in het eiwitdeel plaats 
kunnen vinden.
In verband hiermee is het relevant om te onderzoeken hoe de productie van agrine wordt 
beïnvloed door fysiologische parameters. Aangezien agrine alleen lijkt te worden 
geproduceerd door gedifferentieerde podocyten, is de opheldering van mechanismen die 
dedifferentiatie van de podocyt bewerkstelligen zeer interessant. Nieuwe methoden voor het 
kweken van podocyten onder gedifferentiëerde en gededifferentiëerde omstandigheden bieden 
veelbelovende mogelijkheden om zulke vraagstellingen te onderzoeken.
Of de heparansulfaatketens van agrine onmisbaar zijn voor het reguleren van de 
doorlaatbaarheid van de GBM, kan worden beoordeeld door het gericht aanbrengen van 
mutaties in zogenaamde transgene muizen. Het is nog niet bewezen welke 
aanhechtingsplaatsen voor suikerketens ook daadwerkelijk benut worden in het menselijke 
agrine. Om dit te onderzoeken kunnen naast het toepassen van gerichte mutaties 
electronenmicroscopische technieken worden gebruikt. Ook rijst de vraag hoe de 
agrineproductie verandert tijdens de ontwikkeling van de nier in het embryo en na de 
geboorte.
Om meer inzicht te werven in de functies van agrine in de GBM is het belangrijk om te weten 
met welke moleculen het een wisselwerking heeft. Bekende voorbeelden zijn a-dystroglycan, 
integrine en laminine. Het zou interessant zijn om te weten welke effecten de binding van 
agrine met het celoppervlak teweegbrengt.
Tenslotte is het niet uitgesloten dat de GBM, naast agrine en perlecan, nog andere HSPG- 
soorten bevat. Er bestaan aanwijzingen voor het bestaan van zo’n HSPG, dat een eiwitdeel 
van 22 kDa zou bevatten. De identiteit van dit molecuul en de mogelijke rol ervan in het 
functioneren van de nier verdient zeker de aandacht.
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